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Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder (FGID) 
associated with reduced quality of life, significant health care costs, and has an estimated 
global prevalence of 11%. Due to its variable phenotype and multifactorial 
pathophysiology there are currently no satisfactory biomarkers for IBS diagnosis. 
Additionally, the current ‘gold standard’ validated clinical tool for FGID diagnosis, the 
Rome IV criteria, is a consensus driven criteria which do not take pathophysiology into 
account. Many different pathophysiologies for IBS have been intensively investigated, 
including aberrant sub-clinical inflammatory responses, dysbiosis, small intestinal 
bacterial overgrowth, genetic polymorphisms and alterations to gastrointestinal (GI) 
barrier permeability. However, these have historically been investigated in isolation 
rather than holistically. This current body of knowledge has created an extensive 
scientific background of inconsistent or contradictory results of the pathophysiology and 
treatment of IBS and other FGID. 
The COMFORT (Christchurch IBS cOhort to investigate Mechanisms FOr gut Relief and 
improved Transit) study is an observational case-control study which recruited 
participants with IBS, functional constipation (FC) or diarrhoea (FD) as well as 
asymptomatic controls. This cohort is designed to take a ‘multi-omics’, systems biology 
approach to the investigation of FGID pathophysiology by collecting and integrating 
demographic, GI and non-GI symptoms, and a range of biological data (blood, breath, 
stool, urine, and colonic tissue samples). Participants also completed a three day Food 
And Symptoms Times (FAST) diary to investigate correlations between food 
consumption and the onset, duration, and severity of GI symptoms experienced over 
those three days.  
This research aimed to investigate the association of fibre consumption with the faecal 
microbiota (as a proxy of the gut microbiota), subsequent butyrate production and 
colonic epithelial tight junction gene expression in the biological samples collected from 
the COMFORT study participants. Additionally, this research explores the way in which 
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COMFORT participants cluster together without the framework of Rome IV criteria and 
apply these results to biological data in comparison to Rome IV diagnostic groups. 
Section One provides a cohort description of the COMFORT study, and risk factors of 
concomitant symptomatic anxiety and depression in FGID participants. The clustering of 
participants using unsupervised analysis is also compared to Rome IV diagnostic criteria 
using faecal microbiome data in order to test the validity of applying this analysis to a 
biological dataset. 
Section Two details the associations, captured in the FAST diary, of fibre and fermentable 
oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) consumption 
with the onset of the GI symptoms within three hours of meal consumption. This analysis 
provided a more nuanced understanding of the relationship between GI symptoms and 
two food components commonly identified to exacerbate IBS symptoms, fibre and 
FODMAP. 
Section Three presents tight junction and Nerve Growth Factor gene expression data and 
faecal butyrate concentration data. These data were correlated with fibre and FODMAP 
consumption, GI and non-GI symptoms, faecal microbiota relative abundance, and 
demographics. The results were interpreted using clusters determined by unsupervised 
analysis.  
This thesis demonstrates the biological plausibility of the relationships between diet, 
faecal microbiota, faecal butyrate concentration and colonic tight junction and Nerve 
Growth Factor gene expression. Additionally, the use of data from multiple biological 






The development and recruitment of the Christchurch IBS cOhort to investigate 
Mechanisms FOr gut Relief and improved Transit (COMFORT) study was a part of the 
High Value Nutrition, National Science challenge funded by the Ministry of Business, 
Innovation, and Employment. As part of this wider project, the COMFORT study aimed to 
identify mechanisms of irritable bowel syndrome (IBS) pathogenesis by comparing 
clinical and biological data between IBS patients and controls, and to identify novel 
biomarkers that may respond to therapeutic intervention.  
This thesis explores the associations of components of the luminal microenvironment 
(dietary fibres, faecal microbiota, faecal butyrate concentration, and tight junction gene 
expression) in the context of gastrointestinal and extra-intestinal symptoms experienced 
by participants. The boundaries of this research were established due to the work of two 
further PhD projects utilising COMFORT study data. In brief, PhD Candidate Shanalee 
James who will explore the metabolome and bile acid malabsorption in IBS participants 
and PhD Candidate Caterina Carco who will explore the microbiome of IBS participants. 
The original proposal submitted for this PhD was to utilise dietary, and biological data, 
and clinical symptoms to investigate pathophysiological mechanisms of functional 
gastrointestinal disorders. This aim remained largely unchanged throughout the PhD 
project, with the addition of utilising symptom data to regroup participants outside of the 
Rome IV framework. Additionally, while colonic mucosa gene expression was quantified 
at the University of Otago, Christchurch, subsequent quantification and localisation of 
proteins was intended to be performed by myself at the University of Newcastle, 
Australia. This was in order to access their facilities, equipment, and established 
protocols. However, due to COVID-19 travel restrictions in 2020-2021, and subsequent 
delay in the retrieval of paraffin embedded COMFORT study colonic biopsies from the 
central laboratory due to the pandemic, these analyses have been delayed. It is hopeful 
that these analyses will take place in the future. 
The COMFORT study protocol has been translated into a clinical trial named COMFORT 
PSYKI (clinical trial registration number ACTRN 1261 8001 2862 35p). This was a cross-
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over, single blinded, intervention study completed in 2019, which compared the effects 
of kiwifruit and psyllium on gastrointestinal and extra-intestinal symptoms in 
constipation predominant IBS patients. I acted as the unblinded researcher in this clinical 
trial, and so provided interventions and support to participants during the trial. I 
maintained the blind by assessing FAST diaries for completeness, digitising 
questionnaires, and maintaining a register of any adverse reaction events. Additionally, I 
helped with the collection and processing of biological samples. Initially, baseline data 
collected from COMFORT-PSYKI was intended to be included in this PhD. However, as 
diet diary data has not yet been digitised and analysed, the inclusion of this data into the 
thesis was of limited benefit.  
Two papers directly relating to this project have been published and have been integrated 
into this thesis, although they have been modified for relevance, consistency and 
continuity. The first publication, a literature review entitled Irritable Bowel Syndrome 
and the Gut Microbiota was published in the Journal of the Royal Society of New Zealand 
in 2020.(1) This publication has been included in Chapter 1 and in its unmodified state in 
Appendix A. The second publication: Cohort Profile: The Christchurch IBS cOhort to 
investigate Mechanisms FOr gut Relief and improved Transit (COMFORT) was published 
in Inflammatory Intestinal Diseases in 2020(2). This publication is included in Chapter 2 
and in its unmodified state in Appendix B. 
Finally, all statistical analyses performed in this thesis were performed under the 
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1.1 What is IBS? 
Irritable bowel syndrome (IBS) is a common, chronic, and distressing condition that is 
part of the functional gastrointestinal disorders (FGID) family. IBS is characterised by 
abdominal pain associated with a change in bowel habit; these symptoms may remit and 
recur in a patient over time.(3) Patients diagnosed with IBS are often categorised based 
on their predominant symptoms into constipation-predominant (IBS-C), diarrhoea-
predominant (IBS-D), or mixed phenotype-predominant where the patient alternates 
between constipation and diarrhoea (IBS-M). Some criteria also include unidentified IBS, 
in which the symptoms experienced by a patient are typical of IBS but do not meet the 
criteria for any of the other subtypes.(4) Post-infectious IBS (PI-IBS) is also considered a 
subtype of IBS, where infectious gastroenteritis precedes the onset of IBS-D like 
symptoms.(5)  
IBS directly and indirectly impacts patients’ quality of life. The burden of IBS symptoms 
that affect patients’ quality of life is compounded by the complex and multifactorial 
pathophysiology of IBS which has historically meant that there are no reliable treatments 
or ‘cure’. Treatments for IBS are generally directed towards symptom relief and, while 
they may provide symptom relief, they are not consistently effective for all individuals. 
One study of 1966 IBS patients found that 18% were using narcotics for pain relief. 
Additionally, 25% would give up 25% of their remaining life and 14% would risk a 0.1% 
chance of death to receive a treatment that would relieve their symptoms altogether.(6) 
Work absenteeism, presenteeism (loss of productivity while at work), and activity 
impairment are increased in IBS patients compared to healthy controls.(7) Increased 
financial costs are also associated with IBS, with one study reporting that IBS patients 
spent (US)$2486 per year more on health care than healthy controls.(7) There is also 
significantly increased health care utilisation by IBS patients. Pare et al. (2006) reported 
that in their cohort of 1555 IBS patients, 86.7% had received treatment for IBS in the six 
months prior to the study, 60.3% used ≥three therapies (over the counter medication 
and/or alternative medications), and 30.9% of patients used ≥five therapies to treat their 
symptoms. Of these patients, 72.5% had undergone a medical procedure, 13.2% of these 
in the month before the study, and 1.3% had been hospitalised for their IBS symptoms.(8)  
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1.1.1 IBS Epidemiology 
IBS constitutes a major health problem in the western world. The reported prevalence of 
IBS differs worldwide; in 2016, a systematic review estimated the global prevalence was 
approximately 11%.(9) Due to methodological heterogeneity and variations in 
prevalence in different countries, the authors of this review felt that it was more 
appropriate to focus on regional or cultural prevalence of IBS, which is more likely to 
reflect different underlying pathophysiologies.(9) Geographical variations in IBS 
prevalence are thought to be due to diagnostic and cultural factors. These include 
different cultural beliefs about what constitutes a ‘disorder’ and therefore what 
necessitates a visit to a physician. Another important factor concerns applying diagnostic 
criteria that are validated for predominately European populations to non-European 
populations. Furthermore, historically several different diagnostic criteria for FGID have 
gone in and out of vogue, resulting in different countries applying different diagnostic 
criteria to patients over several decades (Table 1.1).  
1.1.2 Rome Criteria 
Individuals with FGID, by definition, do not have an obvious organic cause to explain their 
symptoms. Furthermore, no reliable biomarkers have been identified for FGID. The 
current ‘gold standard’ criteria for diagnosing a FGID are the Rome IV criteria, a 
consensus criteria that were originally developed by specialist gastroenterologists (the 
Rome committee) in 1994. The first Rome committee published a classification system 
and diagnostic criteria for a previously disparate group of non-organic disorders.(10) 
This system was followed by the publication of the second iteration of Rome II in 
1996.(11)  
Following the publication of these criteria and the pharmaceutical sponsorship of the 
Rome Foundation the number of publications involving FGID increased 8-fold leading to 
the publication of Rome III in 2006.(12) The Rome III criteria capitalised on this new data 
and introduced more evidence-based diagnostic criteria, which were deemed to be more 
representative of patient populations.(4, 13) 
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Table 1.1: Studies comparing IBS prevalence in different countries, using different Rome criteria 














32.3±14.2 1313/1113 24.4 61.4/38.6 
Jeong et al(16) 1417 II Korea 43.9±14.8 655/762 2.2 58.7/41.3 






32 ± 13.0  7.7 57.8/42.2 






26 481/499 18.8  
Talley et al(21) 1037 II 
New 
Zealand 
26 498/539 4.3 60.5/39.5 
Zuckerman et 
al(22) 
411 I Vietnam 27.7 ± 6.9 220/191 7.2 65.5/34.5 
Chen et al(23) 271 § Singapore  143/128 3.2  
Miwa(24) 15000 III Japan  7500/7500 13.1 54.8/45.2 
Dong et al (25) 2126 III China 20.66±1.6 1209/917 7.85 64.1/35.9 
Park et al(26) 1009 III Korea 41.1±16.8 508/501 9.0 61.0/39.0 
Long et al(27) 2115 III China 41±15 997/1002 5.9 48.7/51.3 













Lee et al(29) 221 III Malaysia 39.1±14.7 117/104 10.9 54.2/45.8 
Chang et 
al(30) 
4275 III Taiwan 
42.45±16.
1 
2138/2137 4.4 59.1/40.9 
Celebi et al(31) 1766 II Turkey 
40.26±12.
75 
964/802 6.3 59.8/40.2 
Lule et al(32) 3472 Manning Kenya 40 2048/1424 8  
Morgan et 
al(33) 
357 II Nicaragua  256/101 13.2 75.4/25.4 
Okeke et 
al(34) 
443 II Nigeria 32.2±10.9 233/210 31.6 47.1/52.9 
Yilmaz et 
al(35) 
3000 II Anatolia  1521/1479 10.2 60.8/39.2 
Olubuyide et 
al(36) 
336 Manning Nigeria  85/251 30 33.3/67.7 
Ziółkowski et 
at(37) 
850 II Poland  510/340 12.9 60/40 
Aggarwal et 
al(38) 
2505 II England  1378/1127 9 71/29 
Ebling et 
al(39) 
703 III Croatia 42.23 357/346 29.16 63.3/35.7 
Hillilä et al(40) 3650 II Finland 42.1 2004/1646 5.1 52.7/47.3 
Hungin et 
al(41) 






2397 II Greece 
46.1± 
15.0 
1693/704 15.7 75.3/24.7 
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843 II Sweden  446/397 13.5  
Olafsdottir et 
al(44) 
1336 III Iceland 43 772/564 13 73.5/26.5 
Österberg et 
al(45) 
2707 I Sweden 31.5 1550/1300 10.5 67.5/32.5 
Papatheodoridi
s et al(46) 
700 ‡ Greece 50±18  21.4 68.7/31.3 
Usai et al(47) 1900 II Italy  980/920 4.9 71.3/28.7 
Vandvik et 
al(48) 
4622 II Norway  2588/2034 8.1 68/32 
Wilson et 
al(49) 
4807 II England  2820/1986 11.1 72.6/27.4 
Bommelaer et 
al(50) 




264 I Spain 44±1.0 142/122 13.6 63.9/36.1 
Dapoigny et 
al(52) 
588 II France   4.7 60.7/39.3 
Li et al(53) 437 II Canada  354/83 25.2 74.3/25.7 






51 334/309 12  
Madrid-Silva et 
al(55) 
437 II Chile 45.2±15.2 246/191 28.6 65.6/34.4 
Sander et 
al(56) 
1510 III Brazil 37.6±13.8  24.7 65.8/34.2 
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500 II Mexico 39.8±16.3 305/195 16 64.4/56.2 
Schmulson et 
al(58) 
1021 II Mexico 37.4±0.5 629/392 28.9 67.8/32.2 
Schmulson et 
al(59) 
500 III Mexico 39.6±7 335/165 4.4  
Schmulson et 
al(60) 








47.4 2918/3013 4.6 65.6/34.4 
Sperber et 
al(a),(62) 
981 II Israel 45.0 540/441 2.9 71.4/28.6 
Sperber et 
al(b)(63) 
1755 II Israel 39.1±14.1 1053/702 7.9 58.7/41.3 
Hoseini-Asl 
and Amra(64) 
4762 II Iran 37.9±14.3 2671/2091 5.8 54/46 
Khadmolhossei
ni et al(65) 
1978 II Iran 49.9±11.1 1269/709 10.9 74.9/25.1 
Sorouri et 
al(66) 
9072 III Iran  4527/4545 1.1 71.6/28.4 
Naeem et 
al(67) 
360 III Pakistan  297/63 28.3 85.3/14.7 
Chatila et 
al(68) 
553 III Lebanon 36.1±10.3 292/261 20.1 60.4/39.6 
n, sample population; SD, standard deviation; F/M, female/male; IBS, irritable bowel syndrome; †UK:5999; 
France: 5033; Germany:5002; Italy: 5082; Holland: 5463; Belgium: 5229; Spain: 5097; Switzerland:5079; ‡ 
diagnosis of IBS made by participants reporting symptoms;.§Modified Talley questionnaire(69) 
8 
 
Most recently Rome IV was published in 2016,(70) these modified criteria attempted to 
clarify, update and streamline the diagnosis of FGID for use in clinical practice and 
research. Rome IV made several important changes to the Rome III criteria, including 
reclassifying all FGID as “disorders of Gut-Brain interaction”. Some of the most significant 
changes were to the IBS criteria themselves where the terminology of the diagnostic 
criteria changed as well as the criteria itself. The change in terminology removed the 
word ‘discomfort’ which was considered vague and untranslatable into some languages. 
The diagnostic criteria were updated to increase the frequency of symptoms from ≥ three 
episodes per month to at least one episode per week, and changes to the stool based 
criterion where symptoms are now required to be associated with abnormal stools 
(Bristol Stool Chart 1or 2, 6 or 7).(70) This refinement of IBS symptom thresholds reflects 
the evidence base as opposed to consensus-based opinion. In addition, Rome IV 
reclassified functional bowel disorders, a subgroup of FGID that includes IBS, functional 
constipation (FC), functional diarrhoea (FD) and functional bloating. Rome IV considers 
FGID to be on a spectrum, where the diagnostic ‘borders’ of these disorders are not 
always clear and there are common or overlapping pathophysiologies.(3) When Rome IV 
criteria were applied to IBS patients diagnosed using Rome III criteria, those patients who 
met Rome IV criteria had more severe gastrointestinal (GI) symptoms, more severe 
emotional distress/mood disorders, and a poorer quality of life.(71) Therefore a large 
proportion of Rome III-diagnosed IBS patients would now be below the threshold for 
diagnosis, and studies using Rome III criteria may not be directly comparable to those 
using Rome IV. Another new feature of the Rome IV criteria is the acknowledgment that 
FGID, and in particular functional bowel disorder patients, are clustered together in spite 
of differing pathophysiologies.  
1.2 The Brain-Gut Axis 
Following the introduction of the Rome IV criteria in 2016 it is now commonly accepted 
that functional bowel disorders and FGID are grouped under the umbrella of disorders of 
Brain-Gut interaction. However, multiple biological systems and unreliable responses to 
treatments (72) have been implicated in different study populations under this umbrella 
term. The interaction of the brain and the gut is referred to as the Brain-Gut Axis (BGA) 
(73) which describes the bidirectional communication between the cognitive and 
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emotional areas of the central nervous system (CNS) and the peripheral functions of the 
GI tract. The BGA is mediated by neurons, hormones, neurotransmitters, and the immune 
system (74-76) as well as the GI microbiota.(77)  
Dysfunction of the BGA in IBS has led to the concept that symptoms can come about from 
a ‘top-down’ or ‘bottom-up’ pathophysiology, i.e. the progress of this disorder can be 
primarily centrally driven or primarily peripherally driven. Dysfunction of (at least 
partially) centrally controlled processes such as visceral hypersensitivity or the high level 
of centrally mediated co-morbidities (such as anxiety or depression, which can be co-
morbid in up to 50% of cases) provides evidence for the ‘top-down’ pathophysiology of 
IBS.(78) Whether this is a risk factor for developing IBS or a symptom of IBS is still 
debated. It had been found that one-half to two-thirds of non-health care seeking IBS 
patients develop GI symptoms before anxiety symptoms,(79, 80) while health care 
seeking patients are two-fold more likely to develop anxiety symptoms preceding GI 
symptoms.(80) Patients hospitalised for infectious gastroenteritis and who scored highly 
on psychometric tests for anxiety, depression, somatisation, and neuroses have been 
found to be more likely to subsequently develop PI-IBS.(81)  
Evidence of ‘bottom-up’ IBS pathophysiologies centres on how the GI tract reacts to 
luminal contents including the GI microbiota. The effects of the GI microbiota on the BGA, 
particularly in ‘bottom-up’ signalling has led to the concept of the ‘Microbiota-Brain-Gut 
Axis’ (microbiota-BGA), where bi-directional communication between the brain and the 
gut is inextricable from GI microbiota signalling. Anatomical and immune system 
abnormalities of the GI tract have been described in germ-free mouse models,(82, 83) 
suggesting that the GI microbiota directly affects the gut mucosa. In addition altered GI 
motility, noted in germ-free animal models, was ‘normalised’ by introducing conventional 
GI microbiota (84, 85) while bacterial components such as flagellin have been shown to 
induce an immune system reaction, and autonomic nervous system mediated altered 
motility.(86, 87) Another notable anatomical difference found in germ-free animal 
models is the significantly increased enteroendocrine cell density,(88) which could 
explain the differences in GI motility observed in these models. Interestingly the far-
reaching effects of the GI microbiota have been demonstrated in the pathogenesis of 
depression and anxiety.(89, 90)  
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The vagus nerve, a principal component of the peripheral nervous system, is part of the 
autonomic nervous system, which regulates many involuntary bodily functions, including 
digestion and absorption, and plays a vital role in the microbiota-BGA. This single nerve 
innervates most (or, according to some anatomists, all) of the GI tract; it is comprised of 
both efferent (20%) and afferent (80%) nerve fibres and is responsible for relaying 
interoceptive (stimuli that come from organs) and exteroceptive (stimuli that come from 
outside of organs) signals from the GI tract to the CNS.(74) Afferent vagal nerve fibres 
innervate all layers of the GI tract wall but do not penetrate through to the lumen; instead 
afferent vagal nerves rely on signals from enterochromaffin cells in the gut which secrete 
hormones and neurotransmitters in response to the anticipation of eating or the contents 
of the lumen as a part of digestion.(91, 92) Enteroendocrine cells can also detect the 
microbiota through expression of pattern recognition receptors.(93, 94) These receptors 
are specific to bacterial components (e.g. lipopolysaccharide (LPS) or flagellin) and 
products of microbial metabolism such as the short-chain fatty acid (SCFA) butyrate.(95) 
The signals created binding these ligands to their cognate receptors are relayed through 
the enteroendocrine cells to vagal afferents and subsequently to the CNS where these 
signals are integrated into the central autonomic network. This network is a system of 
cortices and structures in the CNS, including the anterior cingulate cortex, amygdala, and 
hypothalamus, which integrates and ultimately responds to signals from the GI tract and 
resident microbiota via vagal efferent nerves.(96) Intriguingly, activation of the vagal 
nerve has anti-inflammatory effects, and has been shown to be effective in treating 
symptoms in a small cohort of inflammatory bowel disease patients.(97) Vagal activity in 
IBS patients has shown to be dysregulated (98) suggesting that this vital part of the 
microbiota-BGA may have a significant role in the pathophysiology of IBS.  
Morphological differences in regions of the brain that control fear, anxiety, and stress (as 
well as reduced anxiety-like behaviour) have been demonstrated in germ-free animal 
models, highlighting the important role that the GI microbiota plays in the development 
of these structures.(99, 100) Furthermore, GI infections have shown to induce anxiety-
like behaviour in mouse models; activation of brain regions involved with mood, fear, and 
anxiety has been noted in these animals.(101, 102) Modulation of the GI microbiota by 
probiotics,(103) diet,(104) and antibiotics (105) have all been shown to modulate 
anxiety- and depressive-like behaviours in mouse models. In human trials, reduced 
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depression symptoms were reported by participants taking probiotics, which correlated 
decreased amygdala and limbic system activation measured with functional magnetic 
resonance imaging. This finding suggests that a probiotic organism could modulate the 
CNS and the hypothalamic-pituitary-adrenal  axis in humans.(106) In contrast, some 
components of the inflammasome complex, which mediates immune responses to the 
presence of pathogens and is a key mediator of physical and psychological stress, are 
altered in patients with depression. When caspase-1, which is activated by the 
inflammasome, was pharmacologically inhibited in mice a decreased exhibition of 
depressive behaviour was observed.(107)  
The symptoms classically experienced by IBS patients fall broadly into two categories: 
altered bowel habit  and visceral hypersensitivity. These have been demonstrated to have 
multiple different pathophysiologies. These symptoms can be either mediated through 
the CNS (‘top-down’) or can themselves modulate the CNS (‘bottom-up’).(108)  
1.2.1 Visceral Hypersensitivity 
Visceral hypersensitivity, or an abnormal pain response to a normal stimulus, was 
elegantly demonstrated in IBS patients in 1973, when James Ritchie established that 
inflating a balloon in the colon resulted in pain in more IBS patients than healthy 
controls.(109) This finding suggests a lower pain threshold in this group.(110) Current 
research suggests that decreased pain thresholds in IBS patients likely contribute to 
visceral hypersensitivity, but the underlying mechanism within the CNS remains 
unknown. Intriguingly, functional magnetic resonance imaging and positron emission 
tomography brain scans of IBS patients identify functional alterations in various regions 
of the CNS that include the thalamus, hippocampus, and prefrontal cortex.(111, 112) 
These are areas that are important in memory, emotion, behaviour, and the perception of 
sensory and motor signals.(112-114) Resting-state functional magnetic resonance 
imaging, in which the brain’s functional architecture and functional connectivity are 
investigated, found abnormal regional brain activity in IBS patients in the absence of 
colorectal stimulation, suggesting that IBS patients are functionally adapted to 
experience visceral pain.(114) Further studies have suggested that abnormal functional 
connectivity leading to visceral hypersensitivity could be caused by enhanced input to 
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the CNS from the periphery, and increased activity of pathways that ‘pay attention’ to 
sensation in the GI tract within the CNS causing hypersensitivity.(115) 
1.2.2 Altered Bowel Habit 
The other defining symptom common to IBS patients is altered bowel habits. Originally it 
was thought that IBS patients exhibit abnormal colonic motility that, in turn, translated 
to both visceral pain and altered bowel habit,(116) and early studies suggested that IBS 
was primarily a disorder of the motility of the GI tract.(117, 118) However, altered GI 
motility is also shown to correspond poorly with visceral pain (119) and only a subset of 
IBS patients exhibit abnormal colonic motility. Moreover, there is no overriding pattern 
that defines these patients.(120, 121) More recently, a French study demonstrated that 
different IBS subtypes have different colonic responses to food compared to the other IBS 
subgroups and healthy controls. The most obvious difference between IBS-C patients and 
constipated patients who did not meet Rome criteria was in the hindgut (splenic flexure 
to anus), in which emptying was delayed in IBS-C patients. Conversely, increased 
emptying of the ascending colon was observed in IBS-D participants compared to patients 
with diarrhoea who did not meet Rome criteria.(122) While the exact mechanisms by 
which symptoms correlate to colonic motility remain unknown, patients who exhibit this 
abnormal colonic motility (particularly IBS-C patients), tend to respond well to 
pharmacological interventions that stimulate gut motility.(123, 124)  
By Rome IV definition, all IBS patients exhibit altered bowel habit and pain (visceral 
hypersensitivity). This pathophysiological heterogeneity makes IBS particularly hard to 
study. Even the most stringent study inclusion criteria, if based on clinical symptoms 
alone, may still result in a heterogeneous pool of IBS participants. Given this 
heterogeneity, it is not surprising that current guidelines describe IBS pathophysiology 
as ‘dysregulation of the BGA’, an ‘umbrella’ term under which all the symptoms and 
mechanisms of IBS can sit. This gains significance with evidence that the GI microbiota 
has the ability to regulate the BGA at all levels, from the CNS to the GI epithelial barrier. 
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1.3 Gastrointestinal Hormone Physiology 
The physiological act of eating and digestion interacts at all points with the BGA. The CNS 
is involved in the anticipation stage of ingesting food, where it signals the release of 
hormones in preparation for digestion. The change in pH and mechanical distension of 
the GI tract triggers myenteric reflexes governed by the enteric nervous system. 
Additionally, as the digesta is moved through the GI tract its composition triggers the 
release of various enzymes and hormones from enteroendocrine cells throughout the GI 
mucosa as well as signalling to the CNS. The passage of digesta through the GI tract also 
triggers feedback loops to the CNS to signal satiety.(125) Alterations in the production 
and secretion of these hormones have been documented in IBS patients. Ghrelin, which 
is involved in GI motility and satiety, has been found to circulate at a higher concentration 
in IBS patients.(126, 127) Cholecystokinin, which is stimulated by fats and protein in the 
proximal GI tract, has effects in increasing GI motility and increasing rectal 
hypersensitivity. It has also been found to have increased circulation in fasted IBS 
patients and post prandially.(128) The ingestion of fat is also involved in the gastro-
colonic response, which has been shown to be exaggerated in IBS patients due to a 
common area of referred pain.(129, 130)  
5-hydroxytryptamine (5-HT, also referred to as serotonin) acts as both a 
neurotransmitter and hormone and is present in the CNS. 80% of 5-HT in the body is 
secreted by enterochromaffin cells in the gut. The actions of 5-HT in the GI tract include 
peristalsis, communication with the enteric nervous system, and the stimulation of 
secretion. They terminate by the re-uptake of 5-HT into cells, mediated by the 5-HT-
reuptake transporter. Polymorphisms of the gene for this transporter, leading to 
increased circulating 5-HT, have been associated with patients diagnosed with IBS-
D.(127, 131, 132) The GI microbiota have an important role in the regulation of 5-HT 
production. Germ free animal models have significantly less circulating 5-HT than 
conventional animals (Sjogren et al, 2012; Wikoff et al, 2009) as well as altered 
morphology of endochromaffin cells (uribe et al, 1994). Some studies have postulated 
that some bacterial species can produce 5-HT directly (Tsavkelova et al, 2006; Yano et al, 
2015). Additionally, the composition of the GI microbiota has been shown to influence 
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that expression of different 5-HT receptors via products of bacterial fermentation 
(acetate) (Bhattarai et al, 2017; Ge et al, 2018).  
The changes in the concentration of these GI hormones and neurotransmitters, and 
decreases in the density of their associated endochromaffin cell populations are 
potentially a physiological basis for alterations to GI motility and altered visceral 
sensation/perception in IBS patients. Interestingly a Norwegian study found that 
modulating the GI microbiota of IBS patients through diet and faecal microbial transfer 
increased enterochromaffin cell density towards the level of healthy controls, which was 
associated with improvements to both GI symptoms and quality of life.(133, 134) 
1.4 Gastrointestinal Microbiota and IBS 
The GI microbiota is believed to be one of the main contributors to the aetiology of IBS. 
However, past and current research have been unable to determine what components of 
the GI microbiota play a part in IBS development.(1) An early study found that IBS 
patients had a greater proportion of facultative anaerobes cultured from stool samples 
compared to healthy controls.(135) More recently, a systematic review and meta-
analysis of IBS studies using bacterial culturing techniques found consistent reductions 
in Bifidobacterium and Lactobacillus in IBS patients compared to healthy controls.(136) 
Anaerobic culturing techniques are no longer considered appropriate for studying the 
complex ecology of the GI microbiota. Instead, genetic sequencing techniques are now 
widely used, particularly 16S ribosomal (r)RNA sequencing, which allows the 
investigation of complex microbial communities by amplifying the evolutionarily 
conserved 16S rRNA gene.(137) This sequencing technique can identify bacterial 
colonies that grow poorly in culture and detect previously uncultured species of bacteria. 
Subsequent analyses comparing culture and sequencing techniques found that 60-80% 
of bacteria present in human stool samples are unculturable and only 24% of the 
sequencing results identify species that corresponded to previously described 
organisms.(138)  
A recent systematic review collated 16S rRNA studies and found consistent detectable 
alterations in the GI microbiota of IBS patients, which may have a significant association 
with IBS pathophysiology. In particular, the study identified a reduction in the GI 
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microbiota α diversity (diversity within an individuals’ microbiota (139)) and a shift in 
the Firmicutes: Bacteroidetes ratio. The Firmicutes and Bacteroidetes are the two 
anaerobic bacterial phyla that dominate the human GI tract, with IBS patients 
demonstrating a higher abundance of Firmicutes and lower abundance of Bacteroidetes 
compared to healthy controls.(140) While this finding has been consistent among 
different IBS populations, it is unknown how it is related to IBS pathophysiology and 
aetiology. It has been speculated that increases in Firmicutes could lead to increased GI 
epithelial barrier permeability and acid production (driven by Clostridia species) leading 
to low-grade inflammation and visceral hypersensitivity in the GI tract.(140, 141) In 
contrast, a lower abundance of Bacteroidetes could lead to increased inflammation 
through decreased bacterial production of anti-inflammatory compounds.(142, 143) 
Additionally, the use of generalisations, such as the bacteroides:firmicutes ratio, may also 
not present an accurate assessment of the function of the a complex ecosystem such as 
the GI microbiota.(144) 
There is also evidence for differences in the composition of the GI microbiota between 
different IBS subtypes. Some studies have associated IBS-C, but not IBS-D, with an 
increased rate of breath methane production.(145) Breath methane has been suggested 
as a potential diagnostic test for IBS-C.(146) However, methane is also detectable in 
healthy (asymptomatic) individuals and is not produced by all IBS-C patients. Methane 
gas has been shown to delay colonic transit, and while a causative role has not yet been 
established it is believed that methane may act as a neuromuscular transmitter.(147)  
There has been no consensus on a microbial signature for IBS-D, although several studies 
have observed decreases in the relative abundance of Lactobacillus species and 
Faecalibacterium prausnitzii and an increase in the Enterobacteriaceae family compared 
to healthy controls.(148-150) This observation has led to speculation that a disruption in 
the ratio of ‘good’ and ‘bad’ bacteria in IBS-D could contribute to this pathophysiology. 
However there is currently no mechanistic evidence for this, nor is this disruption 
considered sufficient to explain the symptoms and altered physiology of IBS-D.(151)  
Modulation of the GI microbiota with antibiotics, probiotics, prebiotics, and synbiotics 
has shown to be effective in treating IBS symptoms. Clinical improvements in IBS patients 
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was clearly demonstrated in 2000, when Pimentel et al. published a landmark paper 
reporting that 48% of IBS patients with concomitant small intestinal bacterial 
overgrowth were cured by antibiotic treatment.(152, 153) Subsequently antibiotics have 
shown to be more effective than placebo in treating IBS-D patients.(154) Conversely, 
some studies implicate antibiotic use in the onset of IBS symptoms (155-157) while 
others have demonstrated that the efficacy of the treatment reduces over time.(158) 
Mechanistic information as to the role of antibiotics in the pathogenesis of IBS is still 
lacking, but animal studies suggest that transient alterations in the GI microbiota 
triggered by antibiotics are associated with altered GI motility,(159, 160) increased 
inflammatory activity, and increased release of Substance P (a neurotransmitter 
associated with increased visceral hypersensitivity to colonic distension).(161) 
Probiotics (defined as “live microorganisms which when administered in adequate 
amounts confer a health benefit on the host” (162)) have also been shown to alleviate IBS 
symptoms.(163-165) This finding is reinforced by more recent evidence that certain 
probiotic organisms, singly or in combination, are associated with a reducing global 
symptom severity in specific subsets of IBS patients.(166-168) However, significant 
heterogeneity and evidence of publication bias in studies of probiotics mean that it is not 
yet possible to determine the efficacy of probiotics in the treatment of IBS.(169)  
Prebiotics are carbohydrates that are unable to be absorbed by the human GI tract and 
are available for fermentation by a specific organisms in the GI microbiota considered to 
impart health benefits to the host. They are defined as “a substrate that is selectively 
utilised by host microorganisms conferring health benefit”.(170) Increased relative 
abundance of Lactobacilli and Bifidobacteria have demonstrated in clinical trials with 
prebiotics which were associated with alleviation of IBS symptoms.(154, 171, 172) 
Additionally, increased prebiotic consumption has been associated with increased 
bacterial metabolism and production of SCFA which have additional health 
benefits;(173) this aspect will be discussed further in Chapter 8. However, Wilson et al. 
reported in a 2019 systematic review that some studies report exacerbation of symptoms 
associated with prebiotic supplementation; additionally no significant overall 
improvement of IBS symptoms was found.(172)  
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Synbiotics are a mixture of prebiotics and probiotics designed to synergistically promote 
‘healthy’ bacterial growth. While there have been few clinical trials with synbiotics, and 
those few do report improved IBS symptoms.(174, 175) However, the scarcity of clinical 
trials and significant heterogeneity in study methods mean that it is not yet possible to 
ascertain the efficacy of synbiotics in the treatment of IBS symptoms.(154)  
Faecal microbial transfer also modifies the microbiota of symptomatic individuals in 
order to alleviate symptoms. The faecal microbial content of a ‘healthy’, asymptomatic 
individual is given to a diseased individual either orally, via colonoscopy, or enema.(176) 
There are inconsistencies in the efficacy of FMT in the treatment of IBS symptoms. A well-
designed multicentre, double-blind, randomised controlled trial report lower symptom 
severity in IBS-D patients 24 weeks after faecal microbial transfer compared to those 
treated with placebo.(177) A recent study explored the effect of repeated faecal microbial 
transfer or increased the dose of faecal microbial transfer (from the same donor) on IBS 
patients who failed to respond to faecal microbial transfer. While the trial only involved 
10 participants, 7 (70%) showed improvement to GI and non-GI symptoms.(178) 
Conversely, repeated faecal microbiota transfer in another study found a reduction of 
efficacy in treatment of symptoms over time. Additionally, repeated treatments did not 
alleviate symptoms in those that did not respond to initial treatment.(179) Another study 
found that while faecal microbial transfer altered the faecal microbiome it did not treat 
IBS symptoms.(177, 180, 181) 
1.5 Stress 
Alterations in the activity of the hippocampus in IBS patients (described in Section 1.2.1) 
are interesting, as the hippocampus plays a vital role in the inhibition of stress, a major 
trigger for IBS patients. The hippocampus contains a high abundance of glucocorticoid 
receptors, making it vulnerable to long-term stress. Glucocorticoid receptors in the 
hypothalamus are responsible for negative feedback of the hypothalamic-pituitary-
adrenal axis; therefore, decreases in glucocorticoid receptor expression create an 
exaggerated hypothalamic-pituitary-adrenal axis response to stress. Exaggerated stress 
responses have been noted in IBS patients.(182) Early adverse life events are a known 
risk factor for IBS (183) and have been shown to be associated with exaggerated 
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hypothalamic-pituitary-adrenal axis responses, decreased glucocorticoid receptor 
messenger RNA (mRNA), and increased overall IBS symptom severity.(184) In animal 
models, colorectal distension caused persistent visceral hypersensitivity and depression-
like behaviour in rats who had experienced neonatal trauma compared to those who had 
not. This observation was also associated with decreased hippocampal glucocorticoid 
receptors, and hippocampal (pro-inflammatory) cytokine accumulation.(89) 
Interestingly changes in glucocorticoid receptors in the hypothalamic-pituitary-adrenal 
axis are also demonstrated to be involved in the pathophysiology of depression.(185)  
Corticotrophin releasing hormone, a vital mediator of the hypothalamic-pituitary-
adrenal axis and the stress response, is also thought to have a role in mediating IBS 
symptoms. It has been shown to modify components of the inflammasome, a receptor 
complex that initiates inflammation responses to the presence of pathogens causing 
visceral hypersensitivity and increased GI epithelial barrier permeability.(186, 187) 
Corticotrophin releasing hormone and Nerve Growth Factor (NGF) are also both 
implicated in the pathogenesis of IBS caused by early adverse life events.(188, 189) NGF 
is a neurotrophic factor that is primarily released by mast cells in the GI mucosa. Mast 
cells are a component of the innate immune system, activated in times of stress.(190) 
Corticotrophin releasing hormone has also been implicated in altered colonic motility in 
IBS patients,(108, 191) as it can activate peripheral neurons which project to both the 
CNS and the parasympathetic nervous system (a part of the peripheral nervous system; 
in the GI tract this is mainly vagal nerve fibres). These vagal afferents innervate the 
descending colon and therefore are able to alter colonic transit (191) and are sensitive to 
stress; as mentioned earlier. Vagal activity has shown to be dysregulated in IBS patients. 
During stress responses it is thought that (at least some) IBS patients exhibit 
dysautonomia (or increased sympathetic nervous system activity and decreased 
parasympathetic activity), which has reportedly been correlated with circulating 
adrenaline.(192)  
1.6 Immune Activation and Inflammation 
Immune activation and low-grade inflammation have been associated with IBS for many 
decades after initial findings that patients who develop PI-IBS have an abnormal 
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inflammation response in their colonic mucosa during and after infection.(193) After this 
initial finding, alterations in the immune system and inflammatory responses in IBS 
patients have become both a common finding and is now common knowledge in IBS 
pathophysiology.(194) Increased abundance CD4+ and CD8+ T lymphocytes and 
increased expression of the gut homing integrin β have been observed in IBS patients. 
Additionally, increased levels of CD8+ lymphocytes have also been observed in the GI 
mucosa of these patients.(195, 196)  
A recent systematic review of 51 studies found evidence of increased numbers of 
activated T and B lymphocytes and increased mast cells in IBS patients, as well as an 
increase in the expression of the gut homing integrin β on these lymphocytes.(197) 
Activated T lymphocytes release pro-inflammatory cytokines. While there is significant 
heterogeneity between studies generally, IBS has been associated with a dysregulation of 
pro- and anti-inflammatory cytokines,(198-201) particularly overexpression of the pro-
inflammatory Interleukin (IL)-6 (198) and under-expression of the anti-inflammatory IL-
10.(202) Furthermore, circulating white blood cells from IBS patients have been reported 
to express pro-inflammatory cytokines (tumour necrosis factor (TNF)-α, IL-1β, and IL-6) 
when unstimulated, and increased IL-6 when stimulated with LPS compared to healthy 
controls.(200) Stimulation of IL-6 results in a maximal induction of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) activation and its translocation into the 
nucleus and subsequent production of pro-inflammatory cytokines perpetuating 
inflammation.(203)  
While there may be little nonspecific inflammation or no macroscopic histological 
abnormalities in IBS patients, immunohistological studies report increases in activated 
lymphocytes in the lamina propria.(204) This finding suggests dysregulation of both the 
systemic and local mucosal immune systems in IBS patients creating low-grade 
inflammation. However, the mechanism of these responses are likely different in different 
patients as significant heterogeneity, and poor classification of IBS subgroups exist 
between different studies.(197) 
Low-grade inflammation potentially underpins visceral hypersensitivity in IBS patients 
through several different mechanisms. An increased number of mast cells have been 
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demonstrated to be near the myenteric plexus of patients with IBS, with visceral pain 
positively correlating with the physical closeness of mast cells to enteric neurons.(205, 
206) NGF also mediates visceral hypersensitivity by increasing the expression of the 
transient receptor potential cation channel subfamily V member 1 (TRPV-1), a pain 
sensor (nociceptor) in the GI mucosa.(207) Histamine (also released by activated mast 
cells) is also associated with increased visceral hypersensitivity.(208) When activated, 
mast cells also release 5-HT which regulates both GI motility and nociception, as well as 
mediators of inflammation.(209, 210) Additionally, increased GI epithelial barrier 
permeability has been associated with increased inflammation and immune system 
activation.(211) Exposure of the enteric nervous system (due to increased GI epithelial 
permeability) to luminal antigens can perpetuate a positive feedback loop of 
inflammation, visceral pain, and altered colonic motility. 
Low-grade inflammation in the GI mucosa can also be linked to the GI microbiota, which 
is emphasised by activation of enteric neurons following the application of bacterial 
supernatants from enteric mucosal biopsies.(212) Colonic biopsy supernatant from 
patients with IBS-D (but not IBS-C) was also shown to cause neuronal excitement via the 
protease signalling pathway.(213) More recently, a genetic predisposition for visceral 
hypersensitivity has been demonstrated in PI-IBS patients due to a polymorphism which 
produces an increased expression of ion channels known to be involved in the 
transmission of nociceptive signals to the CNS.(214) Intriguingly these are the same ion 
channels that become sensitised during inflammation.(215)  
However, while inflammation potentially has a role in triggering visceral 
hypersensitivity, it is not necessarily involved in its maintenance. A longitudinal study of 
inflammation in PI-IBS patients could not detect increased immune cell or inflammation 
cell counts or activation in colonic mucosa two years after infection. Although it was 
demonstrated that inflammation sensitises TRPV-1 receptors via activation of Histamine 
Receptor 1 (212, 216) suggesting that initial inflammation responses may sensitise 





IBS has been shown to aggregate in families. Having a first degree relative with a history 
of pain and changes in bowel habit is significantly associated with IBS and functional 
dyspepsia.(217) This observation lends support to the idea that both genetic factors and 
familial environment may contribute to the development of IBS.(218, 219) It was 
observed in a cohort of 686 pairs of Australian twins that 56.9% of the statistical variance 
in the resulting genetic model was attributed to genetic variance and the remaining 
43.1% to the environment.(220) Furthermore, it has been observed that children who 
have parents with IBS exhibit “illness behaviour” (the reporting of excess symptoms), 
which could be related to how solicitous parents are when children say they are ill or feel 
unwell. Children with parents who have IBS and responded solicitously to their child’s 
symptoms missed more school days and attended more doctors’ visits for investigation 
and management of their symptoms.(219) While this provides evidence for a certain 
degree of learned behaviour in individuals where family members have IBS, there is 
compelling evidence for genetic pathophysiologies. 
Large scale genome-wide association studies have implicated several single nucleotide 
polymorphisms that are risk factors for developing IBS and other FGID.(221) No single 
genetic cause of IBS has been discovered, which suggests it is more likely there are several 
different genetic factors that either lead to symptoms associated with FGID or predispose 
patients towards these symptoms that become apparent under certain environmental 
stressors (such as stress).(222) A polymorphism of the TNF Superfamily member 15 gene 
identified as a risk factor for the development of inflammatory bowel disease (i.e. Crohn’s 
disease and ulcerative colitis) has been found to be present in IBS populations at a higher 
rate than control populations.(223, 224) This gene codes for the TNF-like ligand 1A 
protein (a member of the TNF superfamily), whose binding to its receptor causes a 
stimulatory effect in CD4+ T lymphocytes and augments inflammatory responses. 
Dysregulation of the immune system and aberrant inflammation responses have been 
noted in many studies of IBS.(225) Polymorphisms of the TNF Superfamily member 15 
gene are thought to prolong inflammation responses, thereby causing adverse 
effects,(226) as detailed above. Polymorphisms in Toll-Like Receptor-9, IL-6 and E-
cadherin have been found to be a risk factor for PI-IBS (227) but this has been hard to 
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replicate in other IBS subtypes. IBS has also been associated with polymorphism of the 
Neuropeptide S Receptor 1 gene, which is involved in the synthesis of GI hormones (e.g. 
CCK, Peptide YY, Ghrelin) which is thought to impact the motility of the gut.(228) A single 
nucleotide polymorphism associated with the gene Klotho Beta has been associated with 
IBS-D. This gene is an important part of bile acid synthesis, and the polymorphism (a 
missense mutation) is thought to reduce bile acid synthesis which could ultimately lead 
to rapid colonic transit times and diarrhoea.(229) 
1.8 The Role of Diet in IBS 
While IBS pathophysiology is multifactorial, diet is known (or at least perceived) to 
trigger symptoms in most IBS patients. Between 70-90% (230, 231) of IBS patients 
believe that their diet or specific foods trigger their symptoms, and up to 62% (232) of 
IBS patients restrict their dietary intake of specific foods or entire food groups. No 
prospective studies of the causative role of foods or food components have been 
conducted for IBS, although a recent study found that food related immune activation, 
localised to the colonic mucosa is associated with abdominal pain in the small number of 
IBS patients included in the study (Aguilera-Lizarraga et al, 2021). Other studies have 
associated ‘Western’ diets (those higher in fats, sugars and processed foods) are 
associated with worsening IBS symptoms in cross-sectional studies (Eslampour et al, 
2021; Buscail et al, 2017; Black and Ford et al, 2020). 
A potential physiological basis for worsening of IBS symptoms after meal consumption 
could be alterations of enteroendocrine cells and the hormones via enteroendocrine cell 
signalling to the enteric nervous system, autonomic nervous system, and CNS. Differences 
in the secreted and circulating levels of GI hormones and neurotransmitter have been 
observed in IBS patients, and differences between IBS subgroups have been found. The 
changes to GI hormones compared to healthy populations could be due to several factors. 
These include CNS, autonomic nervous system and enteric nervous system control of 
enteroendocrine cell secretion, increases or decreases in the population of 
enteroendocrine cells and the density of enterochromaffin cells in the GI tract.  
Studies of GI hormones are, however, inconsistent. Some finding increased circulation of 
(for example) 5-HT or increased counts of cells containing 5-HT, some finding decreased 
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circulation and cell counts, others finding no differences between their IBS cases and 
healthy controls. However, it was also shown that concentrations of GI hormone in IBS 
patients differ between countries.(131) These differences could be due to different 
genetics, different exposures to pathogens during childhood, or inherently different diets. 
Notably, many of these studies do not consider habitual diet, as it was demonstrated that 
decreased numbers of enterochromaffin cells in IBS patients were normalised towards 
that of a control population after undertaking a therapeutic diet for three to nine 
months.(134, 233)  
1.8.1 The Habitual Diet of IBS Patients  
Generally, the habitual diets of IBS patients have been found to be nutritionally adequate 
regardless of dietary restrictions, but some differences in habitual consumption of diets 
have been reported in different populations of IBS patients. A cross-sectional study of IBS 
patients in the Netherlands found that, compared to the general population, IBS patients 
had diets lower in fibre and fructose but higher in fat, added sugars, and energy.(234) 
This finding is contradicted by a similar study in Swedish IBS patients which found few 
differences in macronutrients to the general public, but IBS participants had increased 
micronutrient intake.(235) Similarly, the dietary intake of IBS patients in the United 
Kingdom met the United Kingdom dietary reference values and showed adequately 
balanced, macronutrients, but micronutrient intakes which exceeded the reference 
nutrient intakes.(236) A North American study also found no differences in 
macronutrients compared to an age-matched population, but did find that IBS patients 
had higher copper: zinc ratios than controls.(237)  
Foods that IBS patients typically perceive to trigger their symptoms includes fruits and 
vegetables, spicy foods, fatty foods, and foods containing dairy.(230, 235, 238) IBS 
patients were reported to ingest fewer fruits than healthy controls by Lee et al.,(238) 
Tigchelaar et al.,(234) and Mazzawi et al. (133) but another study reported that they 
consume more fruit.(235) Decreased ingestion of pasta, alcohol, and vegetables (that 
were high in fermentable carbohydrates) and lower intakes of meat and dairy-containing 
products were also reported.(133, 234, 238)  
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Different foods have been found to be associated with GI symptoms in different IBS 
subtypes. For example, IBS-D participants had higher symptom scores with lower fibre 
consumption (234) and higher consumption of fruits, berries, carbonated drinks, and 
alcohol.(239) IBS-C participants have a positive correlation of abdominal discomfort and 
constipation with apple consumption and a positive correlation of flatulence with cereal 
consumption.(234) Increased symptom severity was also associated with higher 
vegetable and potato intake in IBS-C patients.(239) IBS-M participants experienced a 
negative correlation between gingerbread (a traditional breakfast food or snack in the 
Netherlands) and discomfort and pain. In contrast, a positive correlation existed between 
apples and discomfort,(234) and an increased overall symptom severity was associated 
with vegetable intake in IBS-M patients.(239) 
1.8.2 How do Foods cause Symptoms? 
1.8.2.1 Allergy and Intolerance 
The actions of food in causing symptoms in IBS patients has been studied extensively, 
particularly the role of allergy and intolerance. Food allergies are considered dramatic, 
acute reactions to food in which immunoglobulin (Ig) E causes mast cell degranulation 
shortly after the offending food has been ingested. IgE is thought to have evolved as a 
defence against venoms, but more commonly is known for its role in Class 1 
hypersensitivity (allergic reactions). Allergic reactions are triggered by re-exposures to 
dietary antigens and are usually accompanied by pain and vomiting as well as extra-GI 
symptoms such as headache, wheezing, rashes, or anaphylaxis. There is also some 
evidence that IgG and its subtype IgG4 also mediate allergic reactions.(230) However, the 
role of allergy mediated by both IgE and IgG in IBS pathophysiology remains a 
contentious and disputed topic.(240)  
In contrast, food intolerances are non-IgE mediated, instead caused by excessive cytokine 
production by antigen-presenting cells or T-lymphocytes that are activated by food 
antigens. As such, these responses tend to be more chronic than allergy-mediated 
responses. Unfortunately, laboratory testing for allergy and intolerance tends to be 
unreliable and have a high false-positive rate.(241) The prevalence of true food allergy is 
not higher in IBS patients compared to the general population.(242-245) While around 
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20% of the general population report themselves as having a food intolerance this is 
considered a gross overestimation, with the true prevalence thought to be under 
6%.(246)  
While IgE mediated atopic diseases, such as eczema, asthma, and animal dander allergies 
have been shown to be associated with IBS,(247, 248) the presence of IgE was not 
associated with IBS symptom severity.(248) However, recent evidence indicates a role 
for the activation of mast cells and sensitisation of histamine receptors following 
bacterial infection, leading to the development of food-specific IgE localised to the GI 
mucosa. This evidence suggests a model for food-related abdominal pain in IBS patients, 
where repeated exposure to food to which a patient has developed IgE causes a localised 
mast cell reaction and subsequently pain via sensitised histamine receptors.(249) This 
finding is certainly an attractive mechanistic model of visceral hypersensitivity caused by 
food, however it is likely to be relevant only to a subset of immunogenically reactive IBS 
patients.(249, 250)  
A case has also been made for IgG and IgG4 in the onset of IBS symptoms, however these 
results remain controversial and their significance debated.(251) IBS patients have been 
found to have more circulating IgG specific to food antigens compared to control 
populations.(252) Zar et al. reported that IBS participants had more IgG4 antibodies for 
wheat, beef, pork, and lamb compared to healthy controls,(243) while Zuo et al. found 
increased IgG antibodies specific to crab, egg, shrimp, soya bean, and wheat compared to 
controls.(253) A double-blind randomised trial of 150 IBS participants who had positive 
IgG test for specific food antigens was conducted where these participants were 
randomised to a diet that excluded the specific foods that they had IgG antigens for or a 
sham diet. The specific exclusion diet resulted in a 26% reduction of symptoms when 
compliant to the diet.(254) These findings are, however, controversial. Other studies 
have found no differences in food-specific antibodies between IBS and control 
participants (239) or found that the reported food intolerance was largely a placebo 
effect upon reintroducing ‘trigger’ foods.(255) These findings compound the issues that 
plague food-related studies, namely that these studies often have inappropriate control 
populations or do not take IBS subgroups into account. It also lends some credence to the 
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theory that the food-specific IgG antibodies found in IBS patients may reflect the patient’s 
habitual diets as these antibodies are also found in control populations.(239) 
1.8.2.2 Gluten, FODMAP and Fibre 
Gluten is one of the food components that IBS patients often perceive as a trigger for their 
symptoms. The generation of an autoimmune response due to the presence of gluten is 
the pathophysiological cause of coeliac disease, which has some symptoms that mirror 
IBS symptoms, albeit with associated macroscopic and microscopic changes to the small 
bowel.(256) The similarities in symptomatology have resulted in many studies 
investigating the potential of gluten as a pathophysiological factor in IBS.(257-259)  
The polymorphisms that are considered to create genetic susceptibility to coeliac disease 
are common in the general population. These polymorphisms are in the HLA-DQ gene 
(which encodes for surface protein on antigen-presenting cells) called HLA-DQ2 positive 
or HLA-DQ8 positive depending on the polymorphism. HLA-DQ2 or -8 positivity has been 
found to be predictive of whether an IBS-D patient will respond to a gluten-free diet.(260) 
However, the prevalence of true gluten allergy or intolerance in IBS is thought to be 
low.(259) Wheat-containing products (which is the part of the diet that often contains 
gluten) also contain other potentially antigenic or symptom inducing components, 
notably fructooligosaccharides (fructans, a poorly absorbed carbohydrate). While IBS 
symptoms typically improve when following a gluten-free diet,(259) a study by 
Biesiekierski et al. found that when IBS patients were already following a diet low in 
poorly absorbed carbohydrates, the increase in the severity of symptoms reported after 
re-challenge with either whey protein or gluten did not differ between the two.(261) 
Interestingly, a further study by Skodje et al. also demonstrated that IBS patients had 
worse symptoms when ingesting a fructan-containing product compared to a gluten-
containing product or placebo.(262)  
Over the last 15 years there has been increasing evidence concerning the efficacy of low 
FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) 
diets which have shown to consistently alleviate IBS symptoms.(263) The two 
mechanisms through which FODMAP are thought to induce GI symptoms in IBS patients 
are: firstly, through osmotic actions in the small intestine (264, 265) and secondly 
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through rapid fermentation by the GI microbiota in the proximal colon.(266) These 
effects cause increased water content and gas production (respectively) producing 
luminal distension which can be perceived as pain in patients with pre-existing visceral 
hypersensitivity.  
A high FODMAP diet has been shown to increase GI epithelial barrier permeability in 
healthy animal models, potentially through an increased abundance of inflammation-
inducing bacterial antigens.(267) In humans, physical changes following the direct 
application of food antigens to the small intestinal mucosa have been reported to cause 
increased intra-epithelial lymphocyte recruitment and loss of GI epithelium barrier 
integrity minutes after antigen application in IBS patients but not in healthy 
controls.(268) This increased permeability could enable luminal bacterial antigens to 
enter the systemic circulation and induce a low-grade inflammatory response (through 
mast cell and intra-epithelial lymphocyte recruitment and activation), impacting visceral 
hypersensitivity and GI motility. These observations lend credence to the idea that IBS 
pathogenesis is multifactorial and that the action of FODMAP in individuals could be 
induced by increased GI epithelial barrier permeability rather than by increased bacterial 
gas production. 
However, the restriction of FODMAP in the diet does have ramifications for the GI 
microbiota.(267) Habitual diet shapes the GI microbiome and, additionally, some 
FODMAPs act as prebiotics for the GI microbiota, restriction of FODMAPs has therefore 
been associated with altered composition of the microbiota. A 50% reduction in FODMAP 
ingestion led to a 6-fold reduction in the relative abundance of Bifidobacteria in IBS 
patients compared to controls.(269) Another study found that the total bacterial load and 
absolute abundance of Bifidobacteria were reduced by a 3 week restriction of FODMAPs 
(270). A decreased relative abundance of B. longus and B. adolescentis and reduced 
absolute abundance of F. prausnitzii were found in participants consuming a low 
FODMAP diet compared to a sham diet.(269, 271, 272) While altered breath hydrogen 
has been demonstrated, indicating a shift in GI microbiota fermentation patterns (269), 
studies also often report that alpha diversity of the GI microbiome is not altered by 
restriction of FODMAPs in the diet.(273) Additionally, studies report no difference in the 
by-products of bacterial fermentation (SCFA).(274-276) Notably, most low FODMAP diet 
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studies are less than six months duration and the long term consequences of this 
disruption to the composition and potentially the metabolism of GI microbiota are 
unknown.(277)  
Dietary fibres are indigestible carbohydrates of plant origin which can be divided into 
two categories, soluble and insoluble. Soluble fibres can subsequently be further divided 
into a viscous and non-viscous fibre. Dietary fibre increases GI transit time and laxation 
through providing increased bulk to the digesta, triggering mechanoreceptors that reside 
in the myenteric and submucosal plexus and therefore triggering peristalsis.(278, 279)  
Historically IBS was considered a disorder of the urban shift away from an agrarian 
lifestyle associated with a reduction in dietary fibre, and therefore fibre has been 
prescribed for relieving symptoms of IBS for many years.(280) As mentioned above, IBS 
patients in the Netherlands were found to ingest less dietary fibre than healthy controls 
(234) while others found no difference,(133) and yet others found increased fibre 
intake.(235) A systematic review which evaluated the use of fibre to treat IBS symptoms 
found that while fibre supplementation does reduce IBS symptom severity, this is limited 
to soluble fibre.(281) Another systematic review has found that fibre effectively relieves 
IBS symptoms, particularly soluble fibre, particularly for constipation. However there 
was no improvement in pain symptoms found and insoluble fibre was associated with 
worsening IBS symptoms.(281, 282) 
Fibre is the major dry weight component of the digesta when it reaches the caecum as it 
is indigestible to humans. It is therefore available for digestion by certain bacteria. The 
end products of this process are then available for absorption into the colonic epithelium. 
One category of these end products, SCFA, and particularly butyrate, is considered 
important for the health of the colonic epithelium for several reasons. Butyrate is the 
primary energy source of colonocytes and has the well-documented ability to suppress 
inflammation via the inhibition of the NF-κB pathway, increase mucin production, and 
decrease mucosal permeability. This last function is thought to be due to upregulation of 
tight junction (TJ) proteins.(283) Levels of butyrate in stool samples are reportedly 
decreased in IBS patients,(284) which could reflect low fibre intake and/or fewer 
butyrate-producing bacteria in IBS patients.(140) Reductions in butyrate production are 
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thought to affect GI motility and sensation and increase GI epithelial barrier 
permeability.(285-287) 
1.9 The Role of Microbial Metabolites in IBS 
The interactions between the diet, the GI tract and its commensal bacterial population 
can confer health benefits or detrimental effects to an individual. Historically, the 
products of these interactions were seen as either saccharolytic (beneficial) or 
putrefactive (detrimental).(288) Increases of putrefactive bacteria in the GI tract, 
brought about by ingesting meat or an unhealthy diet were viewed as the cause of 
symptoms experienced by some individuals. Therefore, IBS has been associated with 
dysbiosis of the GI microbiota for many years. The metabolites produced by the 
microbiota in response to dietary-modulated changes in their composition and activity 
are potentially involved in the pathophysiological mechanism of IBS symptoms. 
1.9.1 Microbial Metabolites in IBS Patients  
1.9.1.1 Bile Acids  
A meta-analysis found that bile acid malabsorption is present in 16.9-35.3% of IBS-D 
patients.(289) In agreement with this, a recent longitudinal study reported that there 
were significantly higher amounts of unconjugated primary bile acids in stool samples in 
IBS-D and lower amounts in IBS-C patients. This study also found that primary bile acids 
were elevated during symptomatic ‘flares’ in IBS-D and IBS-C patients.(290) Primary bile 
acids are produced in the liver (cholic acid and chenodeoxycholic acid). These are 
deconjugated from their glycine or taurine conjugate by microbial bile salt 
hydrolases.(289) 95% of bile acids are then reabsorbed and recycled, the remaining 5% 
becomes a substrate for bacterial modification.(291) Some forms of bile acids, such as 
hydroxylated bile acids, have been found to increase fluid secretion into the GI lumen, 
and therefore could be a physiological mechanism for bile acid-induced diarrhoea found 
in IBS-D patients.(292) Studies have also shown increased concentrations of different 
secondary bile acids in the plasma and faeces of patients diagnosed with IBS-D relative to 
IBS-C and controls (Wong et al, 2012; Shin et al, 2013; duboc et al, 2012). Additionally, 
IBS-D patients with bile acid malabsorption were more likely to have a shift in their gut 
30 
 
microbiota that correlated to changes in their faecal microbiota and diet (Jefferies et al, 
2020). 
1.9.1.2 Purines  
Using a metabolomic approach to identify novel microbial pathways in IBS 
pathophysiology, Mars et al. recently demonstrated that faecal lysine and uracil were 
decreased in IBS-C and faecal hypoxanthine was decreased in IBS-C and IBS-D 
participants compared to controls.(290) Hypoxanthine is thought to serve as a 
colonocyte energy source and promote GI epithelial barrier development.(293)  
Subsequent interrogation of metagenomics data in IBS patients by Mars et al. found 
increased xanthine dehydrogenase/oxidase and xanthine phosphoribosyl transferase in 
faecal samples of IBS-C participants, suggesting increased purine breakdown by the GI 
microbiota in IBS patients. Interestingly, the expression of the xanthine oxidase gene was 
elevated in colonic biopsies in both IBS-D and IBS-C participants compared to healthy 
controls. This finding suggests that depletion of the hypoxanthine pool could also result 
from increased xanthine oxidase activity from both the GI microbiota and the host.(290) 
GI epithelial cells rely mostly on salvage pathways for purines rather than biosynthesis, 
suggesting that an elevated degradation of purine nucleotides by GI microbiota and the 
host induces metabolic stress in colonic tissue.(294) This stress effect could also lead to 
a compensatory response by increased purine salvage, potentially leading to low energy 
states of colonocytes and lower capacity for mucosal repair.(290)  
1.9.1.3 Hydrogen and Methane 
Hydrogen is produced by GI microbiota fermentation of carbohydrates, which can be 
further metabolised to create hydrogen sulphide and methane gas by sulphate reducing 
bacteria or methanogens, respectively.(295) No difference has been found in the 
production of hydrogen gas between IBS cases and controls, the symptoms associated 
with hydrogen production are considered to be associated with luminal distension of in 
IBS patients who experience visceral hypersensitivity.(Symons et al, 1992; Tuck et al 
2018) Conversely, the production of methane was associated with longer transit times 
and constipation.(296) While antibiotics were able to relieve constipation symptoms in 
methane gas-producing IBS patients (153) potentially implicating methane-producing 
31 
 
Archaea in constipation, it appears that methane gas is sufficient to slow colonic 
transit.(297)  
1.9.1.4 Short-Chain Fatty Acids  
SCFAs are the product of the fermentation of undigested carbohydrates by bacteria in the 
colon. These include acetate, propionate, and butyrate which are reported as generally 
being produced in a ratio of 60:25:15 Moles. Lactate is also often produced as a by-
product of bacterial fermentation which can be cross-fed to other bacterial species to 
produce acetate, propionate, butyrate. Production of SCFA are associated with a luminal 
decrease in the pH of the colon, which is associated with the inhibition of pathogenic 
bacterial growth and increased nutrient absorption (Macfarlane et al, 2012).  Acetate is 
taken up primarily by the liver and used as a substrate for cholesterol and fatty acid 
synthesis, it is also metabolised in skeletal muscle. Propionate is also taken up by the liver 
and is used in gluconeogenesis. Butyrate is utilised as the primary energy source of 
colonocytes and has multiple functions in maintaining the gut epithelial barrier, initiating 
apoptosis of cancer cells, and regulating the immune system (Martin-Gallausiaux et al, 
2020; Blaak et al, 2020; Bloemen et al, 2009; Rauf et al, 2021). 
The bacteria that produce butyrate represent bacteria with similar functions rather than 
a closely related genus, family or phylum.(298) Well documented, and highly abundant 
butyrate-producing bacterial species in the human gut include F. praunitizii, Roseburia 
intestinalis, Butyrivibrio fibrisolvens, Eubacterium hallii and Eubacterium rectale.(298) 
Once produced, butyrate is efficiently absorbed into the colonic mucosa either by passive 
diffusion or by active transport via monocarboxylate transporters or by Solute Carrier 
Family 5 member 8 (vitamin B3 receptor). As such, only a small proportion of the 
butyrate synthesised is excreted in bowel motions.(299)  
Butyrate has well known anti-inflammatory properties which are mediated through its 
ability to suppress inflammatory reactions and its ability to regulate gene expression via 
its role as a Histone Deacetylase inhibitor.(299, 300) The ability of butyrate to suppress 
inflammation has been demonstrated in both cell lines and animal models. In these 
models the application of butyrate at physiological concentrations has been shown to 
increase trans-epithelial electrical resistance (TEER) and decrease permeability.(286, 
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301-303) While there are several putative mechanisms for this, several studies have 
implicated activation of 5’ adenosine monophosphate-activated protein kinase (AMPK), 
a cellular energy gauge. Activation of AMPK by butyrate has been implicated in regulating 
the assembly of TJ proteins at the cellular membrane (303) and in preventing the 
phosphorylation of myosin light chain (MLC) II. The phosphorylation of MLC II causes 
contraction of the actomyosin cytoskeleton, which in turn increases mucosal 
permeability in the GI tract.(304) The activation of AMPK by butyrate may also provide 
the energy required in colonocytes for the energy-intensive actions of TJ protein 
synthesis.(301)  
Furthermore butyrate binding to GPR43 and subsequent activation of the inflammasome 
has been associated with upregulation of the Zonula Occludens-1 (ZO-1) and Occludin 
(OCLN).(305) In a porcine jejunal cell line, butyrate also downregulated the expression 
of Toll-Like Receptor-4 by suppressing LPS stimulation of this pathway.(306) Butyrate 
was also shown to upregulate the expression of Claudin (CLDN)-1, -3 and -4 in this study. 
When LPS binds to Toll-Like Receptor-4, it activates the NF-κB pathway leading to the 
production of pro-inflammatory cytokines. Butyrate has been shown to not only decrease 
the expression of Toll-Like Receptor-4 in cells (307) but also to inhibit the NF-κB pathway 
by stabilising the inhibitory subunit of the NF-κB protein complex and therefore 
preventing an immunological response.(308, 309) Interestingly, in a mouse model of 
colitis, butyrate increased the acetylation of histone H3, effectively reducing NF-κB 
function as a transcription factor.(309) 
Butyrate is a potent histone deacetylase inhibitor and influences gene transcription by 
loosening chromatin wrapping around histones, allowing transcription factors to access 
SP1 and SP3 promotor sites. In its role as a histone deacetylase inhibitor, butyrate also 
increases the expression of the Mucin 2 gene, an essential component of the GI mucus 
layer.(310) CLDN-1 gene expression was shown to increase by a factor of 10 when 
cultured cells were treated with butyrate. A chromatin immunoprecipitation assay 
confirmed a direct association between the SP1 site and the CLDN-1 promoter region, 
indicating that butyrate increased CLDN-1 expression at a transcriptional level.(286) The 
role of butyrate as a histone deacetylase inhibitor is also demonstrated in colonic tissue 
from ulcerative colitis patients. Their symptoms are associated with hyper-activation of 
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the NF-κB pathway linked to increased interferon (IFN)γ production by T lymphocytes 
that accumulate in the colon. In animal models of ulcerative colitis, butyrate induces T 
lymphocyte apoptosis via the inhibition of Histone deacetylase 1, bound to the Fas 
promoter region. The subsequent increase in Fas expression in these T lymphocytes led 
to apoptosis activation and eventual cell death, reducing inflammation.(311) 
Furthermore, butyrate has been implicated in the activation of the inflammasome (via 
binding to G protein Coupled Receptor (GPR) 109A) leading to the differentiation and 
activation of T lymphocytes that produce (the anti-inflammatory cytokine) IL-10.(305)  
1.9.2 Butyrate Metabolism in IBS 
Reduced butyrate production has been observed in IBS patients. Undseth et al. found that 
IBS patients had less serum propionate, acetate, and butyrate than healthy controls,(312) 
while Mars et al. found reduced butyrate concentrations in stool samples from IBS-C 
patients.(290) These results are corroborated by Sun et al. who also found decreased 
butyrate in faecal samples from IBS-C patients. They also found increased butyrate in IBS-
D and –M patients.(313) Conversely, Pozuelo et al. found that IBS patients, particularly 
IBS-D and IBS-M patients, were characterised by decreased butyrate production.(142) 
The beneficial effect of butyrate in IBS and healthy subjects have been noted in several 
studies. Vanhoutvin et al. found that self-administered butyrate enemas in healthy 
individuals reduced pain and discomfort during a rectal barostat test in a dose-dependent 
manner.(314) In animal models of colitis, butyrate was found to decrease abdominal pain 
and inhibit inflammation through both AMPK activation and inhibition of heat shock 
protein 70 and the NF-κB pathway.(315-318) In IBS patients, oral butyrate ingestion 
decreased abdominal pain, urge after defecation, and increased quality of life with no 
adverse events.(319)  
Interestingly several animal studies have indicated that butyrate may also increase 
visceral hypersensitivity. Tarrerias et al. using a rat model of colitis showed that animals 
given butyrate enemas of 40mMol twice a day for 14 days had increased pain duration 
when visceral hypersensitivity was tested. Visceral hypersensitivity in these animals was 
independent of increased inflammation.(320) This finding is consistent with a study that 
showed that rats treated with butyrate had dose-dependent colonic hypersensitivity and 
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referred cutaneous mechanical hyperalgesia responses.(321) The discordance between 
in vitro and in vivo studies has been termed the “butyrate paradox”.(322) Interestingly, it 
has been demonstrated that butyrate can cause colonic hypersensitivity in an NGF 
dependent manner.(323) Butyrate is known to increase the expression of NGF,(324) 
which binds to sensory neurons causing nociception. Additionally, unlike many microbes 
or microbial metabolites, butyrate can directly bind to and activate vagal afferent nerves 
in the GI wall.(325) 
There exists many inconsistencies in the effect of butyrate in the generation of worsening 
or alleviating visceral hypersensitivity, as well as reported increased or decreased 
amounts of butyrate in different populations of IBS patients relative to control 
populations.(142) The amount of detectable butyrate in faecal samples could be affected 
by several variables, these include the composition and function of the GI microbiota 
(142, 313), of which, as previously mentioned, a subset produce SCFA as a by-product of 
fermentation). Additionally, the amount of dietary fibre in the habitual diet will affect the 
amount of SCFA produced by the GI microbiota.(326) Colonic transit is another major 
factor in the amount of butyrate able to be detected in faecal samples. As butyrate is 
efficiently absorbed by the GI epithelium, slower colonic transit allows an extended 
period of time for absorption to occur, leaving less butyrate to be detected in stool 
samples.(313, 327) Conversely, fast colonic transit could have increased detectable faecal 
butyrate. Diet, GI microbial composition and colonic transit time are rarely assessed or 
adequately controlled for in studies of butyrate concentration in humans which could 
explain the variation and inconsistencies present in literature. Regardless, literature 
indicates that butyrate supplementation in FGID and IBD patients relieves symptoms 
suggesting patients may benefit from butyrate supplementation .(326) However, the 
mode of application of butyrate supplementation needs to be thoroughly assessed in 
well-designed in-vivo studies as inconsistencies between oral butyrate supplementation 
and supplementation via enema would likely confound these results.(328-330) 
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1. 10 Gastrointestinal Permeability in IBS patients 
1.10.1 What is the Gastrointestinal Epithelial Barrier? 
The GI epithelial barrier has a vital role in maintaining the homeostasis of the GI tract and 
the lamina propria. The GI tract is the largest surface of the human body that interacts 
with the external environment. The environment of the lumen includes antigens from 
ingested food, as well as antigens, toxins, and the GI microbiota. The GI epithelial barrier 
therefore must simultaneously prevent the unchecked diffusion of the luminal contents 
into the peripheral circulation while permitting nutrients and water through. This barrier 
involves several different elements; facing the lumen is the GI microbiota. These bacteria 
protect the GI epithelial barrier by competing with pathogenic bacteria for space and 
nutrients and by secreting anti-microbial peptides. These bacteria live in and on the 
mucus layer, which itself contains two layers. The outer mucus layer, a loose and watery 
mucus, functions as a home and food for bacteria and lubrication for the luminal contents. 
The inner mucus layer resides next to the GI mucosa and contains immunoglobulins and 
anti-microbial peptides. The inner mucus layer is sterile, providing distance between the 
GI microbiota and the colonocytes that form the GI mucosa.(331)  
The mucosa of the colon consists of a monolayer of cells and provides a physical barrier 
between the luminal contents and the rest of the body (the GI epithelial barrier). This 
monolayer consists mainly of colonocytes, as well as enteroendocrine cells (neuro-
immune cells) and goblet cells (mucus producers). Colonocytes are bound together in a 
sheet by intracellular and transmembrane proteins forming adherens and tight junctions 
(TJ) between cells and attach to the actin cytoskeleton within the cells.(332) Nutrients 
cross the GI epithelial barrier through specific or non-specific transporters on the surface 
of these cells, or certain small solutes can diffuse through the membrane via the 
paracellular ‘leak’ pathway. Paracellular transport is limited by the protein composition 
of TJ between the colonocytes, which differs in different body tissues. However, genetics, 
inflammation, or infection can lead to the widening of the paracellular space, allowing 
bigger proteins or bacteria to pass through the GI epithelial barrier.(211) 
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1.10.2 What are Tight Junctions? 
Humans have around 40 proteins that can be inserted into TJ complexes, differences how 
these proteins interact create smaller or larger paracellular spaces,(333) creating 
differences in physiology between tissues. For instance, the small bowel is naturally 
‘leakier’ than the colon as it absorbs the vast majority of the nutrients. TJ are the apical-
most part of the GI epithelial barrier and define the apical to basal polarity of cell 
membranes as well as gate-keeping the paracellular space, only allowing small solutes 
past the apical membrane. Adherens and gap junctions are usually formed underneath 
TJ, with desmosomes forming under these. The actomyosin cytoskeleton forms a 
circumferential belt around cells that form the GI epithelial barrier and interacts with 
intracellular TJ proteins, which is vital for mechanosensing and mechanotransduction in 
these cells.(334) Therefore, the gate-keeping function of TJ can be modified via the 
contractions of or physical stressors to the actomyosin cytoskeleton in these cells. Three 
of the most well defined TJ proteins are the CLDN superfamily, OCLN and ZO-1 (referred 
to collectively as TJ components). 
1.10.2.1 Claudins 
CLDN proteins are considered the ‘backbone’ of TJ. There are at least 18 different 
members of the CLDN superfamily in humans and differential expression of isoforms is 
the main driver of differences in paracellular permeability in different tissue types. These 
proteins are transmembrane and therefore have both intracellular and extracellular 
structures. The transmembrane portion of the proteins either homodimerise or 
heterodimerise with different CLDN isoforms or with OCLN. CLDN-2, -7, and -12 have 
been shown to increase paracellular permeability while CLDN-1, -3, -4, -5, and -8 decrease 
paracellular permeability.(335)  
1.10.2.2 Occludin 
Similar to CLDNs, OCLN proteins dimerise either with themselves or with CLDN isoforms. 
However, the presence of OCLN always decreases the permeability of the tissue it is 
expressed in.(336) Cell line experiments in which cells only express OCLN at the TJ show 
that these cells can only form focal adhesions (337) and, therefore, OCLN is unable to 
form a TJ by itself. Animal models in which OCLN has been knocked down show a wide 
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variety of phenotypes, however, all mucosal layers form normally in these animals 
demonstrating that OCLN is not vital for the development of epithelial layers. These 
animals do show an increased likelihood of developing gastritis suggesting increased GI 
epithelial permeability.(338)  
1.10.2.3 Zonula Occludens 
The ZO family consists of intracellular scaffold proteins that connect the transmembrane 
TJ proteins to the actomyosin cytoskeleton. ZO-1 plays a vital role during vertebrate 
embryonic development (339) and in gene transcription for cell cycle progression.(340, 
341) The interaction of ZO-1 proteins with actin and transmembrane proteins is thought 
to regulate TJ functions and organise TJ structure.(341) There is also evidence that ZO-1 
plays a vital role in the recruitment and integration of CLDNs, OCLN, and proteins into TJ 
in a tissue and time sensitive manner.(342) 
1.10.3 The Role of Gastrointestinal Permeability in IBS 
Increased permeability of the GI epithelial barrier during inflammation or infection is 
well documented, and ultrastructural changes to TJ have been observed in different 
diseases. IBS, by definition, is diagnosed by exclusion of organic disease and, therefore, 
the colonic and small intestinal mucosa of IBS patients is macroscopically normal. It is 
difficult to elucidate mechanisms of IBS pathophysiology both due to its multifactorial 
nature and as a dysregulation of the BGA. However, a recent systematic review by 
Hanning et al. has demonstrated that increased epithelial permeability in the GI tract is 
consistently observed in IBS patients.(343) The effects include decreased TEER, a 
measure of increased GI epithelial permeability, in GI biopsies and increased ‘leakage’ of 
GI epithelial barrier.(257)  
Functional, in-vivo measures of GI barrier permeability involve ingestion of indigestible 
probe molecules which are excreted in urine. Monosaccharides are often used as probes 
in combination with disaccharides; the difference in size results in increased 
permeability of monosaccharides compared to the larger disaccharides. An increased 
ratio of monosaccharide:disaccharide excretion in the urine therefore would reflect 
increased GI barrier permeability.(343) Small bowel permeability is often measured 
using mannitol and lactulose while large bowel permeability has been measured by 
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sucralose ingestion (as sucralose is not fermented by the GI microbiota).(344, 345) Ex-
vivo measures of GI barrier permeability involve the use of small or large bowel biopsies 
in Ussing chambers in which the flux of probes across the GI barrier, or the TEER is 
measured.(211, 346) 
Studies comparing TJ proteins and GI permeability are shown in Table 1.2. Paracellular 
permeability assessed by TEER of biopsies from IBS patients also correlates with GI and 
extra-GI symptoms.(216, 347) Studies reporting these correlations are shown in Table 
1.3. Therefore dysfunction of the GI epithelial barrier could be a pathophysiological 
mechanism in at least a subset of IBS patients.  
Whereas TEER is noted in almost all studies to be decreased in biopsies taken from IBS 
patients, the mechanism(s) underlying increased permeability are inconsistent between 
different studies. One study reporting jejunal permeability in IBS patients showed that, 
ZO-1 and ZO-3 mRNA were decreased. In contrast, ZO-1 and ZO-2 protein levels were 
decreased and internalised (away from the cell membrane) indicating a breakdown or 
dysregulation of the ultrastructure of the TJ.(348) CLDN-2, a member of the CLDN 
superfamily associated with increased permeability, was upregulated compared to 
controls in these same biopsies. OCLN was found to be downregulated and internalised 
in these patients.  
The reduced gene expression of TJ proteins in IBS patients can allow microbes or 
microbial products (measured by circulating LPS and/or anti-flagellin antibodies(349, 
350)) through the GI epithelial barrier and into contact with enteric and autonomic 
nervous system nerve endings causing inflammation, immune responses, and pain.(351) 
Increased MLC phosphorylation was also found in IBS-D patients. Phosphorylation of 
MLC is related to contractions of the actomyosin skeleton.(348) Bertiaux-Vandaele et al., 
found no differences in gene expression (ZO-1, OCLN, CLDN-1) in colonic biopsies from 
IBS patients.  
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n, sample population; ZO1, zonula occludens 1; OCLN, occludin; CLDN-1, claudin-1; NGF, nerve growth factor; MLCK, myosin light chain kinase; pMLC, 
phosphorylated myosin light chain; IBS, irritable bowel syndrome; IBS-D, diarrhoea predominant IBS; IBS-C, constipation predominant IBS; IBS-M, mixed 
phenotype predominant IBS; IBS-U, undefined IBS; *children; †increased pain severity; SB, small bowel; RT-qPCR, real time quantitative polymerase chain reaction; 
IHC, immunohistochemistry; IF, immunofluorescence; H+E, Haematoxylin and Eosin stain; WB, western blot; ↓, decreased expression; ↑, increased expression; = , 
unchanged expression; I, protein internalised away from the periphery; p-OCLN, phosphorylated Occludin protein; =n, cell count; probe flux, increased 
permeability in small bowel or colonic biopsies; probe excretion, increased excretion of orally ingested probes, ↑ultrastructure, increased widening of gaps 






     Table 1.3: Studies reporting association of gastrointestinal symptoms or changes in bowel habit and increased gastrointestinal permeability 
Reference Rome Criteria n GI symptom 
GI symptom 
Description 
ΔBH ΔBH Description 
Zhou et al(364) III 76 (54 IBS-D) + permeability 
Functional bowel 
disorder  severity 








Mujagic et al(365) III 
186 (34 IBS-D; 21 
IBS–C; 30 IBS–M; 7 
IBS–U) 
+ permeability 








correlated with ΔBH 
Piche et al(351) II 
65 (17 IBS-D; 19 IBS-
C; 15 IBS-M) + permeability 
Abdominal pain (IBS-







83 (19 IBS-D; 14 IBS-
C; 15 IBS-M; 2 IBS-U) 





altered TJ proteins 
  




with altered TJ 
protein expression 
+ mast cell activation 




with mast cell 
activation and altered 
TJ protein expression 
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Reference Rome Criteria n GI symptom 
GI symptom 
Description 





46 (22 IBS-D; 12 IBS-
M) - JAM-A expression 
Pain Severity and 
symptom onset (IBS-
M) negatively 
correlated with TJ 
proteins 
  
Barbaro et al(366) III 
35 (9 IBS-D; b8 IBS–C; 





Lee et al(354) III 
95 (33 IBS-C; 21 IBS-
D; 5 IBS-M) - OCLN and CLDN-1 
Pain severity (IBS-C) 
correlated negatively 
with TJ proteins 
  














Reference Rome Criteria n GI symptom 
GI symptom 
Description 
ΔBH ΔBH Description 
Gecse et al(369) III 
53 (18 IBS-D; 12 IBS-
C; 13 Ulcerative 
Colitis) 







46( 22 IBS-D; 12 IBS-
M) 
E-cadherin 
Pain severity and 





n, sample population; GI, gastrointestinal; IBS, irritable bowel syndrome; IBS-D, diarrhoea predominant IBS; IBS-C, constipation predominant IBS; IBS-M, mixed phenotype 
predominant IBS,; IBS-U, undefined IBS; OCLN, occludin; CLDN-1, claudin-1; ZO-1, zonula occludens-1; JAM-A, junction adhesion molecule-A; E-cadherin, epithelial cadherin; 







They found reduced and internalised ZO-1 and OCLN protein expression and a positive 
correlation between OCLN and CLDN-1 protein expression and duration of IBS 
symptoms. There was also a negative correlation between ZO-1 mRNA and IBS 
severity.(353) Gender-specific differences may also exist between pathophysiological 
mechanisms of IBS, Lee et al. found that lower ZO-1 was associated with increased IL-1β 
in colonic biopsies taken from female IBS patients compared to males.(354)  
A next-generation sequencing study, which showed 3806 genes differentially expressed 
between IBS-D cases and healthy controls, used pathway analysis to reveal that genes 
related to TJ signalling were an important point of difference.(373) MicroRNAs-125b and 
16-5p were found to be significantly downregulated in IBS-D patients. These miRNAs 
have binding sites on CLDN-2, which was upregulated when the miRNAs were knocked 
out. Furthermore, miRNA expression was negatively correlated with bowel habit and 
mast cell count while CLDN-2 was positively correlated.(373) These differences observed 
between different studies could be an artefact of different populations, inclusion criteria 
and/or laboratory methodologies. However, it is also likely that increased mucosal 
permeability is caused by different mechanisms in different IBS populations and subtypes 
leading to similar GI symptoms. 
1.10.3.1 Microbiota and Permeability 
The ability of commensal bacteria to alter the expression of genes involved in the 
development and maintenance of the GI epithelial barrier is another potential mechanism 
of IBS pathophysiology.(374-376) As previously mentioned, in-vivo and ex-vivo testing 
of GI barrier permeability can be measured in the small and large bowel by the 
consumption of indigestible probes. or using the flux of a probe across the GI barrier of a 
biopsy. It is noteworthy that the composition and function of the microbiome is unlikely 
to be involved alteration of small bowel permeability where there is relatively little 
commensal bacteria in comparison to the large bowel.(377, 378) 
As inflammation is a known cause of increased GI permeability, it could also lead to a 
positive feedback loop of inflammation and increased GI epithelial barrier 




subsequent inflammation are known to be driven by dysbiosis in a subset of IBS 
patients.(380)  
Apart from inflammation driving these increases in permeability, there are well-
documented pathogens that create focal disruptions in the GI epithelial barrier during 
infection. For example, Clostridiodes difficile endotoxin A disrupts TJ by targeting and 
disrupting the actomyosin cytoskeleton leading to increased GI barrier 
permeability.(381) Conversely probiotic ‘good’ bacteria have shown to expedite the 
maturation of TJ in postnatal mice by promoting the expression of CLDN-3, which was 
shown to decrease permeability.(382) Lactobacillus rhamnosus GG, another common 
probiotic bacterium, has also been shown to protect against inflammation by 
upregulating ZO-2 (383) while Escherichia coli Nissle 1917 upregulates ZO-1 in a mouse 
model of colitis.(384) Interestingly, stimulation of the vagus nerve (which is known to 
have anti-inflammatory properties) has been shown to ameliorate and reverse the 
ultrastructural damage to TJ caused by intraperitoneal injections of LPS in mice. 
Increases in ZO-1 and OCLN abundance were also observed following vagal nerve 
stimulation.(385)  
1.10.3.2 Diet and Permeability 
A randomised, controlled trial of high- and low-gluten diet was carried-out with IBS-D 
patients. These patients were genotyped to determine if they were HLA-DQ2 positive or 
HLA-DQ 8 positive. This study found that ZO-1, CLDN-1, and OCLN mRNA levels were each 
decreased in the IBS-D participants ingesting a high-gluten diet compared to a low 
FODMAP diet, and that this finding was more pronounced in the HLA-DQ-2 and -8 positive 
patients.(371)  
Furthermore, CLDN-15 (thought to be functionally homologous to CLDN-2) abundance in 
colonic biopsies was increased after participants consumed a high-gluten diet and 
decreased after the gluten-free diet. Phosphorylated MLC was also found to be positively 
associated with a high-gluten diet, as shown by increased excretion of the indigestible 
probe, 13Mannitol, in urine.(257) A high FODMAP diet fed to rats that increased the 
abundance of faecal gram-negative bacteria was associated with elevated circulating LPS, 




and OCLN expression. Circulating serum LPS is also reportedly increased in IBS patients, 
indicating GI epithelial barrier dysfunction.(267) 
1.10.3.3 Inflammation and Permeability 
Pro-inflammatory cytokines, TNF-α, and Interferon (IFN)γ both disrupt TJ through 
increased expression and activation of MLC kinase and by internalising TJ proteins 
(notably CLDN-1 and OCLN) away from the periphery of the cell. Interestingly, increased 
expression of IFNγ and TNF-α has been observed in IBS patients; however, their role in 
the pathophysiology of IBS remains a subject of debate.(201, 386) A limitation that makes 
studying the effects of these cytokines on TJ proteins difficult (particularly on MLC kinase 
which may only create temporary increases in permeability) is that groups of study 
participants are likely to have heterogeneous pathophysiologies.  
Tryptase, which is released from activated mast cells, has been implicated in the 
modulation of TJ via activation of protease-activated receptor-2, which subsequently 
induces the activation of MLC kinase.(372, 387) Increased mast cell counts were 
positively correlated with increased tryptase expression. The latter was negatively 
correlated with ZO-1 protein expression (352, 388) and positively correlated with 
increased bowel motion frequency and with tight junction dysregulation (or an over-
expression of CLDN-2) in IBS-D patients.(354) Increased NGF expression in the colon of 
IBS-C patients positively correlated with pro-inflammatory cytokines.(354) Another 
study found that the increased NGF expression in IBS patients was positively correlated 
with symptom severity, anxiety, and circulating serum diamine oxidase (indicating 
increased GI barrier permeability). There was also a negative correlation between NGF 
and visceral sensation thresholds.(216)  
Coëffier et al. demonstrated that proteasome activity (i.e., enzymes that degrade 
proteins) was increased in colonic biopsies of IBS patients compared to healthy controls. 
OCLN, a known target of proteasome activity, was shown to be decreased in these same 
colonic biopsies.(357) Increased serine protease activity has been observed in IBS 
patients. These are expressed by both eukaryotic and prokaryotic cells and could derive 
from either mast cells or from a dysbiotic GI microbiota. Mice administered with faecal 




internalised ZO-1 was observed as well as increased visceral sensitivity. These same 
effects were also seen in constitutively activated Protease Associated Receptor-2 mouse 
models and were blunted in Protease Associated Receptor-2 knock out mouse models or 
when these animals were treated with a serine protease inhibitor.(389)  
Conversely, cysteine protease activity was found to be increased in IBS-C participants 
which correlated positively with abdominal pain. OCLN was found to be decreased in IBS-
C patients compared to healthy controls. In vitro, increased cysteine protease activity was 
found to negatively correlate with OCLN. A knockout mutation in mouse models was 
found to blunt these effects of cysteine protease.(362)  
1.11 Summary 
IBS describes a cassette of similar symptoms that are driven by highly heterogeneous 
pathophysiologies. The current ‘gold standard’ diagnostic criteria for IBS are insufficient 
to determine underlying biological mechanisms driving these symptoms in individuals 
and, therefore, introduces a huge amount of variability into IBS research. While many 
pathophysiological mechanisms have been described in IBS, it is only recently that data 
from multiple biological systems, particularly diet, have been captured and integrated 
from a single cohort.  
The Christchurch cOhort to investigate Mechanisms FOr gut Relief and improved Transit 
(COMFORT) study captures demographics, medical history, symptom scores, mental 
health scores, and biological data (including stool, blood, breath, urine, and colonic 
mucosa biopsies) as well as a comprehensive three-day diet diary in which participants 
recorded their diet along with any concomitant GI symptoms.(2)  
This thesis will explore a part of the data collected from this cohort by studying the 
association of fibre and FODMAP consumption, with the microbes present in stool 
samples, subsequent butyrate production, and epithelial TJ gene in the biological samples 
collected from the COMFORT study participants. While Rome IV criteria has been applied 
to this cohort, I will also investigate how the IBS, FC and FD participants in this cohort 




1.12 Chapter Outlines 
This thesis is divided into sections and chapters to group related analyses. 
Section One describes the COMFORT cohort and the independent risk factors of being 
diagnosed with a FGID in the COMFORT cohort and finally compares the Rome IV 
diagnostic groups to results from an unsupervised analysis. 
Chapter Two describes the recruitment and the collection of data and biological samples 
of the COMFORT cohort. Application of the Rome IV criteria to participants and analyses 
of the questionnaire data collected are also discussed. 
Chapter Three discusses the analysis of the independent risk factors of an IBS diagnosis 
in the COMFORT cohort. 
Chapter Four discusses the results of a principal component analysis that utilised 
questionnaire data collected from COMFORT study participants. The results of this 
analysis are then applied to 16s rRNA sequencing of the faecal microbiota to determine if 
they can better describe biological variations in the COMFORT study compared to Rome 
IV diagnostic groups. 
Section Two contains chapters describing the analysis of the dietary data collected from 
COMFORT study participants.  
Chapter Five analyses the macronutrients reported in diet diaries and their relationships 
to acute and non-acute GI and extra-GI symptoms of COMFORT study participants 
Chapter Six analyses the FODMAP intake reported in diet diaries and their relationships 
to acute GI and non-GI symptoms of COMFORT study participants 
Section Three describes the gene expression of the TJ components in colonic biopsies 
collected from COMFORT study participants as well as discussing the relationships 
between biological results and questionnaire data 
Chapter Seven describes the differences in gene expression of the TJ components and 
Nerve Growth Factor between diarrhoea predominant participants (FD and IBS-D) and 





Chapter Eight analyses the relationships between the faecal microbiota composition data, 
dietary fibre and FODMAP data and faecal SCFA concentration. Relationships between 
the biological data and questionnaire data are also explored.  
Chapter Nine brings collective results together in a discussion and summary for each 
chapter. The direction of future research is also described. 
Table 1.4 summarises the publications arising directly from this thesis at the time of 
submission. As data was used in this thesis which was processed by colleagues an 
additional summary of the collection, analysis and processing of biological samples has 
been assembled into Table 1.5. 
 
Table 1.4: Publications arising directly from this thesis 
Citation Reference 
Chapter based on 
publication 
Appendix 
Heenan et al, 2020a (1) 1 A 
Heenan et al, 2020b (2) 2 B 
  
Table 1.5 Summary of the contribution of individuals to data and sample collection, sample processing, 





Section One will provide a cohort description and risk factors of concomitant anxiety and 
depression in COMFORT study participants. Additionally, this section will compare a 
biological dataset with and without the framework of the Rome IV diagnostic criteria. 
Chapter Two will provide a cohort description of the recruitment, sample collection, and 
analyses of questionnaire results. Chapter Two is based on a published manuscript which 
has been modified in this thesis for relevance, continuity, and consistency.(2) Chapter 
Three will explore the risk factors of a symptomatic Hospital Anxiety and Depression 
Scale (HADS) Anxiety or Depression score in COMFORT study participants. Finally, 
Chapter Four will explore how COMFORT study participants cluster together using an 
unsupervised statistical analysis. These results will then be tested for relevance in a 
















FGID are a heterogeneous group of disorders that involve different pathophysiologies. As 
discussed in Section 1.2 all FGID are now considered disorders of brain-gut 
interaction.(70) Dysregulation of the GI microbiota,(140) local and systemic immune 
system dysregulation,(197) and increased GI epithelial permeability (343) are frequently 
implicated in the onset of IBS symptoms in study populations around the world. These 
findings suggest that these biological systems contribute to a core set of symptoms 
(visceral hypersensitivity and altered motility) that superficially look similar despite 
differing underlying mechanisms.  
However, biological systems do not exist in isolation; for instance, dysregulation of the GI 
microbiota (dysbiosis) has been implicated in increased immune system activity in the GI 
tract.(140) Conversely, increased immune system activity has been implicated in 
dysbiosis.(212) Additionally, the gut microbiota is influenced by diet.(390) It therefore 
may be inappropriate to study the aetiology of heterogeneous disorders such as IBS in a 
single biological system. However, due to recent technological advances, researchers are 
increasingly moving towards a systems biology approach to address the multifactorial 
aetiology of FGID.(391) As such, the COMFORT study was designed to capture and 
integrate a wide range of biological, clinical, demographic, psychological, and dietary data 
to study the pathophysiology of IBS.  
As a prospective observational case-control study, the COMFORT study aimed to 1) 
Develop a cohort specifically designed to investigate a wide range of variables and their 
association with IBS pathogenesis, activity, and prognosis, 2) Develop dietary profiles and 
correlate them to IBS symptomology in those with and without IBS, 3) Correlate and 
integrate this dietary data with biological, clinical, and psychological variables of 
participants, and 4) Develop a repository of biological specimens that will allow for 
prospective in vitro and ex vivo experiments to identify novel interventions in IBS.  
This chapter is based on the published cohort description of the COMFORT study which 
has been modified for relevance and consistency.(2) The unmodified published 




2.1.1 Aims and Hypotheses 
The aims of the analyses included in Chapter 2 were to describe the recruitment of the 
COMFORT study participants and the collection of demographic, questionnaire and 
biological data. The differences in the questionnaire data between different Rome IV 
criteria groups were explored. The hypotheses generated from these aims are as follows: 
That differences in GI and non-GI symptoms will exist between FGID groups and 
controls 
That IBS participants will experience increased GI and non-GI symptom severity 




Full ethical approval for the COMFORT study and associated bio-banking of the biological 
samples was granted by the Northern A Health and Disability Ethics Committee in April 
2016 (16/NTA/21, and 16/NTA/50, respectively). An amendment to the original study 
protocol was sought to include recruiting participants from the general public, which was 
granted full approval in August 2017 (16/NTA/21 AM01)(Appendix C). 
2.2.1.2 Participant Selection - Cases 
Participant recruitment began in July 2016 at Christchurch Hospital Gastroenterology 
day ward and the Southern Cross Hospital Southern Endoscopy Centre in Christchurch, 
New Zealand. Participants who were undergoing colonoscopy at one of these two 
endoscopy units in Christchurch, New Zealand, were referred by their treating physician 
prior to their procedure. Participants undergoing colonoscopy were enrolled in the study 
after a date had been booked for their colonoscopy. Subsequent to ethical amendments 
other potential participants (both cases and controls) who responded to advertisements 
were also recruited to supplement the number of participants recruited through 
endoscopy lists. However, this was at the expense of collecting a colonic biopsy sample 




research team and provided with further information about the study, participants 
provided informed consent before enrolment into the study. The process of Rome IV 
diagnosis and sample collection is described in section 2.2.2. 
The eligibility of participants (18-70 years inclusive) was assessed by the research 
team.(4) The presence of concomitant FGID was not assessed. Due to the prospective 
nature of participant recruitment, participants with “red flag” symptoms indicative of 
organic disease, including blood in the stool, nocturnal symptoms, unexplained weight 
loss, or anaemia, were excluded from the study in order to minimise the risk of including 
participants with organic disease. Participants (both from endoscopy lists and the 
general public) who had a history of GI diseases, abdominal surgery, were pregnant, were 
unable to give informed consent, or with a positive faecal occult blood test and/or a 
calprotectin level >50 were also excluded from the study. Additionally, participants 
undergoing colonoscopy were retrospectively excluded if significant organic bowel 
disease, including familial polyposis syndromes, was discovered.  
2.2.1.3 Participant Selection - Controls 
Participants who did not meet exclusion criteria described in section 2.2.1.2, and who had 
no significant GI symptoms (functional or otherwise) were enrolled in the study as 
healthy controls (referred to as controls). As described in section 2.2.1.2, participants 
recruited from tertiary centres were referred to the study team by their 
gastroenterologist. These participants were undergoing colonoscopy due to a personal or 
familial history of sporadic polyps or colorectal cancer and were undergoing surveillance. 
Additionally, recruitment of control participants was supplemented by recruitment of the 
general public through advertisement.  
2.2.2 Collection and Processing of Samples and Data 
Once written informed consent was obtained (Appendix D), an electronic case report 
form was generated for each participant, who were each de-identified and given a unique 
five-digit ID number. These, and all other information pertaining to participants, were 
stored physically or electronically according to ethical requirements. The research team 
organised the start date of the study with each participant to optimise the completion of 




sample collection in those who underwent colonoscopy. Questionnaires and biological 
sample collection equipment were labelled with the participants’ five-digit ID number 
and posted to the participant. The dietary data collection and questionnaires were 
completed over three days the study schedule is summarised in Figure 2.1. All data and 
biological samples except colonic mucosal biopsies were collected from participants 
undergoing colonoscopy before the commencement of bowel preparation (no later than 
48 hours prior to colonoscopy).  
 2.2.2.1 Questionnaires 
Many variables were collected as part of the COMFORT Cohort study procedures (Figure 
2.1, Appendices F-J). Several questionnaires were used to collect clinical, demographic 
and psychological variables. The Modified Hunter New England Survey (79) included 
Rome IV diagnostic criteria (70) to classify participants as controls, cases and sub-
phenotypes, Short Form 12 for quality of life (SF-12),(392) medical history questions, and 
demographics. 
2.2.2.1.1 Metabolic Equivalent to Task 
Participants’ physical activity level was assessed by a questionnaire developed by the 
Australian Bureau of Statistics; this questionnaire collected information on participation 
in physical activity in three domains: walking, moderate exercise, and vigorous 
exercise.(393) Metabolic equivalent to task (MET) was then calculated by weighting each 
level of exercise, walking was multiplied by 3.3, moderate exercise was multiplied by 5.0, 
and vigorous exercise by 7.5. A sum of these scores was calculated to produce a single 
score which was reported as MET.(393) These scores were then averaged by Rome IV 
diagnosis and labelled according to guidance by the Australian Bureau of Statistics into 
sedentary, low, moderate, and high. Sedentary scores included any score <100, including 
a MET of ‘0’ (i.e., no exercise), low scores included 100-1599, moderate scores 1600-















2.2.2.1.2 Hospital Anxiety and Depression Scale 
The HADS questionnaire was developed in 1983 originally as a screening tool to assess 
the level of anxiety and depression in patients admitted to hospital or in outpatient 
clinics.(394) This questionnaire was designed to capture the level of distress in 
individuals by using actual absence, probable absence, possible presence, or probable 
presence to answer each of their questions. This inclusion made the questions more 
realistic than using “yes-no” questions relating to whether the condition is present. HADS 
has subscales for both anxiety and depression, which contain seven questions each; these 
are scored from 0-3, giving a minimum possible score of 0 and a maximum score of 21. 
The final score is a composite score composed of several Likert scales and is used 
routinely as a continuous variable. Additionally, there are accepted cut-off scores (0-7 is 
considered normal in both subscales, 8-10 is considered borderline abnormal, and 11-21 
is considered abnormal). A 2001 systematic review found that, almost 20 years later, the 
HADS questionnaire had been used extensively in a wide variety of topics and performed 
well in assessing symptom severity in psychiatric and primary care patients, and the 
general population.(395) 
2.2.2.1.3 Structured Assessment of Gastro-Intestinal Symptoms Scale  
The validated Structured Assessment of Gastrointestinal Symptoms (SAGIS) (396) 
evaluated a wide range of GI symptom severities. This assessment was produced using a 
Factor analysis on patients experiencing GI symptoms. This analysis led to the 
development of a 22 item questionnaire which was then grouped into five categories 
(domains) referred to as Epigastric Pain (Epigastric), IBS-D, Acid regurgitation/gas 
(Acid), Nausea/Vomiting (Nausea) and Constipation. The epigastric symptoms were 
averaged from post-prandial and epigastric pain, bloating, fullness, early satiety, 
retrosternal discomfort, and abdominal cramps items. The IBS-D category contained 
diarrhoea, loose stools, urgency to defecate, pain/discomfort pain to defecation, 
excessive gas flatulence, and incontinence items. The Acid category included dysphagia, 
excessive belching, and acid eructation items. Nausea included sickness, nausea, 
vomiting, and loss of appetite items, and finally, the Constipation group included 
constipation and difficulty defecating items. The authors of this questionnaire found that 




significantly higher scores in all categories of this questionnaire except for the Nausea 
category.  
2.2.2.1.4 Economic Living Standards – Short Form  
The Economic Standard of Living Index short form (ELSI-sf) (397) is a validated, 
comprehensive measure of living standard developed as part of the Ministry of Social 
Development’s research programme on living standards in New Zealand populations. 
This questionnaire assesses ownership restrictions (seven questions), social 
participation restrictions (seven questions) as well as economising (going without 
certain essential or non-essential material goods in order to save money, eight questions). 
It also assesses how an individual feels their material standard of living (three questions). 
The answers from each section are scored and weighted; the final score range extends 
from 0-31, which are then categorised from ‘severe hardship’ (scored between 0-8) and 
‘very good’ (scored between 29-31).  
2.2.2.1.5 Patient-Reported Outcomes Measurement Information System 
The Patient-Reported Outcomes Measurement Information System (PROMIS®) (398-
400) is a validated tool developed by the National Institutes of Health to capture the 
burden of GI symptoms and emotional distress in a cohort, which can then be compared 
to population norms. PROMIS questionnaire (item) scores measure the burden of the 
symptoms in participants’ lives; the higher the score, the more severe the burden of the 
symptom. The answers provided by participants are uploaded to the HealthMeasures© 
(Northwestern Univeristy, Illinois, United States of America) calculator 
(https://www.healthmeasures.net/score-and-interpret/calculate-scores) using the 
provided template Microsoft® Excel® sheet. The answers are provided as T-scores, in 
which a score of 50 is the mean of the population norm (reference population), and 10 is 
one standard deviation (SD). Higher PROMIS scores indicate more of the symptoms being 
assessed; therefore, the higher the T-score, the greater the burden of the symptoms on 
the patient. Guidance from health measures also advises that a T-score that is 0.5-1.0 SD 
above 50 indicates the mild burden of symptoms, 1.0-2.0 SD above 50 indicates the 





2.2.2.1.6 FAST diaries 
The Food And Symptom Times (FAST diary) is a validated three day estimated food diary 
which records all aspects of participants’ diets and GI symptoms 
contemporaneously.(401) The FAST diary allows for temporal relationships between 
food and symptoms to be explored. This tool was validated against classic IBS severity 
questionnaires. FAST diaries will be discussed further in Section Two. 
2.2.2.2 Biological samples 
Stool and urine samples were collected on the last day of the FAST diary at participants’ 
homes into provided 60mL specimen containers. Samples were kept at 4°C and delivered 
to the research team within 24 hours of collection, at which time 58mL of blood and 3L 
of breath were obtained from the participant. Samples were initially processed at the 
University of Otago, Christchurch; volatile metabolites were extracted from the breath 
samples onto a carbon-trap within an hour of collection and stored sealed at 4°C. Stool 
and urine samples were kept at 4°C until they were sorted into 1g aliquots and then snap-
frozen with liquid nitrogen within 24 hours of collection. Previous studies have shown 
that both microbial composition and faecal metabolites are stable when kept at 4°C for 
up to 24 hours before aliquoting. Most variation between samples transported in this way 
has been found to be due to differences between individuals rather than the method of 
transportation. Additionally, by transporting samples at 4℃ the degradation of microbial 
composition by freeze-thaw cycles is also avoided (Gorzelak et al, 2015; Gratton et al, 
2016; Wu et al, 2019; Choo et al, 2015; Tedjo et al, 2015). 
Lithium Heparin treated blood (18mL), Ethylenediaminetetraacetic Acid (12mL) treated 
blood and untreated blood (10mL) samples were centrifuged at 2000 times gravity, and 
plasma was distributed into 0.5mL aliquots and stored at -80°C. Peripheral blood 
mononuclear cells (PBMCs) were extracted from the remaining 18mL of Lithium Heparin 
treated blood, two-thirds of which were stored in RNA cell protect at -80°C and the last 
third in a solution of 90% foetal bovine serum, 10% dimethyl sulfoxide and stored in the 
gaseous phase of liquid nitrogen.(402, 403) The participants who underwent 
colonoscopy and who consented for biopsies to be taken for research purposes had eight 
colonic mucosa samples collected (four from the right and four from the left colon). Two 




the rest of the biopsies were fixed in formalin and then embedded in paraffin blocks. Due 
to the nature of this research, the inability to give a complete set of biological samples 
was not considered grounds for exclusion from the study (i.e. participants with 
constipation may not be able to give sufficient amount of faecal sample to fill every 
aliquot). Therefore, stool, urine, and blood samples were prioritised for the collection 
because they were considered more vital to the overall project (Appendix E).  
2.2.3 Statistical Analysis 
All subsequent statistical analyses were performed using the Statistical Package for the 
Social Sciences (SPSS)® v25 software (IBM®, Armonk New York, United States of 
America). Kolmogorov-Smirnov and Shapiro-Wilk tests for data normality were 
performed on demographic, PROMIS, SAGIS, and HADS data (Appendix K[A]).  
The SAGIS sub-scores within each SAGIS category were averaged to create a single score 
(domain) for each of the five categories. One-way ANOVA and post hoc Games-Howell 
tests were used to compare SAGIS scores between FGID groups (all IBS groups combined, 
a combined FC and FD group (‘other FGID’) and controls and to adjust for multiple 
comparisons. A one-way ANOVA was used to compare the variance of the means of the 
dependent variables (the questionnaire scores) between the independent variable 
(Rome IV diagnostic groups). 
PROMIS item T-scores were generated using the health measures scoring service. T-
scores for FGID groups were compared using one-way ANOVA and post hoc Games-
Howell tests. Additionally, PROMIS T-scores were categorised into normal (<55), mild 
(55-60), moderate (60-70), or severe (>70). These categories were used to categorise 
FGID groups (IBS, ‘other FGID’, and controls) were compared to one another using χ2 
analyses and adjusted z-scores in order to determine which categories were significantly 
different from one another. χ² was used as both of these variables are categorical. As a 
post-hoc test an adjusted z-score of either >1.96 or <-1.96 was considered significant, 
converted into a χ score and a p-value was generated. Every p-value underwent a 
Bonferroni correction in order to control for type 1 error. A p-value of <0.003 was 




(abnormal, borderline abnormal, and normal) were compared using χ2, adjusted z-scores 
and subsequent Bonferroni corrected p-values. 
2.3 Results  
A total of 1341 people were either invited to participate in the study or expressed interest 
in participating; this included 392 people from the general public, 740 people undergoing 
colonoscopy at Christchurch Public Hospital and 209 people undergoing colonoscopy at 
Southern Cross Hospital. A total of 349 participants were enrolled before December 21st, 
2018, 253 from either Christchurch Public or Southern Cross Hospitals and 96 from the 
general public. The group recruited from the general public did not undergo colonoscopy, 
but provided all other biological samples. 20 participants either subsequently declared 
their unwillingness to participate in the study after initially consenting (15/20) or were 
withdrawn from the study due to colonoscopy findings (5/20, summarised in Figure 2.2).  
In a study of this size, not all participants were able to provide all questionnaire data or 
biological samples as planned. There were a range of reasons for this incomplete data set, 
including an unwillingness to provide some biological samples, loss to follow up, or 
technical issues around specimen collection. Therefore, the number of participants who 
completed each data point and provided biological samples is less than the total number 
of participants in the study Table 2.1. In addition, colonic biopsies were not available for 
participants who did not undergo colonoscopy (95). Participants were identified as a case 
(IBS, FC, or FD) or as a control using Rome IV criteria based on the responses provided 
by participants in the Modified Hunter New England questionnaire, 128 participants met 
the criteria for IBS, and 42 met the criteria for FC and 16 for FD.  
2.3.1 Data normality 
All Demographic, PROMIS, SAGIS and HADS scores were found not to be normally 
distributed (Appendix K[A]). Conservative statistical analyses and post hoc tests were, 
therefore, performed at the expense of statistical power where appropriate. However, the 














This theorem postulates that the distribution of the means in the instance of n>50 means 
that averages will equal a normal distribution of means. Therefore, a sufficiently large 
population size can predict the characteristics of a population and so normality can be 
assumed and parametric tests can be performed where the n is appropriately large. 
2.3.2 Demographics 
The baseline characteristics of the COMFORT participants are summarised in Table 2.2. 
The mean age (±SD) of the study participants was 53.4±12.4 years, with a significant 
difference found between the mean age of those with IBS-M and FC (49.73±13.9, 
57.74±10.5, p<0.05), otherwise the ages of the case groups were not statistically 
different. There was a female predominance in the cohort (70% female) and every sub-
phenotype group. The mean economic standard of living (ESL) among the COMFORT 
cohort was 35.7 (corresponding to the level “comfortable”) with no significant difference 
between the sub-phenotype groups (p=0.60). 
There was no statistically significant difference in education level (p=0.31), alcohol 
consumption (p=0.90), smoking status (p=0.73 for current smoking and p=0.27 for 
having ever smoked), or MET (p=0.05) between the different diagnosis groups. MET 
values were calculated in accordance with the Australian Bureau of Statistics National 
Health Survey: Users’ Guide.(404) 252 participants were born in New Zealand (80%), 2% 
reported themselves as being of Māori descent. 
2.3.3 Questionnaire Results 
2.3.3.1 SAGIS 
When comparing FGID groups with controls by grouping IBS subgroups and FC and FD 
groups (‘other FGID’), IBS participants experienced worse symptoms in all domains 
compared to controls (p<0.01, summarised in Table 2.3). The IBS group also experienced 
worse symptom severity in the Epigastric, IBS-D, Acid, and Nausea domains (p<0.01) 
compared to the ‘other FGID’ group. The IBS and ‘other FGID’ groups were not 
significantly different from each other in the SAGIS Constipation domain, but both 

















When these FGID groups were divided into the constituent subgroups, IBS-D, IBS-C, and 
IBS–M participants experienced significantly worse symptoms than FC, FD, and control 
participants in the Epigastric domain (p<0.01)In the IBS-D domain of the SAGIS 
questionnaire, IBS-D, IBS-M, and FD participants experienced worse symptoms than 
controls and FC participants (p=0.01). IBS-C participants experienced significantly fewer 
symptoms than IBS-D and IBS-M (p=0.03) but not significantly different to FD and FC 
participants. IBS-C participants also experienced significantly more symptoms than 
controls (p<0.01). In the Acid domain all IBS participants experienced worse symptoms 




than controls (p<0.05), and IBS-C also experienced significantly worse scores than FD and 
FC (p<0.05). In the Nausea domain all IBS subgroups experienced worse symptoms than 
controls (p<0.01) and IBS-M participants also experienced worse symptoms than FC 
patients (p=0.01). Finally in the SAGIS Constipation domain all IBS subgroups and FC 
participants experienced worse symptoms than controls (p<0.01). IBS-C and IBS-M 
participants experienced worse symptoms than IBS-D and FD participants (p<0.01). 
2.3.3.2 PROMIS 
IBS participants experienced a worse burden of all PROMIS items measured and worse 
symptoms compared to the ‘other FGID’ group in Anxiety, Belly Pain, Diarrhoea, Bloating, 
and Reflux (p<0.05, summarised in Table 2.3). The ‘other FGID’ group experienced worse 
symptoms than the control group in PROMIS Constipation (p<0.01). Subgroup analysis 
revealed that IBS-D and IBS-M participants were significantly more anxious than controls 
(p<0.01), and IBS-M participants were also significantly more anxious than FD and FC 
participants. IBS-D and IBS-M participants also experienced worse PROMIS Depression 
symptoms than control participants (p<0.03). All IBS participants experienced worse 
Belly Pain scores than controls, FD, and FC participants (p<0.01). All IBS subgroups and 
FC participants experienced more of a burden of PROMIS Constipation symptoms than 
controls (p=0.01) and FD participants (<0.05). IBS-C and IBS-M participants experienced 
worse Constipation symptoms than IBS-D participants (p<0.02). FC participants 
experienced a worse burden of symptoms than FD participants (p<0.01). IBS-D, IBS-M 
and FD participants all experienced worse PROMIS Diarrhoea symptoms than controls, 
IBS-C and FC participants (p<0.05). All IBS subgroup patients experienced significantly 
worse PROMIS Disrupted Swallowing symptoms than controls (p<0.02), while IBS-D and 
IBS-M participants both experienced worse PROMIS Reflux scores than controls (p<0.01) 
and FD participants (p<0.03). IBS-D, IBS- M and IBS-C participants all experienced worse 
PROMIS Bloating scores than controls (p<0.01) and FC patients (p≤0.01), whereas only 
IBS-M and IBS-C participants experienced worse PROMIS Bloating than FD participants 
(p<0.05). 
Differences between normal, mild, moderate, and severe PROMIS categories are 
summarised in Table 2.4. Each category of symptom severity is expressed as a percentage 




prevalence of moderate PROMIS Anxiety scores (29.6% v 10.4%, p<0.01) and 
significantly decreased level of ‘normal’ symptoms (48.0% v 78.4%, p<0.01) compared to 
controls. IBS patients also had a significantly decreased prevalence of ‘normal’ PROMIS 
Depression symptoms compared to controls (62.7% v 83.2% p<0.01), while the control 
group reported significantly less ‘mild’ PROMIS Depression symptoms (9.6%, p<0.01). 
PROMIS Belly Pain scores show that the IBS group had significantly more participants 
experiencing ‘moderate’ (31.7%) and significantly decreased ‘normal’ scores (43.6%) 
compared to the ‘other FGID’ and control groups (1.8% and 3.9% respectively and 94.6% 
and 93.8% respectively, p<0.01). The IBS group also had significantly more participants 
experiencing mild symptoms and severe symptoms compared to controls (19.0% v 2.3%, 
p<0.01). The control group participants experienced significantly less ‘mild’ and 
‘moderate’ PROMIS Constipation symptoms (3.1%) and significantly more ‘normal’ 
symptoms (96.9%, p<0.01, while the IBS group had significantly more participants 
experiencing ‘mild’ symptoms (37.93%, P<0.01) and less experiencing ‘normal’ 
symptoms (25.4%, p<0.01). Significantly more participants in the IBS group experienced 
‘moderate’ PROMIS Diarrhoea symptoms compared to controls (29.6% v 10.4%, p<0.01) 
while significantly less experienced ‘normal’ symptoms (48.0% v 78.4%, p<0.01). The IBS 
group also had significantly more participants experience ‘mild’ and ‘moderate’ PROMIS 
Bloating (35.9% and 29.1% respectively ) compared to the control group (5.7% and 0% 
respectively, p<0.01) and fewer IBS participants experiencing ‘normal’ symptoms 
compared to controls (34.9% v 94.3%, p<0.01). χ2 results for PROMIS Disrupted 
Swallowing results showed no statistically significant difference between symptom 
severity categories. 
2.3.3.3 Hospital Anxiety and Depression Scale 
IBS participants reported significantly increased ‘Abnormal’ Anxiety HADS subscale 
scores compared to controls (21.4% v 4.7%, p<0.01). The aggregated IBS group reported 
worse HADS Anxiety and Depression scores than the control group (p≤0.01) and worse 
Anxiety scores than the ‘other FGID’ group (p<0.01). FGID subgroup analysis found that 
all IBS subgroups participants experienced worse Anxiety symptoms than controls and 




HADS Depression subscale results showed no statistically significant differences between 
symptom severity categories (the results are summarised in Table 2.4). 
2.3.4 Biological Samples Collected 
Participants provided blood, breath, stool, and urine samples where possible. Overall, 
87.5% of stool samples, 90.6% of urine samples, 93.0% of breath samples, 82.4% serum, 
and 71.4% of PBMC samples were supplied by participants (Table 2.1). There was no 
statistically significant difference in the rates of sample collection between the different 
diagnosis types. 203/329 (61.7%) of participants undergoing colonoscopy provided 
colonic mucosal biopsies.  
Table 2.49 Percentage of COMFORT participants that experienced normal, mild, moderate, or severe burden of 





The COMFORT study was designed to collect, integrate, and interrogate various 
pathophysiological data from IBS, FC, and FD cases and compare these between FGID 
groups and to controls to better understand FGID pathogenesis. Within the study period, 
186 participants met the criteria for FGID cases, and 129 controls. Within the case group, 
128 (40.6%) participants met the criteria for IBS. The majority of participants identified 
as New Zealand European while 2% of participants identified as Māori. In the Canterbury 
region, 7% of the population identifies as being of Māori descent.(405) This finding may 
reflect that Māori are more likely to present for colonoscopy with significant “red flag” 
symptoms (406) and were therefore pre-emptively excluded from participation in this 
study. Alternatively, FGID symptoms may be less prevalent in Māori or less likely to be 
reported. However, to date, there have been no studies of the prevalence of FGID in Māori 
populations. Additionally, there are potential other issues around the collection of bodily 
tissues and fluids which are considered tapu in Māori culture. 
There are few studies of FGID in the New Zealand population and, as is common in FGID 
literature, a range of diagnostic criteria have been used in these studies, making 
comparison with the COMFORT cohort difficult. Previous New Zealand FGID studies have 
suggested IBS prevalence of around 20%.(407-410) More recently, a Rome Foundation 
Working Team reported that the prevalence of IBS in New Zealand (pooled with North 
America, Europe, and Australia) of 8% (95% confidence interval of 7.0 to 8.3).(9)  
The mean age of IBS participants in the COMFORT study was 51.5 years, reflecting the 
method of recruitment for the COMFORT study that focussed on those attending for 
colonoscopy to obtain an otherwise unavailable range of biological samples. Incidence of 
IBS is considered greatest in those aged less than 50 years of age,(411-413), however, the 
average age of COMFORT study participants is consistent with other IBS cohorts 
recruited internationally.(9, 414, 415) Additionally, attention has been paid recently to 
the prevalence of IBS symptoms in older (>60 years) populations. A recent review found 
that prevalence of IBS decreases with age, this does not reach statistical 
significance.(416) Prevalence of IBS has been demonstrated to be around 20% in 




populations has been found to differ from younger populations(419). Pain and distension 
were also found to decrease in men over 60 years while women continued to experience 
significant symptoms.(420) 
There was a female predominance in the COMFORT study in each FGID phenotype in the 
case group whereas the control group was closer to a 50/50 gender split. The female 
predominance of patients with IBS is well documented.(414, 421, 422) It has also been 
suggested that female-specific sex hormones or genetics potentially predispose females 
to FGID, however the mechanisms are currently unknown.(115, 423, 424) Notably no 
disparity in health-care seeking behaviour has been reported between male and female 
IBS patients.(411, 425, 426)  
When all cases (all IBS subgroups, FD and FC) were pooled, the aggregated case group 
score was higher for SAGIS, PROMIS and HADS scores than the control group. Comparison 
of FGID groups found IBS patients scored the highest symptom severities while ‘other 
FGID’ scored the second-highest symptom scores and controls the lowest. This result is 
consistent with the Rome IV criteria that view FD, FC, and IBS on a continuum.(3) IBS 
patients often score highly on questionnaires capturing symptom severity as shown by 
Lee et al.(427) 
IBS patients reported higher GI symptom severity and higher symptom burden compared 
to the control group in all categories of the SAGIS and PROMIS questionnaires 
respectively. IBS patients also showed significantly higher HADS Anxiety and PROMIS 
Anxiety scores. Additionally, PROMIS Depression scores were higher in IBS-M 
participants compared to controls, however, there was no difference between the 
different IBS subgroups or ‘other FGID’ and controls for HADS Depression scores. While 
depression has been associated with IBS, anxiety syndromes tend to be more commonly 
associated with increased symptom severity and influence of health-care seeking 
behaviour.(428, 429) HADS and PROMIS questionnaires measure different aspects of 
anxiety and depression. HADS measures the symptoms of anxiety and depression while 
PROMIS measures the burden of these symptoms. While both of these questionnaires are 
based on a composite of Likert scales, PROMIS Likert scales has more points and so could 




than averages. This could be the reason differences were seen in HADS and PROMIS 
anxiety scores but not in HADS depression scores. 
The finding that IBS-D participants reported higher Constipation symptoms than controls 
is relatively unexpected, as was the high SAGIS IBS-D score in IBS-C participants. It is 
worth noting that, in the validation study for the SAGIS questionnaire the IBS-D domain 
could not discriminate between IBS and non-IBS FGID patients irrespective of the 
subgroup.(396) Additionally, the SAGIS IBS-D score is a composite score including 
measurement of pain/discomfort prior to defecation and excessive flatulence. These 
symptoms are potentially experienced by all subtype of IBS which could result in higher 
SAGIS IBS-D scores for IBS-C and IBS-M participants. Therefore, the higher SAGIS IBS-D 
score in IBS-C patients may not necessarily involve increased diarrhoea in these 
participants. The Rome IV criteria for IBS-D stipulates that patients should experience 
>25% of the stools as Bristol Stool chart 1 and 2 (diarrhoea) and <25% of their stools as 
Bristol Stool Chart 6-7,(3) so it is possible that participants who met the criteria for IBS-
D experience more constipation symptoms than controls. A similar result can be seen for 
IBS-C participants whose PROMIS Diarrhoea score was not statistically different from 
that of FD participants. Notably, the FD group was the smallest in the cohort and had a 
large SD so may not have the power to show a difference. It is also possible that these IBS-
C participants were experiencing a higher level of diarrhoea symptoms within the 
constraints of the Rome IV criteria. This result highlights that Rome IV criteria, which do 
not consider the biological mechanisms for symptoms, may create a heterogeneous 
population of participants. 
The levels of educational achievement in the COMFORT study participants were higher 
than that of the New Zealand population in 2015,(430) though similar to that of a United 
States IBS cohort.(431) Participants in the COMFORT cohort also recorded a higher level 
of exercise relative to available statistics on the general New Zealand population (432) 
but was consistent with the reported proportion of participants engaging in exercise in 
an Australian cohort.(422) ESL scores in the COMFORT cohort were higher than that of 
the New Zealand population, with 90% of the COMFORT cohort in the top four (less 
deprived) ESL categories (“Fairly comfortable” to “Very Good”) compared to 76% in the 




times more likely to score the ESL category of “Very good” compared to 10% in the 
general population.(397) There is conflicting evidence about the association of increased 
IBS symptoms with socioeconomic status.(411, 433-436)  
The proportion of COMFORT study participants who reported regular alcohol 
consumption was consistent with the New Zealand general population (437) and an 
Australian FGID cohort.(422) Perceived alcohol intolerance in IBS patients has been 
reported between 12-17% (438, 439) and there is some limited mechanistic evidence for 
the effect of alcohol in worsening IBS symptoms.(440) The proportion of current smokers 
in the COMFORT cohort was lower than the New Zealand general population and an 
Australian FGID cohort which is consistent with current literature which does not 
support an association between smoking status and IBS symptoms.(422, 441-443) 
Together, these observations may also reflect the older age of the COMFORT cohort and 
also that those who present for healthcare such as colonoscopy,(408) or volunteer for 
research may be more likely to come from healthier individuals with higher 
socioeconomic status.(444)  
2.4.1 Limitations 
Limitations of the COMFORT study include the recruitment of participants from 
endoscopy lists. Having access to these participants afforded the collection of samples 
which would not have been possible from the general public. However, as these 
participants had family histories of cancer, or personal histories of polyps they may have 
had genetic or environmental backgrounds not present in the general population. In 
future studies this limitation should be addressed by performing sub-analyses comparing 
participants recruited through endoscopy lists and those recruited from the general 
public. These participants may, therefore, not be directly comparable to the general 
public. Additionally, there may be differences in the perception of symptoms experienced 
by participants in the COMFORT cohort due to their age (average 51.1 years) compared 
to younger IBS patients. The relative underrepresentation of Maori in the COMFORT 
study is another limitation and not representative of the general public. This could be a 
form of selection bias in this cohort. Another limitation is that participants were not able 




compared to cases and is a potential source of selection bias. Additionally, the incomplete 
nature of the biological dataset, and the questionnaires is another potential source of 
selection bias in this cohort. 
Furthermore, the participants who did not undergo colonoscopy may have had diagnoses 
other than FGID. However, these diagnoses had been made by the general practitioner or 
gastroenterologist with patients having had non-invasive investigations or a colonoscopy 
previously. Additionally, a limitation of this study is the incomplete nature of some of the 
biological sample datasets, and the inability to collect stool samples into a nucleic acid 
stabilizer which may have affected the composition of the faecal microbiome. 
2.5 Conclusions 
The COMFORT study is a unique resource that will enable a systems biology approach to 
be taken to understanding the aetiology and pathogenesis of FGID (particularly the 
functional bowel disorders) spectrum of bowel disorders. The cohort is broadly 
comparable to other IBS cohorts and the general population and will be used 
independently and collaboratively to further our understanding of FGID.  
The integration of the clinical, dietary, and a subset of the biological data collected from 
participants in the COMFORT study will be investigated in this thesis. The analysis 
includes exploring dietary fibre and FODMAP consumption, faecal microbiota relative 
abundance, faecal butyrate concentration, demographics, TJ component/NGF gene 















Many studies have demonstrated a significant association between IBS and depression 
and anxiety (445, 446) as discussed in Section1.2. Less is known about the covariates that 
may modulate this association. Psychological distress is known to exacerbate FGID 
symptoms, negatively influence treatment outcomes, and undesirably impact doctor-
patient relationships.(445) Teasing out these covariates could have implications for how 
IBS and FGID are treated clinically.  
3.1.1 Aims and Hypotheses 
The aim of these analyses was to determine if any significant independent risk factors 
existed for anxiety and depression in IBS participants of the COMFORT study. The 
hypothesis for these analyses is as follows: 
That multivariate analysis will identify significant demographic or symptomatic 
risk factors for anxiety and depression in participants meeting the diagnostic 
criteria for IBS and FGID 
3.2 Methods  
The risk of developing anxiety or depression in the COMFORT study was calculated using 
an odds ratio (OR). HADS scores are typically categorised into ‘normal’, ‘borderline 
abnormal’, and ‘abnormal’ (described in Section 2.2.2.1.2). However, for the purposes of 
these analyses ‘abnormal’ and ‘borderline abnormal’ scores were grouped into an 
aggregated ‘symptomatic’ category for HADS Anxiety and Depression subscales. OR with 
95% confidence intervals were calculated to determine the independent associations 
between FGID and HADS Depression/Anxiety disorders. Additionally, the distribution of 
HADS Anxiety and Depression scores are provided in Appendix K(B). OR express the 
likelihood of a symptomatic HADS Anxiety or Depression score based on a diagnosis of 
an FGID in the COMFORT study. Additionally, an OR for Anxiety and Depression was then 
determined based on GI PROMIS scores (using the cut-off point of 55, <55 is considered 




subsequent analyses were carried out with SPSS® v25 software (IBM®, Armonk New 
York, United States of America). 
3.2.1 Univariate Analysis 
Univariate associations with HADS Anxiety and Depression subscales were explored 
using one-way ANOVA and Spearman’s rank correlations. Covariates included in these 
analyses included demographics that were continuous data (age, ESL, education level, 
MET, alcohol consumption (standard units of alcohol consumed per week)), PROMIS 
Belly Pain and Bloating items (described in Section 2.2.2.5) and Rome IV diagnostic 
groups. Spearman’s correlation was used to determine the association between two 
continuous variables, data from the entire cohort was used in this analysis. Variables with 
a p-value <0.05 were identified as significantly related to one another. 
3.2.2 Multivariate Analysis 
A multivariate model was developed using a general linear model to define the relevant 
independent associations of questionnaire or demographic data with HADS Anxiety and 
Depression. This model was used to identify variables that were significantly and 
independently associated with anxiety and depression. Variables with a p-value <0.05 in 
the univariate model were included in the multivariate model. However, as PROMIS Belly 
Pain and Bloating were highly and significantly dependent on each other, therefore 
abdominal bloating was omitted from the multivariate model. Covariates with a p-
value<0.05 were identified a significantly related to one another. Data from the entire 
cohort was used in this analysis. 
3.2.3 Logistic Regression 
The variables identified as significant in multivariate analysis were used in a logistic 
regression. These were used as covariates in analyses co-pairing diagnostic groups to 
determine whether the diagnosis was independently influencing anxiety or depression. 




3.3 Results  
3.3.1 Odds of Anxiety and Depression by Rome IV Diagnostic Groups 
OR analyses in FGID groups have been summarised in Table 3.1. Participants with any 
FGID diagnosis were more likely to have symptomatic HADS Anxiety (OR 2.85, 95%CI 
1.64-4.94, p<0.01) and Depression (OR 3.40, 95%CI 1.35-8.55, p=0.01) subscale scores 
than the control group. When divided into groups of IBS participants and a FC and FD 
group (‘other FGID’), IBS participants were more likely to report a symptomatic Anxiety 
score (OR 3.80, 95% CI 2.13-6.78, p<0.01) and Depression score (OR 3.22, 95% CI 1.23-
8.47, p=0.02) compared to controls. The ‘other FGID’ group was also more likely to have 
a symptomatic Depression score (OR 3.85, 95% CI 1.23-11.71, p=0.02) compared to 
controls. 
In analysing all FGID subgroups, participants diagnosed with IBS-D were more likely to 
report symptomatic HADS Anxiety (OR 3.53, 95% CI 1.74-7.14, p<0.05) and Depression 
(OR 3.52, 95% CI 1.16-10.68, p=0.03) subscale scores compared to controls. IBS-M 
participants were also more likely to report symptomatic HADS Anxiety (OR 6.27, 95% 
CI 2.91-13.53, p<0.01) and Depression (OR 4.25, 95% CI 1.34-13.5, p<0.01) subscale 
scores compared to controls. Additionally, participants diagnosed with FD were more 
likely to have a symptomatic HADS Depression subscale score (OR 10.33, 95% CI 2.68-
40.0, p<0.01) compared to controls.  
3.3.2 Odds of Anxiety and Depression by Symptomatic Gastrointestinal 
Symptoms  
OR analyses for GI PROMIS are reported in Table 3.2. Participants who experienced 
symptomatic PROMIS Belly Pain and Diarrhoea were more likely to report symptomatic 
HADS Anxiety (OR 2.55, 95% CI 1.48-4.39 and OR 3.36, 95% CI 1.86-6.07 respectively, 
p<0.01) compared to controls. Additionally, participants with symptomatic PROMIS Belly 
Pain and Diarrhoea were more likely to report symptomatic HADS Depression (OR 2.62, 


















A symptomatic HADS Depression score was also more likely in participants who 
experienced symptomatic Bloating (OR 3.10, 95% CI 1.42-6.77, p<0.05) and Reflux (OR 
3.73, 95% CI 1.07-13.01, p<0.05) compared to controls 
3.3.3 Univariate Analysis 
A significant positive correlation was found between Anxiety and Depression scores (r = 
0.56; p < 0.01). Table 3.3 shows the covariates significant to HADS Anxiety subscale 
scores. Anxiety was positively correlated with the PROMIS Belly Pain and Bloating T-
scores (r = 0.35 and r = 0.25 respectively; p < 0.01) while significantly negatively 
correlated with ESL and age (r = -0.28 and r = -0.19 respectively; p = <0.05). There was 
no significant association was found between the HADS Anxiety subscale scores and MET, 
education level, or alcohol intake. 
Table 3.4 shows the correlation between HADS Depression subscale scores and a range 
of covariates. Significant positive correlations were found between HADS Depression 
subscale scores and the PROMIS Belly Pain and Bloating T-scores (r = 0.0.23 and r = 0.19 
respectively; p = <0.05). Significantly negative correlations were also found between 
HADS Depression subscale scores and ESL (r = -0.40; p < 0.01), and age (r = -0.025; p = 
0.01). There was no significant correlation found between HADS Depression subscale 
scores and education level, MET, or alcohol intake.  
3.3.4 Multivariate Analysis 
A multivariate analysis was performed using the significant covariates from the 
univariate analyses (ESL, age, and PROMIS Belly Pain) to test whether their effect was 
independently associated with HADS Anxiety and Depression subscale scores. PROMIS 
Bloating was excluded from this analysis as it was highly dependent on PROMIS Belly 
Pain in the model. The multivariate analysis results are shown in Tables 3.3 and 3.4. There 
was a significant independent association between HADS Anxiety and ESL (p<0.01), 
PROMIS Belly Pain (p<0.01) and FGID phenotype (p=0.03). Depression was also shown 








Table 3.12 Covariates significant to HADS Anxiety subscale scores 




3.3.5 Logistic Regression 
Logistic regression results are summarised in Table 3.1. Only ESL was included in this 
analysis as it was significantly independently associated with both HADS Anxiety and 
Depression. While Anxiety was also associated with FGID diagnosis and PROMIS Belly 
Pain these were not included in this model as FGID diagnosis was already included in 
determining the adjusted ORs. 
PROMIS Belly Pain was highly and significantly associated with FGID diagnosis as it is a 
criterion of the Rome IV criteria for IBS and exclusion criterion for the ‘other FGID’ 
groups. It was therefore also excluded from this logistic regression to avoid 
multicollinearity. The logistic regression results are expressed as adjusted OR. These 
show a significant association still exists between HADS Anxiety scores, ESL and IBS-D 
(OR 2.72 95% CI: 1.32-5.63, p<0.05) and IBS-M (OR 4.60 95% confidence interval: 2.09-
10.13, p<0.05) as well as for HADS Depression scores, ESL and FD (OR 5.69 95% CI: 1.29-
25.13, p<0.05).  
3.4 Discussion  
Whilst the association between FGID and increased rates of anxiety and depression is 
well-described in scientific literature, in the COMFORT study ESL was identified as a 
significant independent risk factor for symptomatic HADS Anxiety and Depression. 
PROMIS Belly pain and FGID diagnosis were also independent risk factors for 
symptomatic Anxiety. HADS is used routinely to compare IBS cases to control 
populations. IBS cases reportedly experience higher HADS anxiety scores compared to 
controls. HADS depression scores are similarly higher in cases compared to controls, 
however these scores are also generally lower than anxiety scores. Cho et al found an 
average HADS anxiety score of 6.8 in IBS cases and 4.7 in controls(447) while Jerndal et 
al found an average score of 7.7 in IBS cases and 3.3 in controls.(448) In comparison these 
same authors found an average HADS depression score of 7.7 and 4.9 in IBS cases and 4.2 
and 1.5 in controls respectively.(447, 448) In comparison, COMFORT study IBS 
participants reported an average HADS anxiety and depression score of 8.2 and 3.7 




demonstrate that COMFORT study participants have comparable HADS anxiety and 
depression scores to those of similar cohorts internationally. 
COMFORT study participants diagnosed with IBS-M and IBS-D patients had the highest 
HADS Anxiety and Depression scores and were more likely to report a symptomatic HADS 
Anxiety or Depression score than controls. Thijssen et al. also found higher rates of a 
symptomatic HADS Anxiety and Depression scores in those with IBS-D and IBS-M 
patients, but not IBS-C patients, compared to healthy controls.(449) Additionally, 
Goncalves et al., in their study of 21 patients with IBS, found that those with IBS-M had 
the highest depression and anxiety scores.(450)  
There is, however, a large amount of inconsistency between studies. Others have found 
that IBS-C patients experience the most severe anxiety and depression,(451, 452) 
highlighting the differences between IBS cohorts in different countries, cultures, methods 
of recruitment, questionnaire used, and healthcare settings. This finding also highlights 
the issues of grouping participants based on their predominant bowel habit using the 
Rome IV criteria, which may not be the most effective way of discriminating between the 
independent risk factors related to an FGID diagnosis, leading to discordant results in 
different study populations. 
ESL is a measure of participants’ material standard of living, assessing participants’ 
possession and consumption of goods and services. This measure was found to be a 
significant independent covariate in the correlation between FGID and HADS Anxiety and 
Depression. This association remained significant after logistic regression between HADS 
Anxiety scores, ESL and IBS-D and IBS-M and between HADS Depression scores, ESL and 
FD. These analyses found that patients with symptomatic HADS Anxiety and lower ESL 
were 2.72 times more likely to be diagnosed with IBS-D and 4.60 times more likely to be 
diagnosed with IBS-M. Participants with symptomatic HADS Depression and lower ESL 
were 5.69 times more likely to be diagnosed with FD. This finding is consistent with Jones 
et al. who found that adverse socioeconomic factors were associated with the 
development of FGID in patients with prevalent anxiety and depression.(80) 




psychological morbidity in the general population,(453) which is consistent with the 
results seen in the COMFORT cohort.  
Although Belly Pain was a significant independent covariate for HADS Anxiety and 
Depression in those with FGID, once IBS subgroups were included in the multivariate 
analysis, this association was only significant for Anxiety. In a prospective study, 
Bouchoucha et al. also demonstrated a higher level of anxiety and depression in FGID 
patients with abdominal pain suggesting that abdominal pain is a strong predictor of 
psychological comorbidity.(122) As mentioned in Section 1.2, FGID patients with health-
care seeking behaviour are two fold more likely to develop anxiety and depression 
symptoms prior to the onset of GI symptoms, whereas GI symptom onset prior to mood 
disorder symptoms was more common in non-health care seeking FGID patients.(79, 80) 
This discrepancy in symptom onset in FGID patients suggests that pathophysiologies are 
likely different in health care seeking patients compared to non-health care-seeking 
patients. Additionally, this discrepancy may reflect that health care seeking FGID patients 
were more likely to experience ‘top down’ pathophysiologies compared to non-health 
care seeking patients.(80) Subsequently this observation could mean that ‘top-down’ 
pathophysiologies’ were over represented in the COMFORT study as participants were 
predominantly recruited from tertiary heath care settings. 
Education level did not modulate the association between IBS and depression or anxiety. 
The literature is inconsistent with regards to this association. In a Korean cohort, sex, age, 
education level, and marital status were not associated with anxiety or depression.(452) 
However an Iranian study reported a higher educational level was associated with 
increased psychiatric comorbidity in IBS patients.(454)  
Physical activity (measured by MET in the COMFORT study) was not an independent risk 
factor for HADS Anxiety or Depression in the COMFORT study. There is however a 
relatively consistent body of work reporting that physical activity is associated with 
improved mental health symptoms in patients with IBS.(455-457) A recent systematic 
review also showed that exercise could improve GI symptoms as well as anxiety and 
depression in IBS patients.(458) However, the way in which physical activity is measured 




quantitative measure of physical activity (e.g. MET) will provide a more accurate estimate 
of exercise and any potential associations.  
3.4.1 Limitations 
There are several limitations to these analyses, the COMFORT study was observational 
and therefore does not allow for assessments regarding the causal assumptions relating 
to depression and anxiety to the onset of FGID or vice versa. The questionnaires used were 
also self-administered by participants and under-reporting of alcohol consumption and 
smoking are well established in the literature.(459) Additionally, emotional distress is 
subjective and can be affected by bias. Also, whilst the HADS is a commonly used 
tool,(395, 460) it is a symptom-screening questionnaire rather than a diagnostic tool for 
anxiety and depression. Due to the recruitment of participants from endoscopy lists, the 
proportion of participants reporting symptomatic anxiety and depression could also be 
increased in this cohort compared to the general public. Furthermore, these analyses did 
not have the scope to allow for all potential covariates in the correlation between FGID 
and depression and anxiety such as relationships among families, marital status, or 
employment. While data were collected on the medication’s participants were taking, 
however these data have not been considered for the above analyses. Finally, this was a 
single centre study from Christchurch, New Zealand and the results may not be 
generalizable. These analyses did have several strengths, including the prospective 
collection of data and most participants having a colonoscopy to exclude other diagnoses 
3.5 Conclusions 
ESL is significantly and independently associated with HADS Anxiety and Depression in 
FGID cases in the COMFORT cohort. IBS-D, IBS-M, and FD participants were more likely 
to experience symptomatic Anxiety and/or Depression symptoms compared to controls 
in the COMFORT study. ESL, PROMIS Belly Pain and diagnosis of a FGID were significant 
risk factors of a symptomatic HADS Anxiety score in COMFORT study. Additionally, ESL 
and diagnosis of a FGID were significant risk factors of a symptomatic HADS Depression 
score. When adjusted for these risk factors IBS-D participants were 2.72 times more likely 
and IBS-M participants were 4.60 times more likely to report a symptomatic HADS 




5.69 times more likely to report a symptomatic HADS Depression score. These results 
indicate that ESL could be clinically relevant in mental health co-morbidities experienced 









Factor Analysis leading to Reclassification of 






The Rome IV criteria (discussed in Section 1.1.2) are a valuable clinical tool that provide 
a framework for clinicians to diagnose and treat patients with a disparate collection of 
symptoms. However, as a consensus criteria, Rome IV does not consider underlying 
pathophysiologies, co-morbid psychiatric distress, medical history, or concomitant 
overlapping FGID.(461) Some studies have also shown that Rome IV may not be relevant 
in non-European populations and cultures.(462) 
Other methods of analysis could help to develop a new framework. Factor Analysis (FA) 
is one method of dimension reduction. This technique takes a large amount of (observed) 
variables and combines related variables to produce a reduced amount of data. Another 
common type of dimension reduction is the Principal Component Analysis (PCA). While 
the end-product of both statistical tests is the same (dimension reduction), the goal and 
the mathematical modelling used to achieve this goal are different. 
A PCA reduces data by finding the linear combination (a weighted average) in the 
observed data to create the maximum possible amount of variance. It then groups this 
data into one or more component(s). The first component will have the largest amount of 
variance. The second component will have the next greatest amount of variance and so 
on. A FA, however, presupposes the existence of one or more latent variable(s). A latent 
variable (factor) is a concept that cannot be directly measured by a single variable (i.e. 
IBS), which is measured by the relationships it causes in a set of observed variables (i.e. 
abdominal pain and changes to bowel habit). Each relationship between the factor and 
the observed variables are weighted, and a FA determines the optimal combination of 
factor/variable relationships for each factor.  
Therefore, while a PCA measures how observed variables contribute to components, a FA 
measures how a factor contributes to the relationships between observed variables.(463) 
Moreover, a FA is an unsupervised analysis method and does not make any assumptions 
about how variables are related, grouped, or distributed (396, 462) and, therefore, this 





4.1.1 Aims and Hypotheses 
The aim of Chapter 4 was to carry out analyses to determine if factors produced by a FA 
better reflect differences between IBS patients compared to the Rome IV diagnostic 
criteria and to test this hypothesis using the composition of the faecal microbiota 
composition as a biological readout. The microbiota has been introduced in Section 1.4. 
This aim generated the following hypotheses: 
That a FA of the COMFORT study GI and non-GI symptom severity and symptom 
burden questionnaire data will cluster participants differently to Rome IV 
diagnostic groupings  
That the results of a FA will reflect changes in the composition of the faecal 
microbiota better than Rome IV diagnostic groupings 
4.2 Methods 
4.2.1 Spearman’s Rank Correlation  
Demographic data (including Age, Education, ELS, median units of alcohol per week, and 
smoking status), and data from PROMIS, SAGIS, and HADS questionnaires, were included 
in a Spearman’s rank correlation to determine if any associations existed between any of 
these variables. A FA was performed using questionnaire items that correlated 
significantly. A p-value <0.05 was considered significant. 
4.2.2 Factor Analysis  
A FA was performed to produce groupings of participants as an alternative to using Rome 
IV diagnostic groups. Inter-correlations were calculated between the PROMIS, SAGIS, and 
HADS items, creating factors. These factors then underwent a varimax rotation creating 
different combinations and weightings of the items included in each factor until they 
show the least amount of overlap. Factors that met Kaiser’s criterion (an eigenvalue ≥1) 
were included in subsequent analyses. The items included in this optimal arrangement of 
factors were then correlated, creating factor loadings which in turn were used to 
determine into which factor the items were loaded. Factors loaded >0.4 were significantly 
related to one another and grouped.(464) From this, a factor score per factor was created 




created for each item included in the analysis, multiplied by the loading scores for each 
factor. Factor scores were then used to visualise how the factors related to Rome IV 
diagnostic groups by averaging for every participant according to their group and 
plotting on a bar graph. Controls were excluded from these analyses to create 
comparisons between symptomatic participants only. 
4.2.3 Canonical Correlation Analysis  
Canonical correlation analysis (CCA) is used to measure how two large multivariate 
datasets are related. This type of analysis examines the linear combinations of variables 
similarly to a PCA (i.e., creating a weighted correlation). These correlations account for 
how the relationship between each variable is affected by all the other variables in the 
datasets (i.e., it measures the variability within and between whole datasets). A 
Spearman’s rank correlation can only determine how two variables are related. The 
resulting correlation coefficient score describes the strength of the linear relationship 
between the two variables measured. 
Both the CCA and Spearman’s rank correlations were used to examine the relationships 
between the questionnaire data used in the FA and the faecal microbiota composition 
data. The methods used to extract, sequence, and annotate the faecal microbiota data of 
the FGID patients from the COMFORT study are described below, as are the methods used 
to perform the CCA and Spearman’s rank correlations.  
4.2.3.1 Stool Sample DNA extraction 
Metagenomic DNA was extracted from stool samples collected from the FGID participants 
of the COMFORT cohort by PhD Candidate Caterina Carco. DNA was extracted from 0.5g 
of stool sample per participant according to the manufacturer’s instructions using 
Macherey Nagel NucleoSpin Soil kits (Düren, Germany). An additional mechanical lysis 
step was performed using a BioSpec Mini-Beadbeater 96 (Bartlesville, OK, United States 
of America) set to 4 minutes.(465) 
4.2.3.2 Shotgun metagenomic sequencing and bioinformatic analysis 





bioscience/dna-sequencing-facility/). Subsequent bioinformatic analyses were 
performed by Ms Carco under the supervision of Dr Wayne Young and colleagues at 
AgResearch in Palmerston North, New Zealand. 
DNA shotgun libraries were prepared using the Illumina Nextera XT kit, as described in 
the manufacturer’s instructions, with the following changes. Tagmentation time was 
increased from 5 to 7 min. Following index polymerase chain reaction (PCR) and clean 
up, the fragment sizes of all samples were assessed by running on an Agilent bioanalyser 
using an Agilent High Sensitivity Kit and quantified using a Qubit High Sensitivity Kit. 
The DNA libraries were then pooled in equal molar amounts, and the final concentration 
was determined using the Kapa Library Quantification kit for Illumina. The final library 
was then denatured and sequenced using paired-end sequencing (150 base pairs x 2) on 
an Illumina NextSeq 550 platform using the NextSeq 500/550 High Output Kit v2.5 (300 
Cycles) as per the manufacturer’s instructions. 
The paired sequences were joined using default settings in the Paired-end read merger 
(PEAR, version 0.9.6).(466) Read pairs that did not join were pasted together with a 
string of N’s using the "fuse" function from the BBMAP package (version 38.22-0) (467) 
Both joined and fused reads from different lanes from the same sample were compiled 
into a final “clean” read sample file. Evaluation and detection of host reads were done 
using the bbduk.sh function from the BBMAP package (version 38.22-0),(467) a k-mer 
based filter, with the human GRCh38 genome as a reference. The "blastx" function of 
diamond (version 0.9.22) (468) was used to map the reads against the "nr".(469) 
MEtaGenome ANalyzer (MEGAN version 6) ultimate edition (470) was used to assign 
taxonomy and putative Kyoto Encyclopaedia of Genes and Genomes (KEGG) functions to 
the alignment files produced by diamond. 
4.2.3.3 Canonical Correlation Analysis 
Relative abundance of bacteria (family level) was correlated to PROMIS, SAGIS, and HADS 
items included in the FA (referred to as questionnaires) using the CCA. This analysis was 
performed in R studio (Boston, Massachusetts, United States of America) using the 
MixOmics package.(471) Read depth was normalised using the Upper Quadrant method 




counts, any bacterial families with <100 read counts, and any bacterial families with 
<0.01% of the total read counts for each participant were removed. Participants missing 
any data were removed from analyses, and controls were excluded. The results of the CCA 
were visualised using the Complex Heatmap Package. 
4.3.3.4 Spearman’s Rank Correlation 
Spearman’s rank correlation of the normalised family level microbiome data (described 
in Section 4.2.3.3) and the questionnaires used in the FA was also performed. This 
correlation was performed to obtain correlation coefficients for the relationships 
between these two datasets and determine if any of these relationships were statistically 
significant (p<0.05). 
4.2.4 Wilcoxon Test 
Differences in the faecal microbiome between Rome IV diagnosis groups were 
investigated using a Wilcoxon test. Faecal microbiome data described in Section 4.2.3.3 
was used in this analysis and Rome IV diagnosis for each participant. Significant Wilcoxon 
results indicated if a difference existed between Rome IV diagnostic groups (p<0.05). 
Significant Wilcoxon results underwent a pairwise Kruskal-Wallis test to determine 
between which Rome IV diagnostic groups the difference in the microbiota data existed.  
4.3 Results 
4.3.1 Spearman Results 
Results from the Spearman’s rank correlation between the COMFORT study 
questionnaire and demographic data are summarised in Table 4.1. The full analysis, 
including demographics, are reported in Appendix L. PROMIS Anxiety and Depression 
item scores positively correlated with one another (r=0.745, p<0.01) and HADS Anxiety 










Positive correlations were found between PROMIS Diarrhoea and Constipation items and 
between lower bowel symptoms (PROMIS Diarrhoea and Constipation items) and upper 
GI symptoms (SAGIS Epigastric and Acid domain, and PROMIS Reflux and Disrupted 
Swallowing items). Upper GI symptoms correlated with other upper GI symptoms. SAGIS 
Epigastric, however, correlated with PROMIS Belly Pain (r=0.716, p<0.01).  
Demographic items (age, education, ELS, alcohol use and smoking status) did not 
correlate significantly with other demographic items or with the PROMIS, SAGIS, or HADS 
scores consistently. Therefore PROMIS, SAGIS, and HADS scores were included in the FA 
and CCA, while the demographic items were excluded. 
4.3.2 Factor Analysis 
Four factors were extracted from the FA: Factor 1 explained 32.11% of the variance in 
the data (eigenvalue 4.82), Factor 2 explained 15.08% of the variance (eigenvalue 2.26), 
Factor 3 explained 11.89% of the variance (eigenvalue 1.78) and Factor 4 explained 
9.02% of the variance (eigenvalue 1.35). These results are reported in Table 4.2.  
The SAGIS Domains (Epigastric, IBS-D and Nausea) and the PROMIS GI items: Belly Pain, 
Diarrhoea and Bloating were loaded into Factor 1. These suggest that Factor 1 clusters 
IBS and upper GI symptoms in the COMFORT cohort. When Factor 1 scores were averaged 
according to Rome IV diagnosis, it was shown that IBS-C, IBS-D, and IBS-M participants 
clustered together (Figure 4.1A).  
HADS and PROMIS Anxiety and Depression were loaded into Factor 2, resulting in an 
emotional distress cluster. Averaged Factor 2 scores grouped by Rome IV diagnoses 
showed that this factor clustered FD, IBS-D, and IBS-M participants (Figure 4.1B).  
PROMIS Disrupted Swallowing, and Reflux scores were loaded into Factor 3. The SAGIS 
Acid domain was loaded into both Factor 1 and Factor 3. However, as its loading factor 
was only marginally significant for Factor 1, it was included in Factor 3. The SAGIS Acid 
domain comprised dysphagia, excessive belching, and acid eructation, making it more 
likely to be related to items included in Factor 3, which was comprised of a cluster 




diagnosis, participants diagnosed with IBS-M clustered together and away from all other 
Rome IV diagnoses in this factor, shown in Figure 4.1C.  
Factor 4 consisted of SAGIS and PROMIS Constipation items, making this factor a 
constipation cluster. IBS-M, IBS-C and FC participants clustered together when factor 
scores were averaged by Rome IV diagnosis. These results are summarised in Figure 4.1D. 
4.3.3 Canonical Correlation Analysis 
Results of CCA are shown in Figure 4.2. Variables that showed similar patterns of 
correlations were arranged along the x-axis and y-axis by hierarchical clustering, 
represented by the dendrogram on the left and top of the heat map.  





















Figure 4.2 Results of CCA. The blue and red heat map indicates the positive and negative correlations (respectively) between family-level microbiota and PROMIS, SAGIS, and HADS items. The dendrogram at the top of the figure 




The results show questionnaire items have been clustered into four groups by the 
similarities of correlations between faecal microbiota data and the COMFORT study 
questionnaire scores: 1) PROMIS and SAGIS Constipation items, 2) PROMIS and HADS 
Anxiety and Depression items, 3) SAGIS Acid and Epigastric, and PROMIS Reflux and 
Disrupted Swallowing, Belly Pain, and Bloating (referred to as upper and lower GI 
symptoms) and 4) PROMIS Diarrhoea and SAGIS Nausea and IBS-D. The groupings of 
SAGIS and PROMIS Constipation, and PROMIS and HADS Anxiety and Depression were in 
good agreement with Factors 2 and 4, respectively. 
The hierarchical clustering of SAGIS and PROMIS Constipation items was positively 
correlated with members of the Firmicutes phylum, including Oscillospiraceae and 
Clostridia families, and with Methanobacteria. The cluster of HADS and PROMIS Anxiety 
and Depression items were positively correlated with members of the Proteobacteria 
phylum, including Rhodospirillaceae, members of the Planctobacteria, Verrucomirobia, 
and Chlamydiae (PVC) superphylum Akkermansiaceae, and Verrumicrobia, and 
Methanobacteria. A positive correlation was also observed for Rikenellaceae and 
Odoribacteraceae (members of the Bacteroidetes). Additionally, negative correlations 
were found for members of the Firmicutes phylum. 
The cluster of upper and lower GI symptoms (SAGIS Acid and Epigastric domains, and 
PROMIS Disrupted Swallowing, Reflux, Bloating and Belly Pain items) were positively 
correlated with Firmicutes, including Oscillospriaceae and Clostridia, and negatively 
correlated with other members of the Firmicutes including Enterococcaceae and 
Lactobacillaceae. Additionally, negative correlations were found between the upper and 
lower GI symptoms and members of the Actinobacteria phylum (including Coriobacteriia, 
Eggerthellaceae and Bifidobacteriaceae) and members of the Proteobacteria phylum 
(including Enterobacteriaceae and, Rhodospirillaceae families and Gammaproteobacteria 
class). A negative correlation was also found between the upper and lower GI symptom 
cluster and Methanobacteria. 
The cluster of SAGIS and PROMIS Diarrhoea items were positively correlated with the 
Bacilli class of Firmicutes and the Lachnospiraceae and Clostridia families of the 




cluster and members of the Firmicutes phylum (including Oscillospiraceae, Clostridia, 
Enterococcaceae and Lactobacillaceae), Proteobacteria phylum (Enterobacteriaceae and 
Gammaproteobacteria) and Actinobacteria phylum (Coriobacteriia, Eggerthellaceae and 
Bifidobacteria) as well as with Methanobacteria.  
4.3.4 Spearman’s Rank correlation 
These results of the correlation analysis between normalised microbiota data and the 
questionnaire data included in the FA are summarised in Table 4.3. Significant positive 
correlations are highlighted in red, and significant negative correlations are highlighted 
in blue. The significant positive correlations found by this analysis corresponded to 
positive correlations found in the CCA. The same is true for the negative correlations.  
4.3.5 Wilcoxon and Kruskal Wallis Analysis 
Significant Wilcoxon results are summarised in Table 4.4 (full analyses are reported in 
Appendix M). Significant differences in the composition of the microbiota between Rome 
IV diagnostic groups were found for Coriobacteriia, Lachnospiraceae, Lactobacillaceae, 
Oscillospiraceae, Unclassified Firmicutes sensu stricto and Miscellaneous Unclassified 
Firmicutes sensu stricto. However, after the pairwise Kruskal-Wallis test was applied to 
these significant Wilcoxon results, only differences in Coriobacteriia and Miscellaneous 
Unclassified Firmicutes sensu stricto remained significant. In both cases, the significant 
difference in these bacterial populations was between IBS-D and FC participants.  
4.4 Discussion 
Four clusters were created in the FA of the COMFORT cohort questionnaire data; Factor 
1 represented a cluster of IBS and upper GI symptoms, Factor 2 a cluster of HADS and 
PROMIS Anxiety and Depression symptoms, Factor 3 a cluster of PROMIS and SAGIS 
upper GI symptoms and Factor 4 a cluster of PROMIS and SAGIS Constipation symptoms. 
CCA produced positive and negative correlations between faecal microbiome data and 
the questionnaires used in the FA. Hierarchical clustering of these correlations created 




Table 4.16 Results of Spearman’s rank correlation of normalised faecal microbiota and PROMIS, SAGIS, and HADS items.  
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SAGIS, Structured Assessment of Gastrointestinal Symptoms; PROMIS, Patient-Reported Outcomes Measurement Information System; HADS, Hospital Anxiety and 






These corresponded to PROMIS and SAGIS Constipation, PROMIS and HADS Anxiety and 
Depression, PROMIS and SAGIS Diarrhoea symptoms, and PROMIS and SAGIS upper and 
lower GI symptoms. 
The results of FA analysis revealed four factors. IBS clusters (Factor 1 in this analysis) are 
almost always seen in the FA of FGID groups.(462, 464, 473) This factor almost 
exclusively contained participants diagnosed by Rome IV as having IBS, which 
corresponds well to the loading of the SAGIS IBS-D item into this factor. However, SAGIS 
Epigastric and Nausea domains also contributed to this factor which suggests an overlap 
of IBS participants who also experience upper GI symptoms. SAGIS IBS-D and Epigastric 
domains were shown to discriminate between IBS cases and functional dyspepsia 
respectively in the SAGIS validation study.(396) While functional dyspepsia was not 
assessed in this study, the overlap of IBS and functional dyspepsia patients has been 
noted in several studies that used the FA analysis in IBS patients.(396, 462, 474, 475) 
Factor 3 in this analysis also contained upper GI symptoms, which clustered together 
without lower GI symptoms. This cluster has also been observed in literature; a study of 
Australian, German, United States, and Swedish participants found a distinct cluster of 
diarrhoea and dyspepsia symptoms, a distinct lower GI symptoms cluster and a distinct 
upper GI symptoms cluster.(476) The groups of questionnaires created by CCA also found 
that items most contributed to Factors 1 and 3 formed an ‘upper GI symptoms’ cluster 





(SAGIS Acid and Epigastric domains, and PROMIS Reflux, Disrupted Swallowing, Bloating 
and Belly Pain items) while the remaining items that most contributed Factor 1 created a 
‘diarrhoea’ group (SAGIS Nausea and IBS-D and PROMIS Diarrhoea). 
Factor 4 in COMFORT study participants corresponded to PROMIS and SAGIS 
Constipation symptoms, which is also in line with other studies where the FA analyses 
were applied to FGID patients.(473, 475, 476) FA results were in good agreement with 
CCA, which formed a distinct constipation grouping. This result is not surprising as 
patients with constipation, often have distinct microbiome profiles due to the differences 
in GI motility and increased time in contact with the digesta.(477-479) 
Few FGID studies employing the FA have included anxiety or depression items in their 
analyses despite their being a common co-morbidity of FGID. Different studies often 
attribute different IBS subgroups as having the greatest burden of emotional distress. In 
the COMFORT study, participants diagnosed with IBS-M and IBS-D were found to have 
the highest levels of HADS Anxiety (shown in Table 3.1), which is consistent with some 
international studies.(480, 481) However, other studies have found that IBS-C 
participants have reported the most emotional distress,(482, 483) which could reflect the 
country or culture participants were recruited from or the method in which they were 
recruited. It is also possible, however, that FGID patients with anxiety and depression, 
regardless of their subtype, have distinct pathophysiologies, which could confound the 
results between different study populations. Factor 2 clustered participants in the 
COMFORT study together based on their HADS and PROMIS Anxiety and Depression 
scores, and a similar result was found based on the correlations between the 
PROMIS/HADS Anxiety and Depression items and the faecal microbiota in the CCA 
results. 
Questionnaire responses correlated most highly with bacteria from the Firmicutes, 
Actinobacteria, and Proteobacteria phyla. Interestingly positive associations with 
Methanobacteria were found between constipation and the anxiety and depression CCA 
clusters, while negative associations with Methanobacteria were found with the upper 
and lower GI symptom cluster and the PROMIS and SAGIS Diarrhoea cluster. 




produce methane gas. Methane has been associated with delayed GI transit, particularly 
in IBS-C patients,(145) and shown to be sufficient to slow colonic transit.(297) 
Interestingly, a FA of methane and non-methane producing IBS patients found that 
constipation symptoms were higher in the methane-producing IBS patients. While the 
relationship between mental health symptoms and Methanobacteria has previously been 
reported, no relationship between anxiety symptoms and methane or non-methane 
producing IBS patients was found.(484) This finding here suggests that Methanobacteria 
could be associated with constipation symptoms in the COMFORT study. The relationship 
between Methanobacteria and PROMIS and HADS Anxiety and Depression scores, 
however, seems to be novel. Relationships between faecal microbiota composition and 
IBS symptoms were also demonstrated by Peter et al.,(485) who found a negative 
association between HADS Depression scores and Lachnospiraceae, which is consistent 
with CCA results reported here. Additionally, Peter et al. study found positive correlations 
between Bacteriodetes (Prevotellaceae) and Proteobacteria phyla and depression and a 
positive correlation between Bacteroidetes members and anxiety.(485) These 
correlations are also consistent with HADS Anxiety and Depression CCA results from the 
COMFORT study.  
Bifidobacteriaceae were negatively correlated with PROMIS Belly Pain in the CCA 
analysis, as reported elsewhere.(486) Gammaproteobacteria also correlated negatively 
with the upper and lower GI symptoms cluster and the diarrhoea hierarchical cluster. In 
contrast, a positive correlation between Gammaproteobacteria and IBS symptom 
severity was demonstrated by Rajilić–Stojanović et al.(486) The composition of the faecal 
microbiota is known to vary between individuals and between different 
populations.(487, 488) A host of different factors contribute to these differences, with 
differences in diet prominent among them.(390)  
Positive and negative correlations between GI and non-GI symptoms and bacterial 
families, classes, and phyla have been consistent between COMFORT study participants 
and other studies. However, the mechanism and clinical relevance behind these 
associations are unknown.(151) A putative mechanism of the relationship between 




dysbiosis on the integrity of the epithelial GI barrier (489) and the subsequent effects that 
increased permeability have on the microbiota-BGA.(485)  
It is worth noting here that the handling and storage of stool samples has an effect on the 
microbial and metabolic composition of stool samples.(490) Current best practice 
indicates samples are frozen immediately at -80℃ and the repeated freezing and 
warming of samples is to be avoided.(491, 492) However, this is not always practical as 
the timing of defecation is unpredictable and participants often prefer to collect their 
samples in private.(493) Another alternative option for preserving microbial DNA 
includes the use of stool sample collection kits that contain nucleic acid stabilisers.(491) 
COMFORT study stool samples were kept at 4℃ for up to 24 hours. While this protocol is 
sub-optimal, it is the recommended process to preserve microbial DNA and metabolites 
for stool samples that aren’t chemically preserved or immediately frozen.(491, 492)  
The differences in the correlations of the faecal microbiota with PROMIS Diarrhoea and 
SAGIS IBS-D (lower bowel complaints) and upper GI symptoms, such as PROMIS Reflux, 
are not surprising. Due to the relatively shorter oral-caecal transit time experienced by 
patients with diarrhoea, the composition of the faecal microbiome of these patients is 
known to be affected.(494, 495) Therefore, patients who have similar bowel complaints 
(i.e. patients with diarrhoea symptoms) are potentially more likely to have more 
similarities when correlating the microbiome with symptom questionnaires.  
It should be noted, however, that the SAGIS Nausea domain grouped with the PROMIS 
and SAGIS Diarrhoea items in the CCA hierarchal clustering. The SAGIS Nausea domain 
included symptoms of sickness, nausea, and vomiting, which are all upper GI symptoms. 
Interestingly the SAGIS Nausea domain was the only domain shown in the SAGIS 
validation study not increased in IBS patients.(396) Additionally, the ‘diarrhoea’ and 
‘upper GI’ groups in the CCA remained more closely related in the hierarchical clustering 
than to the other groupings, indicating that the pattern of correlations between the 
microbiota composition and the IBS and upper GI questionnaire items were more similar 
to one another than to the constipation and the anxiety and depression CCA clusters.  
Many studies have found that dysbiosis in the GI tract correspond to increased anxiety 




activation of the inflammasome, neuro-immune reactions, and altered central 
processing.(90, 498) A recent study from Sweden used multivariate analyses to 
determine the interaction of emotional distress with pathophysiological mechanisms of 
IBS and found that anxiety and depression are both complexes and interwoven with 
different potential pathogenic mechanisms in IBS patients.(429) It is therefore 
interesting that these analyses clustered COMFORT participants together based on their 
HADS and PROMIS Anxiety and Depression scores. This result may reflect a cluster of 
participants whose symptoms are primarily driven by a ‘top-down’ pathophysiology, 
however as central processing and autonomic nervous system data were not collected for 
this study, so this interpretation remains hypothetical.  
The Rome IV criteria remain an important and useful clinical tool provides a framework 
to treat the symptoms of FGIDs. However, when strict Rome IV criteria were applied to 
the same faecal microbiota data, few significant differences in the composition of the 
microbiota between different Rome IV diagnosis groups were observed, and even fewer 
remained significant after a Kruskal-Wallis test. The combination of items included in the 
factors produced by the FA more closely corresponded to the results of the CCA compared 
to differences in microbiota composition between Rome IV diagnostic groups. This result 
underlines the difficulty of exploring in-depth investigations of IBS pathophysiology 
while adhering to criteria that do not take biology into account. It is worth noting, 
however, that the clinical relevance of the groupings produced by the FA cannot be 
determined until they have been rigorously tested in other study populations and in 
prospective clinical trials.  
The disadvantage of using strict Rome criteria is apparent in clinical trials of drugs 
targeting FGID. Drugs targeted towards specific mechanisms underlying symptoms often 
do not show significant clinical improvements over placebo, in part due to the 
heterogeneous underlying pathophysiologies inherent when classifying patients using 
Rome IV criteria.(461) 
Itopride, a functional dyspepsia drug, performed poorly over placebo when Rome III was 
strictly adhered to.(499) Interestingly, when the diagnostic criteria were relaxed to allow 




symptoms over the placebo.(500) This result demonstrates that while Rome IV criteria 
may be useful in a clinical setting. Adherence to the Rome IV criteria hinders investigating 
pathophysiologies or treating them.  
4.4.1 Limitations 
There are limitations for these analyses; the presence of FGIDs other than IBS, FD, and FC 
have not been formally assessed in the COMFORT study. Clustering of upper GI symptoms 
and of IBS and upper GI symptoms in Factor 3 and 1 indicate that there is potentially a 
significant overlap of IBS and functional dyspepsia in COMFORT study participants. 
Additionally, as an observational cross-sectional study, the results from the COMFORT 
cohort cannot indicate causal relationships. It is inappropriate, therefore, to speculate 
about whether changes in the relative abundance of the faecal microbiota pre-exist GI and 
non-GI symptoms in this study or vice versa. Additionally, microbiome data was obtained 
from faecal samples that were not kept in optimal conditions for obtaining nucleic acid 
samples. The results of microbiome sequencing may not be representative of the 
organisms associated with the colonic mucosa and/or may be altered due to suboptimal 
stool sample handling. Diet, a major contributor to the composition of the GI microbiome, 
has not been considered in these analyses. It is also noteworthy that colonic transit time 
was not formally measured, and therefore not considered as a confounder of the variation 
present between individuals in the COMFORT study. Increased colonic transit time has 
been associated with increased microbial richness, composition, and a shift in microbial 
metabolism to protein catabolism.(501, 502)  
Furthermore, using family level microbiological data does not provide a nuanced model 
of the composition of the GI microbiome. Using genus or species level data could have 
provided a better, more complex, model of GI microbiome composition. However, in 
depth analysis of the faecal microbiological data is outside of the scope of this thesis, nor 
is it the aim of the above analyses. Another limitation is the use of correlation in the CCA 
and Spearman’s rank analyses, which does not indicate causation. It is also outside the 
scope of these analyses to investigate the functional implications of the changes in the 
relative abundance of the faecal microbiota that exist between clusters of participants as 





The hypothesis statements were that FA would group the participants of the COMFORT 
study differently to Rome IV criteria and that the resulting factors would better reflect 
the composition of the faecal microbiota compared to the Rome IV diagnostic groups. It 
was shown that the four factors extracted from the FA corresponded to a constipation 
cluster, anxiety and depression cluster, an upper GI symptom cluster and an IBS and 
upper GI symptom cluster. Constipation and anxiety/depression clusters were consistent 
with the hierarchical clustering of faecal microbiota produced in the CCA. Conversely, 
there were few differences in the relative abundance of the faecal microbiota between 
the Rome IV diagnostic criteria. These results suggest that clustering participants based 
on their questionnaire responses better reflects underlying biological data than strictly 
adhering to Rome IV diagnostic criteria. The Rome IV diagnostic criteria remain an 
important and clinically useful tool for the diagnosis and treatment of FGID. The factor 
analysis outlined in the above analyses, in its current form, is of little clinical value. Future 
work will need to integrate more biological data into the analysis, including 
metabolomics, diet and microbiome data at genus and species levels. Additionally, this 







Section Two will explore the relationship between GI and non-GI symptoms and the FAST 
diary data. The FAST diary is a novel tool that captures diet data alongside 
contemporaneous GI and non-GI symptom data and correlates meals or food items 
consumed with the onset and severity of acute symptoms. Chapter 5 will describe the 
macronutrient content of participants’ diet of the COMFORT study and explore the 
relationship between dietary fibre consumption and acute GI symptoms. Additionally, the 
relationship between dietary fibre consumption and GI and non-GI symptoms captured 
by the PROMIS, SAGIS, and HADS questionnaires will be explored. Chapter 6 will describe 
the FODMAP content of participants’ diet of the COMFORT study, the relationship of 
individual and total FODMAP consumption with the onset of acute GI symptoms. The 
association of individual and total FODMAP consumption and PROMIS, SAGIS and HADS 















The role of diet in IBS pathophysiology is discussed in Section 1.8. In brief, most IBS 
patients associate their symptoms with their diet or certain food groups, most commonly 
spicy or fatty foods, fibre, alcohol, milk, and wheat.(235) Subsequently, patients report 
excluding foods or food groups that trigger their symptoms.(246) While the mechanism 
behind these different food responses is unknown, one study has found that over 50% of 
IBS patients’ symptoms worsened within 30 minutes and 93% within three hours after 
meal ingestion.(438) It is unlikely, however, that there is only one mechanism mediating 
these symptoms in every IBS patient. Therefore, it is unsurprising that studies of IBS 
patients have found that different foods are restricted by different study populations 
compared to control populations. Given the reported importance of diet in IBS patients’ 
symptoms, it is surprising that diet is rarely reported or controlled in FGID 
pathophysiology studies. Compounding this problem is the historical absence of a 
validated instrument to capture the temporal relationship between food/meal ingestion 
and symptom onset.(401)  
The FAST diary is a tool developed in 2016 to capture the association of meal ingestion 
with symptom onset by incorporating a three-day diet diary with a real-time GI symptom 
scale. The GI symptom scale of the FAST diary captures the onset, severity, and duration 
of abdominal pain, bloating, swelling, fullness, and bowel motions.(401)  
5.1.1 Aims and Hypotheses 
The aims of these analyses were to determine if FGID cases were consuming different 
diets compared to controls. The differences in fibre consumption were investigated and 
its association with acute and non-acute GI and non-GI symptoms. These aims generated 
the following hypotheses: 
That FGID cases will experience more symptoms within three hours of meal 
consumption (acute symptoms) compared to controls 




That increased fibre content in meals will be associated with acute symptom onset 
compared to meals with less fibre content 
That increased fibre consumption will be associated with increased non-acute 
symptoms in FGID cases compared to controls 
5.2 Methods 
5.2.1 Diet and Symptom Data Collection 
COMFORT study participants completed a FAST diary on three non-consecutive days, 
including at least one weekend day. A space for any recipes used by participants was 
provided to ensure that the composition of homemade meals was correctly recorded. 
Participants were also encouraged to provide labels or wrappers from jars or snacks they 
had bought (i.e., not homemade) and consumed. For those participants undergoing 
colonoscopy, the last day of the diet diary was at least one day prior to the 
commencement of bowel preparation. The weights of food or ingredients consumed were 
estimated by participants using kitchen measurement equipment (Section 2.2.2.1.6). 
The GI symptoms that participants experienced on the three days of the diet diary were 
also recorded. The GI symptoms captured by the FAST diaries were abdominal pain, 
swelling/distension (physical distension of the abdomen), fullness (feeling of fullness), 
and bloating (the feeling of bloating in the abdomen). If participants experienced these 
symptoms, they recorded the time of symptom onset, how severe the symptom was on a 
scale of 1-5 (1=not bad at all, 5=very bad) and how long the symptoms lasted. This 
method of capturing symptoms allowed the capture of multiple bouts of the same 
symptom over 24 hours. Participants also recorded the absence of these symptoms if they 
were not experienced by participants over the 24 hours of the diet diary.  
Bowel motions and the time of the bowel motion(s) were recorded (or the absence of a 
bowel motion over the 24 hours of the diet diary) in the FAST diaries. The form of any 
bowel motions was recorded using the Bristol Stool Chart. The Bristol Stool Chart is a tool 
that groups stool characteristics into seven categories. Categories 1-2 indicate 




indicate diarrhoea.(503) Alleviation/worsening of pain, urgency, and straining 
associated with the bowel motion(s) were also recorded.  
5.2.2 Data Management 
5.2.2.1 Dietary Data 
The diet diary portion of the FAST diary was entered into Kai-culator, a dietary 
assessment software developed by the Department of Human Nutrition at the University 
of Otago. All dietary data was entered into Kai-culator software, supervised by Dr Paula 
Skidmore and Elizabeth Fleming in the Department of Human Nutrition at the University 
of Otago. After initial entry, diaries were checked by two experienced researchers to 
avoid data entry errors. The top and bottom 10% of food items were then checked for 
outliers in protein, carbohydrates, and fat to avoid excluding data unnecessarily. Any 
outliers were then checked against the physical diaries to ensure data entry errors had 
not occurred. The raw macro- and micronutrient Kai-culator data for each meal 
consumed were exported into a Microsoft® Excel® sheet. Each meal was labelled with a 
unique identifier composed of the participant ID, the FAST diary day the meal was 
consumed, and a letter corresponding to the time the meal was consumed (e.g. the first 
meal of day one of the FAST diary for participant 90001 was labelled 90001_1_A).  
5.2.2.2 GI and non-GI Symptom Data 
Symptom data from the FAST diaries were transcribed into a Microsoft® Excel® 
spreadsheet and aligned to the times that meals were ingested. The onset of any symptom 
(including bowel motions) reported within three hours after meal ingestion was 
considered an acute symptom. Acute symptoms, the corresponding meal unique 
identifier, and the meal macronutrient and fibre content, were collated in a spreadsheet. 
Additionally, non-acute symptoms captured by the PROMIS, SAGIS, and HADS 
questionnaires were used in these analyses. The description and method of collection for 
these questionnaires is reported in Section 2.2.2.  
5.2.2.3 Analysis 
The subsequent analyses were performed using SPSS® v25 software (IBM®, Armonk 




5.2.2.3.1 FAST Diaries: Analysis of Cases and Controls 
Differences in acute symptoms (pain, swelling, fullness, bloating, bowel motions, and 
Bristol Stool Chart category) experienced between cases and controls were explored 
using a non-parametric Wilcoxon test and a pairwise Kruskal-Wallis test. These tests are 
non-parametric and are used to determine if their population mean ranks differ. A p-
value <0.05 was considered significant. 
5.2.2.3.2 Macronutrient  
The average daily intake of macronutrients and fibre was calculated from the FAST diary, 
and the average energy intake was calculated by multiplying dietary intake by the 
relevant macronutrient energy density.(504) Significant differences in the averaged 
macronutrient composition and fibre consumption between different Rome IV diagnostic 
groups were determined using a one-way ANOVA and post hoc Games-Howell tests to 
adjust for multiple comparisons. A p-value of <0.05 was considered significant. 
5.2.2.3.3 FAST Diaries: Analysis of Acute Symptoms and Fibre Consumption 
The fibre content of individual meals and presence of acute GI symptoms, captured by the 
FAST diary, were explored in IBS participants. The dietary fibre content of meals 
associated with acute symptoms were compared to meals not associated with acute 
symptoms using an independent-samples paired Welch’s t-test which was performed as 
equal variances were not assumed. As Kaiculator is unable to discriminate between 
different types of dietary fibre, therefore, all fibres types were considered in this analysis. 
A p-value <0.05 was considered significant. FAST diary symptoms used in these analyses 
included abdominal pain, swelling, fullness, bloating, and bowel motions, and a sixth 
symptom category called ‘any symptom’. The ‘any symptom’ category included the 
presence of any of the other five symptoms. A symptom was considered acute if its’ onset 
was reported within three hours of meal consumption. 
5.2.2.3.4 Association of Fibre Intake with SAGIS, PROMIS and HADS Questionnaires 
Spearman’s rank correlations were used to investigate associations between fibre 
consumption and SAGIS, PROMIS, and HADS questionnaire items. Subsequently, fibre 




high intake (>25g) per day. A one-way ANOVA and Games-Howell post hoc tests were 
used to explore if differences in mean severity of symptom burden existed between low, 
moderate, and high fibre consumption categories. A p-value of <0.05 was considered 
significant. 
5.3 Results 
There were 292 (92.70%) participants who returned FAST diaries. A brief description of 
the FGID classification of these participants is summarised in Table 5.1(A). A slightly 
higher, but not significant, proportion of women completed the diet diaries (72.26%) 
compared to the proportion of women who completed the study (70.16%) (Table 5.1(B)). 
Among the Rome IV diagnostic groups, participants diagnosed with IBS-M were the least 
likely to complete their FAST diaries (35/40, 85.37%), while participants diagnosed with 
IBS-D were the most likely to complete their FAST diary (56/57 98.25%) Table 5.1(A). 
5.3.1 Acute Gastrointestinal Symptoms 
Abdominal pain, fullness, bloating and ‘any symptom’ were associated with meal 
ingestion in IBS participants compared to FC and FD participants and controls (Table 5.2 
and Figure 5.1). However, the presence of a bowel motion was not significantly associated 
with meal ingestion. Stool form differed significantly between FD and FC participants, and 
FC participants had a significantly lower (more constipated) Bristol Stool Chart score 












Table 5.18 (A) The proportion of participants in the COMFORT study that completed their FAST diaries 
compared to the total cohort. (B) Proportion of males and females that completed their FAST diaries 












Figure 5.1 Box plots of the proportion of participants in each Rome IV diagnostic group (x-axis) for each symptom measured in the FAST diaries (y-axis). A) 
Abdominal Pain, B) Abdominal Swelling, C) Abdominal Fullness, D) Abdominal Bloating, E) Amalgamated category of having experienced any symptom associated 





5.3.2 Dietary Intake 
Table 5.3 summarises the macronutrient intake of COMFORT study participants. FGID 
cases (participants diagnosed with IBS, FC, or FD) consumed significantly less total 
energy, carbohydrate, and protein than controls. In addition, IBS participants consumed 
significantly fewer carbohydrates than controls, while a combined group of FC and FD 
(‘other FGID’) participants ingested significantly less protein than controls.  
The average fibre intake of COMFORT participants was 21.46g per day for women and 
22.45g per day for men. 24.3% of COMFORT participants were found to consume <15g of 
fibre per day (low fibre category), while 30.5% of participants were found to have 
consumed >25g of fibre per day (high fibre category). 
Table 5.3 summarises the fibre intake of COMFORT participants. It was found that FGID 
cases consumed significantly less fibre than controls (20.24g v 23.95g, p<0.05); subgroup 
analysis revealed that only IBS-M participants consumed significantly less fibre than 
controls (18.96g v 23.95g).  
Figure 5.2 Box plots of the mean Bristol Stool Chart score in each of the 





Table 5.20 Summary of the total energy in kilo-joules; carbohydrate, total and saturated fat, protein, and fibre consumed in grams 




Analysis of fibre intake categories (low, moderate, and high) between Rome IV diagnostic 
groups revealed no significant difference between any of these groups (χ2 = 0.35, Table 
5.4). 
5.3.3 Dietary Fibre Associations with Symptoms 
5.3.3.1 Relationship between Fibre Intake and Non-Acute Symptoms 
Consumption of fibre was significantly negatively correlated with SAGIS Epigastric, Acid, 
Nausea, and Constipation domains and with PROMIS Disrupted Swallowing (Table 5.5). 
Participants in the low fibre intake category were found to have significantly higher 
SAGIS Epigastric, Nausea, and Constipation domain scores and with PROMIS Disrupted 
Swallowing item scores. Ingestion of <15g of fibre per day was also significantly 
associated with increased HADS Depression subscale scores (Table 5.5 and Figure 5.3). 
 
Table 5.21 Number of participants (total, %) in fibre consumption categories in each Rome 






Table 5.22 Association between low, moderate, and high mean fibre intake categories and SAGIS 





Figure 5.3 Significant differences between low, moderate, and high fibre intake categories in the SAGIS, PROMIS, and HADS items that reported a 
significant one-way ANOVA result. A) SAGIS Epigastric, Acid, Nausea, and Constipation Domains, B) PROMIS Disrupted Swallowing, and C) HADS 




5.3.3.2 Fibre Intake and Presence of Acute Gastrointestinal Symptoms 
As mentioned in Section 5.3.1, it was determined that the controls, FC, and FD 
participants experienced significantly fewer GI symptoms associated with meal ingestion 
compared to IBS cases (Figure 5.1 and Table 5.1). Controls, FC, and FD participants were 
therefore excluded from the FAST diary analyses to avoid type 1 (false negative) 
statistical error. The resulting analyses found that increased fibre ingestion was 
significantly associated with increased bloating (p<0.05) and with the presence of ‘any 
symptom’ (p=0.03) in the IBS participants. These results are shown in Table 5.6. 
5.4 Discussion 
The FGID cases of the COMFORT study were found to consume less carbohydrate, protein, 
and total energy than controls. Additionally, IBS cases ingested fewer carbohydrates and 
dietary fibre than controls. As previously mentioned, IBS patients often report self-
restricting their intake of certain foods or food groups to control their symptoms.(230) 
 
Table 5.23 Association of fibre consumed in meals with gastrointestinal symptoms 




While self-reported food sensitivities were not collected in this study, the results of these 
analyses suggest that the IBS participants of the COMFORT cohort consume a different 
diet compared to FC and FD participants and controls.  
There are conflicting results from other studies regarding macronutrient intake in IBS 
patients. A Dutch study found that IBS patients consumed less alcohol and higher fat and 
total energy than controls. Protein consumption was higher in IBS patients in a Swedish 
study (505) while a Norwegian study found that IBS patients consumed fewer dairy 
products. This study also showed that decreased intake of potatoes and increased intake 
of alcohol were associated with IBS-M diagnosis.(239) A United States study found that 
IBS patients ingested more fat, saturated fat, and fewer carbohydrates compared to 
healthy controls, but found no difference in energy, fibre, or micronutrient intakes.(506)  
The aforementioned studies used food frequency questionnaires (FFQ). These are 
cheaper and easier for participants to complete, as well as providing information about 
the habitual diet. (507) However, these have several disadvantages including reliance on 
patient recall which introduces significant recall bias. Furthermore, there is limited 
ability to convert FFQ data into food composition databases.(508) Weighted or estimated 
diet diaries correlate more closely with biomarkers of food consumption than FFQs (509) 
and can capture more and better-quality data.  
FAST diaries utilise estimated diet diaries which also capture concurrent acute GI 
symptoms, allowing for correlations between meal or food intake and symptom onset 
and severity. This diary was validated in a cohort of 51 IBS cases demonstrating a 
significant relationship between fibre ingestion and abdominal swelling.(401) However, 
that study did not contain a control group which was remedied in the present study. 
The finding that IBS participants in the COMFORT study reported more abdominal pain, 
fullness, swelling, and bloating compared to controls, FC, and FD participants i0073 
expected due to the Rome IV criteria for these disorders. There was, however, no 
significant relationship between meal ingestion and bowel motions identified in the 
COMFORT cohort. This result is consistent with a study investigating postprandial 




after meals.(510) As one might expect, stool form following meals differed between those 
with FC and diarrhoea-predominant (IBS-D, FD) diagnoses. 
Dietary fibre is of particular interest in FGID patients as there is evidence showing that 
increased fibre consumption is associated with health benefits and symptom relief, 
particularly in constipation-predominant disorders.(278, 282, 511) Interestingly, as a 
group, the FGID cases of the COMFORT study consumed less fibre than controls. This 
result was maintained when cases were divided into IBS and ‘other FGID’ groups and IBS-
M participants in subgroup analysis. Furthermore, the presence of acute GI symptoms, in 
particular acute bloating, was found to be associated with a high fibre content of meals. 
IBS patients often report symptoms of pain and bloating with soluble fibre intake, 
particularly with FODMAP such as fructans and galacto-oligosaccharides (GOS).(438, 
512).The relationship between FODMAP intake and GI symptoms will be discussed 
further in Chapter 6.  
A recent large scale meta-analysis of dietary fibre and human health found that the 
greatest reduction of risk for a range of different GI and non-GI diseases came from 
consumption of between 25-29g of fibre per day.(513) In New Zealand, the 
recommended daily intake of dietary is 25-30g per day which is consistent with most 
European and North American countries.(514) However, the average amount of dietary 
fibre consumed daily by participants of the COMFORT study was 21.46g for women and 
22.45g for men. Additionally, only 30.5% of the cohort were found to ingest more than 
25g of fibre on average per day with no difference between Rome IV diagnostic groups.  
While dietary fibre has many physiological effects on the GI tract, the best-characterised 
effects are on gut motility and, consequently, the prevention of constipation. A 2015 
randomised controlled trial in IBS patients (Rome II) and healthy controls found that 
fibre supplementation (Vege Powder, a mixture of fibre from broccoli, chicory, and dried 
whole grains) relieved constipation symptoms compared to the placebo at both two and 
four weeks.(515) Dietary fibre can absorb water, provide physical bulk to the digesta, 
shorten colonic transit time, and provide ease of laxation.(516) The known effects of the 




measured by the SAGIS questionnaire associated with decreased average fibre 
consumption per day in the IBS participants of the COMFORT cohort. 
Decreased dietary fibre consumption in the COMFORT study was also correlated with 
increased symptoms in the SAGIS Epigastric, Acid, and Nausea domains and PROMIS 
Disrupted Swallowing items. Additionally, it was found that there was an association 
between low fibre intake (<15g per day) and increased SAGIS Epigastric, Acid, Nausea, 
and Constipation symptoms, as well as with PROMIS Disrupted Swallowing symptoms. 
The association between upper GI symptoms and dietary fibre is consistent with 
literature that report high dietary fibre intake has been shown to decrease the risk of 
gastro-oesophageal reflux disease.(517, 518) 
A significant association between low fibre intake and PROMIS Depression was observed 
in the COMFORT cohort. Interestingly lower fibre intake has been linked to depression in 
many studies.(496, 516) Several mechanisms have been proposed, including a 
dysfunctional microbiota-BGA and SCFA signalling via the peripheral nervous system or 
the CNS.(74) Organisms in the colonic microbiota which ferment fibre has also been 
shown to catabolise the mucus layer overlying the epithelium when animal models were 
deprived of dietary fibre.(310, 519) This breach of the mucus layer could allow bacteria 
and bacterial products (such as LPS or flagellin) to enter into contact with the epithelium, 
causing increased GI epithelial permeability and inflammation.(520) Increased 
inflammation is a putative pathophysiological mechanism of depression. Increased 
plasma cytokines have been associated with depression in animal and human 
studies.(498)  
5.4.1 Limitations 
Limitations of this study include challenges common to all studies of dietary intake. An 
estimated diet diary is more accurate than FFQ but is still subject to a degree of recall 
bias.(231). Additionally, the current gold standard for diet diaries is a 7-day diary. The 
analyses carried out here using Kai-culator did not differentiate between soluble and 
insoluble fibre. The distinction within the fibre type could allow a more nuanced 
interpretation of the dietary fibre results. While the entry of diet dairy data was triple 




capture potentially misreporting were not undertaken. Finally, the COMFORT study was 
observational and cross-sectional. As a result, causal relationships between food/fibre 
ingestion and symptoms could not be determined. Similarly, no inference could be made 
as to whether there was a degree of reverse causality when participants who are 
experiencing symptoms instigated a change in their diets rather than a change in diet 
causing symptom onset. Furthermore, while there were significant correlations between 
fibre and symptoms, these are considered weak correlations. It is notable, however, that 
these are correlations between habitual diet data and symptoms, and it is unlikely for a 
strong correlation to be found. 
These analyses, however, provide the first data that FAST diaries can discriminate 
between IBS cases and controls. IBS participants in the COMFORT study have been shown 
to ingest fewer carbohydrates and fibre than controls. This lower intake is potentially a 
reflection that IBS patients in this cohort are restricting their diets of food items/groups 
that they perceive are provoking their symptoms. This finding is corroborated by the 
significant association of fibre ingestion with symptoms captured by the FAST diary and, 
in particular, acute bloating symptoms and the decrease in fibre consumption by IBS 
participants in the COMFORT cohort. Interestingly, decreased fibre intake in the 
COMFORT cohort was also associated with worse upper GI, PROMIS Constipation and 
HADS Depression symptoms. This finding suggests that while acute GI symptoms in IBS 
patients are associated with higher dietary fibre, there are longer-term benefits of 
increased dietary fibre intake, particularly in reduced upper GI symptoms, constipation, 
and depression. The relationship between fibre consumption, symptoms, and biological 
systems will be discussed further in Chapter 8.  
5.5 Conclusions 
In agreement with the hypotheses proposed in Section 5.1.1, a greater proportion of IBS 
participants were found to report acute GI symptom onset associated with meal 
consumption compared to controls, FC, and FD participants. IBS participants were also 
found to consume fewer total carbohydrates and dietary fibre compared to controls. 
Despite the decreased consumption of dietary fibre in IBS participants, increased dietary 




Finally, the hypothesis that increased fibre consumption would be associated with 
increased non-acute symptoms was rejected. Increased dietary fibre was found to be 
associated with decreased upper GI and constipation symptom severity and decreased 
depression symptoms as measured by PROMIS, SAGIS and HADS questionnaires. These 
results suggest that IBS participants in the COMFORT study experienced the onset of GI 
symptoms associated with meals with higher fibre content, on a background of reduced 
habitual dietary fibre consumption. However, increased dietary fibre consumption in IBS 
participants was associated with decreased GI symptom severity in longer-term (non-
acute) measures of GI symptoms, suggesting that increased dietary fibre may have 















Diet and lifestyle changes are currently the first-line treatment for IBS (521) and most 
people with IBS are eager to explore dietary options for treating their symptoms.(522) 
As previously mentioned in Section 1.8.2.2, a reduction in FODMAP intake improves IBS 
symptoms (263, 523-525) and is a key evidence-based therapy for IBS. FODMAP include 
fructans, GOS, and polyols including sorbitol and mannitol.(526) Fructose is also 
considered a FODMAP but only when present in excess of glucose. Fructose is a 
monosaccharide absorbed via diffusion or actively transported across the GI epithelial 
barrier via the glucose transporter-2. The most efficient uptake of fructose is when it is 
in equimolar amounts to glucose activating a disaccharide-related co-transporter in the 
gut.(527) However, when more fructose than glucose is present the excess fructose 
cannot be absorbed and acts as a FODMAP. Additionally, lactose can act as a FODMAP in 
individuals with lactase deficiency.(528, 529)  
FODMAP are poorly absorbed in the small intestine and are therefore, available for 
fermentation by colonic microorganisms.(530, 531) These properties contribute to IBS 
symptomology through luminal distension produced by microbial production of gases 
during fermentation, and by osmotically drawing water into the GI lumen (causing 
diarrhoea).(264, 531) While poor absorption of FODMAP occurs to some degree in all 
individuals (264) the association of IBS symptoms with FODMAP ingestion is believed to 
stem from the hallmark pathophysiologies of IBS, visceral sensitivity, and altered GI 
motility.(264, 266) 
The relationship between FODMAP consumption and IBS symptoms has been shown in 
multiple studies of liquid FODMAP formulations (312, 532-535) however, the 
relationship between habitual FODMAP consumption and IBS symptoms in free-living 
populations are poorly understood. Three studies have assessed habitual FODMAP 
intake; two combined data from different clinical trials of which one study assessed GI 
symptoms during the previous fortnight (536) and the other did not investigate dietary 
associations with symptoms.(537) The third study collected habitual diet data using FFQ 




Chapter 5 explored the associations of total dietary fibre content with symptom onset in 
IBS participants. Chapter 6 will attempt to provide a more nuanced analysis of dietary 
fibre by examining the association of total and individual dietary FODMAP content and GI 
symptoms. The analyses of FODMAP content and acute GI symptoms in COMFORT study 
FAST diaries will provide novel information about the relationship between FODMAP 
consumption in the habitual diet and contemporaneous GI symptoms. 
6.1.1 Aims and Hypotheses 
The aims of this chapter were to investigate dietary FODMAP intake and potential 
associations with acute GI symptoms from the COMFORT cohort FAST diaries. The 
hypotheses that were generated were as follows: 
That increased FODMAP consumption will be associated with acute GI symptoms 
in IBS participants 
That the relationship between FODMAP and acute GI symptoms will be dose 
dependent 
6.2 Methods 
6.2.1 FODMAP Data 
Dietary data from the COMFORT participant FAST diaries were used to estimate the 
FODMAP content of each meal and snack. Meals and snacks (referred to subsequently just 
as meals) containing more than a single item were entered into The Monash FODMAP 
Calculator, a cloud-based platform created by Monash University, Melbourne, Australia 
(https://monashfodmapcalculator.com.au/). The FODMAP content of single item meals, 
such as fruit, vegetables, and grain products, was estimated from published FODMAP 
data.(533, 538-542) The Monash FODMAP Calculator includes a growing food 
composition database; however, the FODMAP composition of many commercial products 
is not available. Unavailable diet diary items, including baked goods, cocktails/mixed 
alcoholic and diet beverages, pizza, seasonings, and sauces were entered into the Monash 
FODMAP Calculator by creating recipes within the database or entering a substitute with 




Monash FODMAP Calculator, or not provided as a recipe by the participant (described in 
Section 5.2.1) were taken from the Edmonds Cookery Book©, common substitutions 
used for these analyses are provided in Appendix N. The Monash FODMAP Calculator only 
includes foods that contain FODMAP; therefore, meat and poultry items were not entered 
but ingredients used to flavour or coat meat products (e.g. onion or breadcrumbs) were 
entered.  
To investigate the impact of FODMAP content on acute GI symptoms each meal was 
entered into the Monash FODMAP Calculator as a single day. This enabled each meal to 
accurately align with subsequent symptoms, if they were present. The FODMAP content 
of each meal was exported from The Monash FODMAP Calculator to Microsoft® Excel® 
alongside the corresponding participant ID, the day of the diary the meal was consumed, 
and a letter corresponding to the time the meal was consumed. This data was used to 
create the same unique identifiers for each meal as detailed in Section 5.2.2.1.  
6.2.2 Symptom Data 
Symptom data from the FAST diaries were managed as described in Section 5.2.2. All 
subsequent analyses were performed using SPSS® v25.0 (IBM®, Armonk, New York). 
6.2.3 Analysis 
Participants were grouped according to Rome IV diagnostic criteria. The average meal 
FODMAP intake for each group was calculated and presented as means and standard 
error. A one-way ANOVA was performed to determine if any difference in FODMAP 
consumption existed between Rome IV diagnostic groups. 
Chapter 5 results indicated that IBS cases experienced significantly more meals 
associated GI symptoms than FC, FD, and controls (Table 5.1, Figure 5.1), who were, 
therefore, omitted from analyses of FAST symptom data in order to avoid type 1 (false 
negative) error. As a result the association of FODMAP and symptom onset in IBS patients 
will be explored and discussed. The mean FODMAP intakes per meal are presented in the 
presence or absence of symptoms; and were compared using one-way ANOVA and post 




The relationship between FODMAP consumption and GI and non-GI (non-acute 
symptoms measured using PROMIS, SAGIS and HADS questionnaires which assess 
symptoms experienced over a 7 day period) was explored in IBS participants as described 
by Nybacka et al.(536, 543) Excess fructose, lactose, sorbitol, mannitol, fructans, GOS, 
total FODMAP intake and total FODMAP without lactose were converted from gram 
amounts to grams per 1000 kJ using FAST diet data described in Table 5.3 to create 
energy adjusted FODMAP amounts (g/1000kJ). The energy-adjusted FODMAP intakes 
were converted into quartiles and correlated to non-acute symptoms (described in 
Sections 2.2.2.3.2, 2.2.2.3.3, and 2.2.2.3.4) using a Spearman’s rank correlation. A p-value 
of <0.05 was considered significant. 
The dose-dependent relationship between FODMAP intake and acute symptom 
generation was also explored in IBS participants. Current literature supports a cut off of 
>0.5g of FODMAP per meal for symptom generation in 75% of IBS patients (<0.5g of 
FODMAP being considered ‘low FODMAP’).(544) FODMAP intake per meal per day was 
categorised as <0.5g (low) or >0.5g (high) of each of the FODMAP carbohydrates (excess 
fructose, sorbitol, lactose, fructans, and GOS). Mannitol was excluded from these analyses 
as no participant consumed >0.5g per day. Participants with a high HADS Anxiety 
subscale score (≥11) were also omitted from these analyses to avoid including 
participants whose psychological symptoms may be altering their perception of acute GI 
symptoms.(429, 545) Independent Welch’s t-tests (equal variance not assumed) were 
used to determine if there was a difference in the proportion of participants who 
experienced a symptom after a low or high FODMAP meal.  
6.3 Results 
6.3.1 FODMAP Intake and Presence of Acute Gastrointestinal Symptoms 
FODMAP consumption in the COMFORT study grouped by FGID diagnosis is summarised 
in Table 6.1. There was no significant difference in average daily intake of total or 
individual FODMAP between FGID groups. As described in Section 5.3.1 (Figure 5.1), FD, 
FC, and control participants did not report increased acute GI symptom onset associated 











The average FODMAP content of meals associated with acute GI symptom onset 
compared to meals that were not associated with acute GI symptom onset in IBS 
participants is described in Table 6.2. 
Meals associated with abdominal pain in IBS participants had a significantly higher 
average intake of excess fructose (0.31g, 0.18g, p<0.05) and sorbitol (0.27g, 0.1g, p<0.01) 
as well as significantly higher total average FODMAP intake per meal (3.46g, 2.96g, 
p<0.05), and total FODMAP without lactose (1.57g, 1.14g p<0.05) compared to meals not 
associated with abdominal pain. Abdominal swelling was associated with meals 
containing increased average sorbitol (0.33g, 0.11g, p<0.01), total average FODMAP 
intake (3.26g, 3.02g, p<0.05), and total FODMAP without lactose (1.67g, 1.15g, p<0.05) 
compared to meals not associated with abdominal swelling. Meals associated with 
abdominal fullness had significantly increased fructans (0.81g, 0.57g, p<0.01), GOS 
(0.20g, 0.14g, p<0.01), lactose (2.81g, 1.79g, p<0.05) and total FODMAP (4.10, 2.91, 
p<0.01) compared to meals not associated with abdominal fullness. Finally, meals 
associated with abdominal bloating was associated with increased GOS (0.18g, 0.14g, 
p<0.05) per meal compared to meals not associated with abdominal bloating. There was 
no significant difference in aggregated or individual FODMAP intake associated with 
increased bowel motions.  
6.3.2 Relationship between Increasing FODMAP Intake and Percentage of 
Participants Experiencing Symptoms 
Consumption of >0.5g of excess fructose was associated with a significantly increased 
proportion of IBS participants experiencing bloating, as well as “any symptom” (Figure 
6.1 A). Ingestion of >0.5g of sorbitol per meal was associated with a higher proportion of 
participants experiencing a bowel motion in the three hours following meal ingestion 
(Figure 6.1 B). A significantly increased proportion of participants experienced acute 
fullness associated with ingesting <0.5g of GOS per meal (Figure 6.1 C). There was no 
significant dose-dependent relationship associated with lactose or fructans for any of the 

















Table 6.25 Mean intake of FODMAP (grams) for those meals associated with an acute symptom compared to those that were not associated 




6.3.3 Relationship between FODMAP intake and Non-Acute Symptoms in 
IBS Participants 
Correlations between energy-adjusted FODMAP content and non-acute symptoms are 
summarised in Table 6.3. Correlations of data from IBS participants found positive 
associations between GOS consumption and SAGIS Nausea and PROMIS Belly Pain. 
Additionally, a negative correlation was found between HADS Anxiety and total FODMAP. 
Correlations of energy-adjusted FODMAP intake of IBS-D participants found negative 
correlations between energy-adjusted excess fructose and SAGIS Acid and total FODMAP 
and HADS Anxiety. 
Figure 6. 1 FODMAP categories (x-axis) with a significant difference in the proportion of 
participants (y-axis) experiencing a gastrointestinal symptom having ingested <0.5g of a 
FODMAP compared to those who had ingested ≥0.5g of that FODMAP. A) Excess Fructose, B) 










Positive correlations between energy-adjusted mannitol intake and SAGIS and PROMIS 
scores for Constipation in IBS-D participants were also found. Correlations of energy 
adjusted FODMAP intake and IBS-C found a negative correlation with SAGIS IBS-D and 
PROMIS Diarrhoea score, and positive correlation between sorbitol and PROMIS Anxiety 
scores. A positive correlation between energy-adjusted GOS consumption and a negative 
correlation between energy-adjusted lactose consumption were also observed for 
PROMIS Belly Pain in IBS-C participants. Correlations between energy adjusted FODMAP 
and IBS-M participants questionnaire scores found positive correlations between 
PROMIS Constipation and PROMIS Disrupted Swallowing and excess fructose as well as 
between PROMIS Disrupted Swallowing and fructans.  
6.4 Discussion 
On average, COMFORT study participants ingested 22.50g/day of total FODMAP. This 
finding is more than the average daily intake of FODMAP reported in an Australian IBS 
population (16.3g/day) (546) and slightly more than a New Zealand elderly population 
(21.7g/day).(547) Lactose contributed most to overall FODMAP intake which is 
consistent with other studies assessing habitual FODMAP intake.(546, 547) There was 
however no significant difference in the amount of overall or individual FODMAP 
ingested by the different Rome IV diagnostic groups in the COMFORT study. 
It is thought that the total FODMAP content of a meal contributes to symptom induction 
rather than intake of individual FODMAP.(251) The FAST symptom results support this 
proposition. In the COMFORT cohort, increased average total FODMAP intake was 
associated with acute abdominal pain, swelling, and fullness in IBS participants. As 
described in Section 5.3.1 IBS participants experienced more acute GI symptoms 
associated with meal consumption compared to controls, FD and FC participants. 
Therefore, only IBS participants were included in these analyses to minimise type 1 (false 
negative) statistical error. However, significant differences in the proportion of 
participants who experienced an acute symptom after individual FODMAP were also 
found. This finding suggests that by collecting contemporaneous GI symptom data 
alongside diet data, the FAST diary provided more power to detect symptoms associated 




For IBS participants, average excess fructose intake was higher in meals associated with 
acute abdominal pain compared to meals not associated with this symptom. At least 50% 
of the general population are unable to completely absorb 25g of fructose.(548) Although 
this is higher than the average NZ consumption (median habitual daily intake 21.6g in 
males and 18.3g in females (549)), it is relevant when considering associations between 
FODMAP intake and acute GI symptoms in FGID cohorts. Additionally, energy-adjusted 
excess fructose was positively correlated with PROMIS Constipation and Disrupted 
Swallowing in IBS-M participants. Conversely energy-adjusted excess fructose was 
negatively correlated with SAGIS Acid in IBS-D participants, and with SAGIS IBS-D and 
PROMIS Diarrhoea in IBS-C participants. These results are inconsistent with published 
literature which show that consumption of unabsorbed fructose, as with any FODMAP, 
are usually associated with increased abdominal pain and diarrhoea in susceptible 
individuals.(550, 551) Nybacka et al. reported similar results, with different FODMAP 
carbohydrates associated, positively and negatively, with different IBS symptoms 
measured over seven days.(536) These inconsistencies could be explained as it is 
believed that symptom onset associated with FODMAP intake is thought to occur 
rapidly.(266, 532) 
High sorbitol intake was associated with an increased proportion of COMFORT study 
participants experiencing acute abdominal pain and swelling. Interestingly, the co-
ingestion of fructose and sorbitol in a meal by IBS patients was found to increase breath 
hydrogen concentration (indicating bacterial fermentation). However, the peak rate of 
hydrogen production was not correlated with increases in symptom scores.(552) This 
finding suggests that symptom onset in IBS patients caused by sorbitol (and mannitol) 
may be independent of bacterial fermentation.(533, 552)  
Higher lactose content in meals was also associated with a higher proportion of acute 
abdominal fullness in IBS participants. Conversely, energy-adjusted lactose was 
negatively correlated with PROMIS Belly Pain in IBS-C participants. High lactose-
containing foods, such as liquid or soft dairy products, are not generally restricted in a 
low FODMAP diet unless a patient has demonstrated symptoms of lactose intolerance or 
malabsorption.(553, 554) Unfortunately the COMFORT study did not collect data on 




hypolactasia is common and dairy products are commonly associated with symptom 
onset by IBS patients.(529) Therefore, lactose was included in the above analyses, and 
the association of symptom onset with both with total FODMAP and total FODMAP 
without lactose was explored. A higher total FODMAP and total FODMAP without lactose 
content were both associated with abdominal pain and swelling onset compared to meals 
not associated with these symptoms. A higher total FODMAP content was associated with 
abdominal fullness, as was lactose content, however, total FODMAP without lactose 
content was not associated with abdominal fullness.  
A higher average fructan intake was also associated with a higher proportion of 
abdominal fullness in IBS participants. Additionally, energy-adjusted fructans were 
positively correlated with PROMIS Disrupted Swallowing in IBS-M participants. An 
elegant randomised controlled trial in non-coeliac gluten sensitivity participants 
demonstrated that fructans induced significantly greater pain, diarrhoea and satiety 
scores compared to gluten or placebo, however, these differences did not meet statistical 
significance.(262) Wheat (high in fructans) and dairy containing products have been 
associated with satiety and fullness in other IBS/FGID cohorts.(555, 556)  
Higher average meal GOS content was associated with both acute abdominal fullness and 
bloating. Energy-adjusted GOS consumption was positively correlated with SAGIS Nausea 
scores in all IBS participants and with PROMIS Belly Pain in all IBS and IBS-C participants. 
Humans do not naturally express the small intestinal hydrolases capable of digesting 
oligosaccharides, including GOS and fructans. These FODMAP are, therefore, unable to be 
absorbed in the small intestine and are available for fermentation by the colonic GI 
microbiota. In agreement with the COMFORT study results, an in vivo study using 
commercially available enzymes to catabolise GOS found that GOS consumption was 
associated with bloating, nausea, and flatulence symptoms in IBS patients.(557) 
However, no correlation was observed between change in breath hydrogen production 
and the placebo or study treatment, an observation which is in agreement with Symons 
et al.(552) suggesting that the mechanism by which GOS cause GI symptoms could be 
independent of bacterial fermentation.(557) The dose dependent association of GOS and 




As mentioned previously, it is believed that luminal distension caused by bacterial 
fermentation of FODMAP in conjunction with visceral hypersensitivity is a mechanism of 
symptom onset associated with FODMAP consumption in IBS populations.(530, 531) The 
observation that symptom onset associated with FODMAP consumption may be 
independent of bacterial fermentation (533, 552, 557) suggests that other mechanisms 
may be triggering symptoms in FGID populations. A potential mechanism has been 
described by Zhou et al., who reported that a diet high in FODMAP given to rat models 
was found to increase the proportion of LPS producing bacteria in the GI tract.(559) A 
subsequent study found, when bacterial supernatant from human IBS patients (shown to 
have increased faecal LPS compared to healthy controls), was intracolonically injected 
into germ-free rats, increased colonic permeability and visceral hypersensitivity 
developed.(267) This finding suggests that proliferation of certain bacteria that have the 
ability to induce an inflammatory response and GI epithelial barrier dysfunction 
associated with FODMAP ingestion. This mechanism could be involved in triggering 
visceral hypersensitivity in a mechanism that is not related to luminal distension.  
While FODMAP intake may be associated with symptom onset in some individuals, GI 
symptoms can be induced by a number of factors including: CNS processing, 
psychological co-morbidities, genetics, and physical factors. Consequently, the 
association between FODMAP and symptoms are likely individualised and highly 
subjective.(560, 561) Cognitive and emotive factors such as anxiety and depression, 
which are common in IBS, are known to affect the processing and intensity of pain 
experienced by an individual (429, 562, 563) and similarly stress has been associated 
with worsening IBS symptoms.(230, 560, 564) Accordingly, participants who had a high 
level of psychological co-morbidity (abnormal HADS Anxiety subscale) were removed 
from analyses investigating a dose-dependent (consumption of <0.5g of FODMAP per 
meal compared to >0.5g per meal) relationship with between acute GI symptoms and 
FODMAP intake in COMFORT study participants.(261, 545) 
The analyses showed that average ingestion of ≥0.5g of excess fructose per meal was 
associated with a higher proportion of IBS patients experiencing bloating (24%), as well 
as ‘any symptom’ (43%). Average ingestion of ≥0.5g of sorbitol per meal was associated 




excess fructose and sorbitol findings support previous research showing that FODMAP 
induce diarrhoea through their osmotic nature.(264) Non-significant trends indicated 
that ingestion of >0.5g of an individual FODMAP was associated with increased 
proportion of participants who experienced a symptom.  
Taken together the findings from the COMFORT study support the known role of 
FODMAP in the induction of IBS pain, bloating, and diarrhoea.(251, 266, 530, 534, 535) It 
is important to note that the COMFORT cohort analyses did not find a difference between 
the proportion of IBS participants that experienced a bowel motion within three hours of 
a meal (Appendix P). Correlations between energy-adjusted FODMAP intake and 
COMFORT study PROMIS, SAGIS, and HADS questionnaire data found negative and 
positive correlations between different FODMAP carbohydrates and different 
questionnaire data. Furthermore, these correlations were inconsistent between different 
IBS subtypes, which as previously mentioned could be due to rapid onset of GI symptoms 
after FODMAP consumption.(266, 532) Therefore, it may be inappropriate to measure 
the relationship between FODMAP consumption and (acute) symptom generation using 
tools that generalise the experience of symptoms over a week or fortnight.  
6.4.1 Limitations 
This study has limitations that should be considered. As mentioned previously, the 
COMFORT study was observational and cannot investigate the causal role of FODMAP on 
IBS symptoms. Furthermore, tests of FODMAP sensitivities were not undertaken. As 
FODMAP sensitivities are likely highly individualised, the inability to discern individual 
FODMAP sensitivities may have contributed to the lack of significant associations 
between ≥0.5g FODMAP ingestion per meal and the proportion of participants who 
experienced a symptom(s).  
6.5 Conclusions 
This was the first study in free living FGID patients and controls that has investigated the 
relationship between habitual meal FODMAP content and acute GI symptoms. This study 
showed the complexity of the role FODMAP play in acute symptoms and highlights the 




Increased consumption of total and individual FODMAP was associated with the onset of 
GI symptoms within three hours of meal consumption in IBS participants of the 
COMFORT study. Furthermore, a dose-dependent relationship between some individual 
FODMAP and acute GI symptoms was observed. Consumption of >0.5g/meal of three of 
the FODMAP carbohydrates was associated with acute symptoms; excess fructose was 
associated with increased bloating and ‘any symptom’, sorbitol was associated with 
increased bowel motions, and GOS was associated with increased fullness. Ingestion of 
≥0.5g of FODMAP per meal was also associated with increased acute GI symptom 
generation in FGID cases, compared to ingestion of <0.5g of FODMAP per meal. These 
results suggest that both total and individual FODMAP consumption is related to acute GI 
symptoms experienced by FGID cases. The type and amount of FODMAP associated with 
GI symptoms is individualized and future research is needed to better understand this 
relationship. This could be addressed by the use of exclusive enteral nutrition with 
supplementation of individual FODMAPs or different types of fibre. Additionally, positive 
and negative correlations between total and individual FODMAP and non-acute GI 
symptoms were found. This finding suggests that it may not be appropriate to measure 
the impact of FODMAP consumption on GI symptoms using questionnaires that cover 






Section Three will further describe biological aspects of the colonic micro-environment 
in COMFORT study participants and then explore the relationship between these 
biological aspects with results described in Chapters 3 to 6. Chapter 7 will describe the 
relative gene expression of the TJ components and NGF in diarrhoea predominant (IBS-D 
and FD) participants and controls. The relationship between the expression of the TJ 
components and NGF and GI and non-GI symptoms is then further explored. Chapter 8 
will describe the faecal butyrate concentrations of COMFORT study participants. Finally 
the relationships between faecal butyrate concentration, TJ component and NGF relative 
gene expression, butyrate producing bacteria, dietary fibre and FODMAP consumption, 
demographics and GI and non-GI symptoms will be explored and put into context in a 
















Changes in the expression of TJ proteins and increased paracellular permeability have 
been documented in studies of IBS pathophysiology. TJ are the apical-most protein 
complex in sheets of epithelial cells such as the GI tract and function to control 
paracellular permeability. The literature about this putative pathophysiological 
mechanism for IBS is discussed in Section 1.10.3.  
Results from GI permeability studies, including changes in TJ protein expression, are 
contradictory, with differences in gene and protein expression varying between different 
IBS subtypes and between different study populations. A summary of the findings of this 
literature is presented in Table 1.2. However, while alterations to gene and protein 
expression are inconsistent, altered GI permeability is consistent in at least a subset of 
IBS patients.(343) While different study populations have demonstrated that all IBS 
subtypes demonstrate a degree of increased paracellular permeability, it has been shown 
to be most prominent in those with IBS-D.(216, 352, 356)  
Therefore, the following analyses investigated changes in gene expression in diarrhoea 
predominant (IBS-D and FD) COMFORT study participants and controls. Although 
reported in isolation in this chapter, the analysis of changes to TJ mRNA detailed in this 
chapter are explored further in the context of diet, microbiota and microbial metabolites, 
demographics, and GI and non-GI symptom data in Chapter 8.  
For the purposes of these analyses three TJ target genes were chosen. OCLN, ZO-1 and 
CLDN-1, were investigated due to their wide expression in the human GI tract and well-
defined functions (see Section 1.10.2). These targets have also been implicated in the 
aetiology of increased GI permeability observed in IBS patients, particularly those with 
IBS-D.(343) Additionally, NGF gene expression was investigated due to the association of 
the NGF protein with visceral hypersensitivity and a positive correlation with GI 
permeability.(216, 354) NGF signalling is thought to both directly and indirectly increase 
GI permeability.(565) Direct increases in GI tract permeability are mediated by NGF 
binding to its high-affinity receptor Tropomyosin receptor kinase A, and have been 
demonstrated by the decreased GI permeability in animal models treated with anti-NGF 




released by activated mast cells in the GI mucosa,(190) and therefore is involved in 
inflammatory signalling. The role of NGF in inflammatory signalling is thought to be 
predominantly in triggering visceral pain by activating TRPV-1 receptors.(216)  
7.1.1 Aims and Hypotheses 
The aims of these analyses were to explore the expression of mRNA for ZO-1, CLDN-1, 
OCLN and NGF in IBS-D participants compared to controls and participants with FD. This 
generated the following hypotheses: 
That TJ mRNA expression will be decreased in IBS-D patients compared to controls 
and FD participants  
That NGF mRNA expression will be increased in IBS-D patients compared to control 
patients and FD participants 
That mRNA expression of the TJ components and NGF will respectively be 
negatively and positively associated with GI and non-GI symptoms 
7.2 Methods 
7.2.1 RNA Extraction 
RNA was extracted from one biopsy collected from the descending colon of COMFORT 
study participants who had consented to tissue sample collection. All RNA extractions 
were performed using RNeasy® Mini Kit (Qiagen, Hilden, Germany). Tissue was 
disrupted using a mortar and pestle followed by homogenisation using a needle and 
syringe. RNA extractions were performed according to manufacturer’s instructions. RNA 
concentration was determined using a Nanodrop™ 8000 Spectrophotometer (Thermo 
Scientific™, Massachusetts, United States of America). 
7.2.2 Reverse Transcription Polymerase Chain Reaction 
RNA was reverse transcribed to cDNA using qScript™ cDNA SuperMix (Quanta 
Biosciences, Maryland, United States of America) according to manufacturer’s 




combined on ice, sealed, and mixed by vortexing. Reverse transcription was performed 
using a SuperCycler (Kyratec, Queensland, Australia), reaction conditions included 5 
minutes at 25°C, 42°C for 1 hour and 85°C for 5 minutes. cDNA was stored at -20°C until 
it was used. 
7.2.3 Primer Validation 
Amplification conditions for genes of interest were optimised using a gradient PCR, 
specific oligonucleotide primer (primer) sequences used are shown in Table 7.1(347, 
566-568). All primer sets were optimised in order to find an annealing temperature that 
produced a specific PCR product. This allowed all primers to be run on the same q-RT-
PCR plate which reduced the risk of potential variation between different q-RT-PCR 
plates or between different q-RT-PCR runs.  Primers were diluted to 50µM in 1x TE buffer 
(10mM Tris, 1mM EDTA in distilled water) to create a stock solution. The primer stock 
solution was further diluted to 10µM in Milli-Q H2O to create a working solution. PCR was 
performed using FIREPol® DNA polymerase (Solis BioDyne, Tartu, Estonia), the reaction 
mix is shown in Appendix Q.  
 
Cycling conditions for gradient PCR were as follows; 95°C for 15 minutes, 35 cycles of 
denaturation 95°C for 30 seconds, annealing intervals between 55-66°C for 30 seconds, 
elongation 72°C for 30 seconds, a further 72°C for 2 minutes, and 25°C for 30 seconds. 
One reaction was performed per annealing temperature. The annealing temperatures 
 




were: 56°C, 56.3°C, 56.9°C, 57.9°C, 59.3°C, 60.4°C, 61.7°C, 62.8°C, 64.3°C, 65.3°C, 65.9°C, 
and 66°C.  
Amplified cDNA was run on an agarose gel (2%) in 1xTBE buffer (89mM Tris, 89mM Boric 
Acid, 2mM EDTA in distilled water) at 100 volts using a PowerPac™ 300 (Bio Rad, 
California, United States of America) and a Horizon 58 Agarose (Life Technologies, 
California, United States of America) Gel Electrophoresis chamber. DNA was stained using 
SYBR® safe and the product size was determined using HyperLadder™ 100bp (Bioline, 
London, United Kingdom) Agarose gels were visualised using Alliance™ Q9 Advanced 
imager (UVITEC Cambridge, Cambridge, United Kingdom). An annealing temperature 
which amplified a single product of the expected size for each of the primer sets was 
chosen for Real-time quantitative PCR (RT-qPCR) 
7.2.4 Real-Time Quantitative PCR 
RT-qPCR was performed using Quanta PerfeCTa® SYBR® Green SuperMix® (Quanta 
Biosciences, Maryland, United States of America) with 384 well FrameStar®(Roche, 
Basel, Switzerland). The reaction mixture is shown in Appendix Q and reactions were run 
in a LightCycler® 480 instrument (Roche, Basel, Switzerland). The reaction conditions 
for RT-qPCR were as follows; 1 cycle of preincubation: 95°C for 30 seconds, 45 cycles of 
amplification: 95°C for 5 seconds, 62°C for 15 seconds, and 70°C for 10 seconds. A melt 
curve was also performed as follows: 95°C for 5 seconds, 67°C for 1 minute, followed by 
97°C continuously. A negative control, using DNase and RNase free water was included 
on every plate. All reactions were performed in triplicate.  
7.2.5 Analysis 
Ct values were averaged for gene expression quantification and the 2-ΔΔCT method was 
used to determine relative mRNA expression fold change.(569) This method uses an 
endogenous control gene (in these analyses hypoxanthine phosphoribosyltransferase 
(HPRT) to normalise the relative gene expression of the gene of interest (in these analyses 
ZO-1, OCLN, CLND-1 and NGF). HPRT is a validated and commonly used housekeeping 
gene in the determination of gene fold changes in colonic tissue. (567, 570) Differences 




Kruksal-Wallis test in order to determine if the population means differed between 
diagnostic groups. Finally, gene expression between different categories of GI symptoms 
was determined by using the PROMIS cut off score off 55. PROMIS scores <55 were 
categorised as ‘normal’ and ≥55 were categorised as ‘symptomatic’. A p-value of <0.0020 
was considered significant after Bonferroni correction.  
7.3 Results 
7.3.1 Demographics 
RNA was extracted from 37 participants diagnosed with IBS-D, nine participants 
diagnosed with FD and 40 controls (Table 7.2). There was no significant difference in the 
genders or ages of the diagnosis groups.  
7.3.2 Primer Validation 
Results of gradient PCR and expected PCR product size for each of the genes of interest 
and the house keeping gene are shown in Figure 7.1A-E. An annealing temperature of 
62°C was determined to be optimal for each primer set. 
 






Figure 7.1 Results of gradient PCR for each set of primers analysed run on an agarose gel. A) HPRT, B) CLDN-1, C) NGF, D) OCLN, E) 
ZO-1, and F) the expected size in base pairs for the product of each primer set investigated. The white arrowhead indicates the 





7.3.3 Real-Time Quantitative PCR 
Differences in mRNA expression of the TJ components and NGF between the Rome IV 
diagnostic groups were determined using Wilcoxon and pairwise Kruskal-Wallis tests. 
ZO-1 and OCLN mRNA expression were significantly decreased in IBS-D participants 
compared to both controls and FD participants (Figure 7.2A-D). A significant decrease in 
NGF expression was also found in IBS-D participants compared to controls. No significant 
difference in CLDN-1 expression was found. There was no difference in the expression of 
any of the genes investigated between males and females, and there was no significant 
correlation with age (Appendix R). 
Figure 7.2 Comparison of 2-ΔΔCT gene expression fold change results (y-axis) between controls, 




7.3.4 Associations between Gene Expression and Symptoms 
Significant differences in mRNA expression between ‘normal’ and ‘symptomatic’ PROMIS 
scores are shown in Table 7.3. Significantly decreased ZO-1 expression was associated 
with symptomatic bloating. Decreased OCLN was significantly associated with 
symptomatic PROMIS Belly Pain and Reflux items. Significantly decreased expression of 
CLDN-1 was associated with symptomatic PROMIS Anxiety, Bloating, and Constipation 
items. Significantly decreased NGF expression was associated with symptomatic PROMIS 
Belly Pain, Bloating, Constipation, Depression and Diarrhoea items. 
7.4 Discussion 
The results from COMFORT study diarrhoea-predominant cases (IBS-D and FD) and 
controls demonstrate that the mRNA expression levels of ZO-1 and OCLN in IBS-D were 
decreased in comparison to controls and FD participants. This finding is consistent with 
other human studies which have demonstrated decreases in the mRNA for these genes or 
in the protein level of colonic (351, 354) and jejunal (352) biopsies. These decreases of 
TJ protein expression in these studies positively correlated with increased paracellular 
permeability in both ex vivo and in vivo experiments.(351, 359) Conversely other similar 
studies have found no difference in mRNA expression of ZO-1 or OCLN.(353, 355)  
Similarly, in the COMFORT study IBS-D participants there was no difference found in the 
expression of CLDN-1 mRNA between different Rome IV diagnostic groups. This result is 
again consistent with some (353, 360) but not all studies.(354, 356) CLDN-1 is one of 
dozens of members of the CLDN gene superfamily. Therefore, it is possible that changes 
in CLDN genes may occur differentially between patients. For example, CLDN-15 has been 
found to be decreased in colonic tissue of IBS-D patients (257) while increased 












Table 1.2 provides a summary of the current literature involving TJ protein expression in 
IBS patients. That these results are not consistent across all studies is likely indicative of 
differences in the pathophysiology of IBS symptoms in different populations 
Additionally, TJ are not static structures; they exist in a state of flux and are able to 
respond to environmental changes and challenges.(572) Therefore, a single biopsy from 
a single region in the GI tract may not provide a full picture of the state of tissue wide 
fluctuations in gene expression and permeability. Furthermore, differences exist in the 
permeability of the mucosa between different parts of the GI tract and individuals likely 
have different baseline levels of GI permeability.(573) Methodological differences, 
differences in location of biopsies taken, or in patient recruitment, as well as confounders 
such as diet may cause differences in gene expression results.  
Regardless of the lack of agreement of the mechanism of increased GI permeability, a 
recent systematic review has shown that up to 62% of IBS-D patients, up to 50% of PI-
IBS patients, and up to 25% of IBS-C patients have increased GI permeability.(343) 
Whether the increased GI permeability in these studies are the cause or a result of IBS or 
another pathophysiology is yet to be elucidated. 
The decreased expression of ZO-1 was associated with a significantly higher burden of 
PROMIS Bloating and PROMIS Belly Pain item score, although this did not meet statistical 
significance. Decreased OCLN expression, was found to be associated with increased 
PROMIS Belly Pain and Reflux scores, however, these did not remain significant after 
adjustment for multiple comparisons. Interestingly, while CLDN-1 expression was not 
found to be significantly decreased in IBS-D participants, decreased expression was 
significantly associated with increased PROMIS, Bloating and Constipation symptom 
burden. Similarly, to OCLN, these p-values did not remain significant after adjustment for 
multiple comparisons. 
Correlations between TJ mRNA expression and symptoms have been reported in several 
studies which are summarised in Table 1.2. In particular, associations of TJ protein 
expression and abdominal pain have been demonstrated in a number of studies,(353, 
354) as has an association between TJ proteins and upper GI symptoms.(365) 




also been demonstrated in numerous studies.(367-369) An association between small 
bowel permeability and increased depression symptoms was demonstrated in a Chinese 
population by Li et al.(574) Psychological distress is known to alter GI barrier 
permeability,(575) although the mechanism is incompletely understood,(574, 576) it is 
thought that psychologically mediated activation of mast cells and subsequent 
inflammation are involved.(577) The association found in COMFORT study analyses 
between decreased expression of CLDN-1 mRNA and increased PROMIS Anxiety 
symptoms appears to be the first association reported between altered TJ mRNA 
expression and anxiety symptoms. Additionally, to date these analyses appears to report 
the first significant association found between TJ mRNA expression and PROMIS Bloating 
and Constipation symptoms in FGID patients. Notably, these associations are in 
diarrhoea-predominant participants, therefore, constipation symptoms are unlikely to be 
significant or frequent. The associations with CLDN-1 expression could represent a 
distinct pathophysiology for these symptoms in diarrhoea-predominant participants. 
As mentioned in Section 1.10.3 there are several different putative mechanisms for 
altered GI permeability in IBS patients. These include immune system activation and 
inflammation, dysbiosis, and stress.(357, 374, 578) While increased GI permeability (as 
measured by detection of excreted indigestible probes) is thought to correspond to 
altered expression of TJ proteins there is also evidence for disruptions to the actomyosin 
cytoskeleton in increased GI permeability. The interaction of the actomyosin 
cytoskeleton with TJ protein complexes is a vital component of the control of paracellular 
permeability and the ability of the GI epithelial barrier to respond to the luminal 
environment.(334)  
Martinez et al. demonstrated increased activation of MLC kinase in the jejunum of IBS-D 
patients as well as phosphorylation of MLC II.(352) The phosphorylation of MLC II was 
also observed in duodenal tissue of IBS-D patients (257) and in the colon of stressed 
mouse models.(579) Phosphorylation of MLC II by MLC kinase causes cytoskeleton 
contraction and has been implicated in increased GI permeability in both human IBS 
cases,(352) in mouse models treated with colonic supernatant from IBS-D patients,(389) 
and in mouse models of PI-IBS.(580) Additionally, bacterial proteases have been 




permeability in PI-IBS (581) and IBS-D patients.(389) The actions of soluble mediators 
such as proteases, cytokines, and mast cell-derived histamine and tryptase have also been 
implicated in the onset of visceral hypersensitivity in IBS patients.(389, 582)  
Altered NGF signalling is implicated in stress-induced visceral hypersensitivity and GI 
epithelial barrier dysfunction, both of which are present in IBS-D patients.(565) 
Additionally, it has been demonstrated in animals models of colitis that mice treated with 
anti-NGF antibodies do not develop increased GI permeability.(583) Surprisingly, results 
from the COMFORT study found that NGF mRNA expression was decreased in IBS-D 
participants compared to controls, the opposite of another study that found levels of NGF 
mRNA significantly increased in the colon of IBS patients.(354) Furthermore, decreased 
NGF mRNA expression in the IBS-D participants was found to associated with 
symptomatic PROMIS Belly Pain, Constipation, Diarrhoea, and Depression symptoms in 
COMFORT study analyses, despite a reported link between NGF and visceral 
hypersensitivity.(216) 
NGF is a neurotransmitter that is initially expressed as a pre-pro-protein before 
undergoing both post-transcriptional and post-translational modifications.(584) The 
primers used in these analyses were selected to amplify a sequence within the first of 
NGF’s three exons (Appendix S) and should consequently not be affected by mRNA 
splicing. It is, therefore, unlikely that post-transcriptional modification of pre-pro-NGF 
was involved in the reduction of NGF expression in these participants. However, another 
possibility to consider is that quantifying NGF mRNA expression does not differentiate 
between the expression of NGF in epithelial tissues or mast cells. NGF is primarily 
released by mast cells and secondarily by epithelial cells in the GI tract.(585) While mast 
cells have not yet been quantified in COMFORT study tissue samples, several studies of 
GI permeability in IBS patients link the decreased expression of TJ mRNA or protein to 
increased mast cell presence and activation.(216, 357) It is unlikely that mast cells were 
increased in number or activation in controls compared to IBS-D patients.(585, 586) 
Thus, decreased NGF mRNA expression detected in IBS-D participants in the COMFORT 




These results may reflect that visceral hypersensitivity in IBS-D participants in the 
COMFORT cohort is not mediated by NGF expression. However, as previously mentioned, 
it is unlikely that everyone with IBS-D has identical pathophysiologies. Therefore, a 
deeper understanding of participants’ individual biology could potentially allow a better 
phenotype of IBS-D participants to be determined in this cohort.  
7.4.1 Limitations  
There are limitations of these analyses to consider; while expression of mRNA in these 
tissues provides insight into gene expression, it does not necessarily translate into 
protein expression or function. Protein analyses need to be completed in these samples 
to verify the results from the RT-qPCR analyses. Additionally, GI permeability in vivo was 
not assessed in the COMFORT cohort. Therefore, these analyses are not sufficient to 
determine if paracellular permeability is affected by the altered expression of TJ mRNA, 
or indeed if GI permeability is greater, or clinically relevant, in the COMFORT study cases 
compared to the controls. Tissue from IBS-D and FD participants were used in these 
analyses, and so future analyses should also include tissue samples from IBS-C, IBS-M and 
FC participants. Furthermore, histological analyses of tissue samples to quantify the 
presence of any immune cells and analyse local and systemic immune and inflammatory 
responses would provide more context of the changes in gene expression observed in 
IBS-D participants in this study.  
7.5 Conclusions 
These analyses partially support the hypotheses proposed in Section 7.1.1. OCLN and ZO-
1 were both found to have decreased expression in IBS-D participants compared to FD 
participants and controls. Additionally, decreased expression of TJ mRNA were 
associated with significantly increased PROMIS Bloating, Belly Pain, Reflux, Constipation 
and Anxiety items. The hypothesis that NGF would be increased in IBS-D participants was 
rejected. NGF was found to be decreased in IBS-D participants compared to controls. 
Additionally, this decreased expression was associated with increased PROMIS Belly 
Pain, Bloating, Constipation, Depression and Diarrhoea items. It is unlikely that 
asymptomatic controls have increased mast cell infiltration in their colon, therefore, this 




participants in the COMFORT study. Further analyses are needed to validate this result. 
The association between the mRNA expression results and results examined in Chapters 
















The pathophysiology of IBS is complex and multifactorial. Studies of IBS pathophysiology 
often focus on single biological systems. However, biological systems do not exist in 
isolation. Increasingly researchers are undertaking systems biology approaches to the 
study of the multiple pathophysiologies of IBS. Attempting to understand IBS 
pathophysiology without taking metabolic products of bacterial metabolism into account, 
one risks missing vital aspects of disease pathogenesis.  
SCFA (particularly butyrate) are key metabolites that reflects variables such as the intake 
and composition of the diet and the composition and function of the GI microbiota. As 
discussed in Section 1.9.2, butyrate is of particular interest in the pathophysiology of IBS 
due to its functions encompassing multiple biological systems. Butyrate is produced by a 
‘functional group’ of bacteria, (i.e., bacteria that may not be closely genetically related but 
perform similar functions.(587) The most abundant butyrate-producing species in the 
human GI tract are F. Prausnitzii, E. rectale, and R. intestinalis.(386, 587, 588) 
Literature supports a positive correlation between fibre and FODMAP consumption and 
the relative abundance of butyrate-producing bacteria (589, 590) and this increased 
abundance has been associated with increased butyrate production.(591, 592) Studies in 
animal models and cell culture models support the association of butyrate 
supplementation with increased TJ protein expression.(303, 305, 593) In addition, 
studies have characterised different combinations of the interactions between diet, the 
GI microbiota, butyrate production, TJ protein expression, and GI symptoms.(216, 589, 
594-596) These interactions have not previously been explored in humans.  
In this chapter, the findings from Chapters 2-7 will be correlated and discussed. 
Additionally, the associations with these results and faecal butyrate concentrations from 
the participants of the COMFORT study will be explored.  
8.1.1 Aims and Hypotheses 
The aims of these analyses were to determine if there were significant associations 
between components of the luminal microenvironment and the demographic and GI and 




parameters of the luminal microenvironment included fibre/FODMAP consumption, the 
relative abundance of butyrate-producing bacteria, faecal butyrate concentration and TJ 
components (ZO-1, CLDN-1, and OCLN) and NGF gene expression. The hypotheses 
explored in this chapter are: 
That a positive association exists between dietary fibre/FODMAP consumption, the 
relative abundance of butyrate-producing bacteria, faecal butyrate concentration 
and TJ/NGF gene expression diarrhoea predominant FGID participants (IBS-D and 
FD). 
That GI symptoms will be negatively correlated with TJ/NGF gene expression 
8.2 Methods 
8.2.1 Measurement of Faecal Short-Chain Fatty Acids 
The collection and storage of stool samples were as described in Section 2.2.2. The 
analysis of organic acids in stool samples was carried out by Dr Janine Cooney and 
colleagues at Plant and Food Research, Hamilton, New Zealand. The protocol is provided 
in Appendix T. The weight of stool samples was normalised by removing water from all 
samples. The resulting butyrate concentration for all samples is provided in µmol/g dry 
weight. Only the butyrate data are reported here. 
8.2.2 Statistical Analysis 
8.2.2.1 Differences in Butyrate Concentration between Groups 
Differences in faecal butyrate concentration between Rome IV diagnosis groups were 
determined using a one-way ANOVA or independent samples Welch’s t-test (equal 
variances not assumed). Additionally, a Wilcoxon test was used to determine if faecal 
butyrate concentration differed between participants with constipation (IBS-C and FC) 
and diarrhoea (IBS-D and FD). Pairwise Kruskal Wallis tests were performed on 
significant Wilcoxon test results in order to determine if population means differed 




8.2.2.2 Correlations between Biological and Questionnaire Data 
The relationship between PROMIS, SAGIS, and HADS questionnaire items, demographics 
(age, MET, alcohol consumption, and ESL), dietary fibre and FODMAP consumption, 
butyrate-producing bacteria relative abundance, faecal butyrate concentration, and 
TJ/NGF gene expression was explored using Spearman’s rank correlation. This analysis 
was used to measure the degree of association between two continuous variables. The 
sequencing, annotation and normalisation of the major known butyrate producers in the 
human stool samples (298) are described in Section 4.2.3.1-4.2.3.2. Normalised species 
with a relative abundance of >0.01% included in these analyses were E. rectale, R. 
intestinalis, Roseburia faecis, Roseburia hominis, Roseburia inulinivorans, Eubacterium 
ramulus, Coprococcus catus, Coprococcus eutactus, Coprococcus comes, F. prausnitzii, 
Anaerotruncus colihominis and Subdoligranulum variabile (Table 8.1). The dietary fibre 
data and FODMAP data used for these analyses were taken from day three of the diet 
diary (Section 2.2.2.1.6). Dietary data were collected within 24 hours of stool sample 
collection and was therefore considered the most relevant to the luminal 
microenvironment data used in these analyses.(390) 
Two sets of Spearman’s rank correlations were performed. The first was in the diarrhoea-
predominant (IBS-D and FD) participants, and the second was in the constipation-
predominant (IBS-C and FC) participants.  




The correlation analysis of diarrhoea-predominant participants included luminal 
microenvironment data and demographics. The constipation-predominant subset 
correlation, however, omitted TJ gene expression as this has not been performed. Both 
correlation matrices were sub-divided. The first matrix reports correlations between 
variables in the luminal microenvironment and demographics. The second matrix reports 
the correlations between variables in the luminal microenvironment and GI (and non-GI) 
symptoms. Correlation coefficients <0.4 were considered weak, between 0.4 and 0.59 
were considered moderate and >0.6 were considered strong, p values of <0.05 were 
considered significant. Correlations between GI and non-GI symptoms were arranged 
into the factors described in Chapter 4 (shown in Figure 4.2). Correlations between factor 
items and the individual components of the luminal microenvironment were considered 
as groups of correlations.  
8.3 Results 
8.3.1 Differences in Faecal Butyrate Concentration between Rome IV 
Groups 
No significant differences were found in the faecal butyrate concentration measured 
between Rome IV diagnostic groups (Table 8.2). A comparison between participants with 
constipation and those with diarrhoea revealed that the former had significantly less 
butyrate in the stool samples (Constipation: 33.9µmol/g versus Diarrhoea: 50.3µmol/g, 
p=0.01; Table 8.3 and Figure 8.1).  




8.3.2 Correlations between Components of the Luminal Microenvironment 
Results from correlations between components of the luminal microenvironment are 
shown in Tables 8.4 and 8.5. Tables 8.6 and 8.7 detail correlations between GI and non-
GI symptoms and components of the luminal microenvironment. Here, each correlation 
matrix has been divided into two tables for ease of interpretation (constipation-
predominant and diarrhoea-predominant). 
. 
Table 8.32 Average faecal butyrate concentration between constipation- (IBS-C and FC) 
and diarrhoea- (IBS-D and FD) predominant participants 
Figure 8.1 Box plots showing difference in mean faecal butyrate concentration (y-
axis, μmol/g) between constipation-predominant (IBS-C and FC), diarrhoea-
predominant (IBS-D and FD) and controls (x-axis). *p<0.05 between constipation- 





Table 8.33 Spearman’s rank correlations between the components of the colonic luminal microenvironment in diarrhoea-predominant participants. Significant 






Table 8.34 Spearman’s rank correlations between the components of the colonic luminal microenvironment in constipation-predominant participants. 




Both matrices are presented in their entirety in Appendix U. Positive correlations are 
highlighted in red and negative correlations are highlighted in blue. Each correlation 
matrix has been divided into two tables for ease of interpretation.  
8.3.2.1 Correlations between Components of the Luminal Microenvironment: 
Diarrhoea-Predominant 
Dietary fibre was weakly to moderately positively correlated with R. intestinalis, F. 
prausnitizii, C. eutactus and R. hominis respectively in diarrhoea-predominant 
participants (between r=0.31 and 0.55, p<0.05). C. catus was positively correlated with 
sorbitol, fructans and total FODMAP (r=0.33, 0.42 and 0.39 respectively, p<0.05). R. 
intestinalis was positively correlated with excess fructose (r=0.34, p<0.05) and lactose 
was positively correlated with S. variabile (r=0.32, p<0.05). E. ramulus, F. prausnitizii, R. 
intestinalis, and R. inulinivorans were weakly and moderately positively correlated with 
faecal butyrate concentration (r=0.36, 0.35, 0.59, and 0.53 respectively, p<0.05). No 
significant correlations were found between faecal butyrate concentration TJ gene 
expression, dietary fibre and/or FODMAP consumption. ZO-1 was found to positively 
correlate with R. inulinivorans (r=0.45, p<0.05) and negatively correlate with E. rectale 
(r=-0.41, p<0.05). CLDN-1 was negatively correlated with R. intestinalis, and R. 
inulinivorans (r=0.40 and 0.59, p<0.05).  
8.3.2.2 Correlations between Components of the Luminal Microenvironment: 
Constipation-Predominant 
No significant correlations were found between dietary fibre and butyrate-producing 
bacteria in constipation-predominant participants. Negative correlations were found 
between C. catus and fructans (r=-0.50, p<0.01) and R. hominis and excess fructose (r=-
0.46, p<0.01). A positive correlation was found between mannitol and S. variabile. There 
were also positive correlation correlations between faecal butyrate concentration and E. 
rectale, C. catus, R. faecis and R. inulinivorans (r= 0.52, 0.41, 0.43, and 0.51 respectively, 
p<0.05). Finally, A. colihominis was not detected in constipation predominant 
participants. This could be due to growth conditions not being favourable in constipation 




8.3.2.3 Correlation between Components of the Luminal Microenvironment and 
Gastrointestinal/Non-Gastrointestinal symptoms 
Associations between PROMIS, SAGIS, and HADS questionnaire data, demographic data, 
and components of the luminal microenvironment are shown in Tables 8.6 and 8.7. 
Correlations for GI and non-GI items were grouped using the FA described in Section 
4.3.2. These corresponded to four factors: Factor 1 (SAGIS Epigastric, IBS-D, and Nausea, 
PROMIS Belly Pain, Diarrhoea, and Bloating), Factor 2 (PROMIS and HADS Anxiety and 
Depression), Factor 3 (SAGIS Acid, PROMIS Disrupted Swallowing and Reflux), and Factor 
4 (PROMIS and SAGIS Constipation). Correlations are reported as groups of positive and 
negative correlations between demographics and individual components of the luminal 
microenvironment and Factors 1 to 4 rather than individual correlations to minimise the 
risk of type 1 statistical error. 
8.3.2.3.1 Diarrhoea-Predominant Correlations 
Correlations between the IBS and upper GI factor (Factor 1) and demographics, 
components of the luminal microenvironment in diarrhoea-predominant participants 
are reported in Table 8.6. These correlations show that Factor 1 items weakly to 
moderately negatively correlated with age (between r=-0.28 to -0.41, p<0.05), the 
relative abundance of C. catus (between r=-0.30 to -0.37 p<0.05) and ZO-1 and OCLN gene 
expression (between r=-0.31 and -0.38, p<0.05). Significant weak negative correlations 
between Factor 1 items and fibre/FODMAP consumption (between r=-0.27 and -0.28, 
p<0.05) were also seen.  
Weak negative correlations were found between Factor 2 items and ELSI-sf scores 
(between r=-0.29 and -0.38). A. colihominis was significantly positively correlated with 
both HADS and PROMIS Depression scores (r=0.37 and r=0.37 respectively, p<0.05), 
whereas E. ramulus was weakly to moderately significantly positively correlated with 
Factor 2 items (between r=-0.33 and -0.43, p<0.05). Factor 2 scores were weakly and 
moderately negatively correlated with ZO-1, OCLN and CLDN-1 gene expression (between 
r=-0.30 and -0.43, p<0.05). Similarly, butyrate and FODMAP consumption were each 
weakly negatively correlated with Factor 2 items (r=-0.34 and -0.27, p<0.05 and r=-0.25 




Correlations between Factor 3 items (SAGIS Acid and PROMIS Disrupted Swallowing and 
Reflux) and demographic, components of the luminal microenvironment are reported in 
Table 8.6. Significant weak positive correlations were found between Factor 3 scores and 
butyrate-producing bacteria (r=0.32 – 0.35, p<0.05). 
Finally, correlations between Factor 4 items (SAGIS and PROMIS Constipation), 
demographic, and components of the luminal microenvironment are reported in Table 
8.6. A weak to moderate negative correlation was found between Factor 4 items and NGF 
gene expression (r=-0.46 and r=-0.35 p<0.05) and a weak positive correlation between 
Factor 4 items and mannitol consumption (r=0.35 and r=0.29, p<0.05).  
 8.3.2.3.2 Constipation-Predominant Correlations 
Correlations between the IBS and upper GI factor (Factor 1 items), demographic, and 
components of the luminal microenvironment in constipation-predominant participants 
are reported in Table 8.7. As found with diarrhoea-predominant participants, Factor 1 
items were found to be weakly negatively correlated with age (r=-0.31 to -0.37), C. catus 
abundance (r=-0.36 and -0.37), p<0.05) and FODMAP consumption (between r=-0.26 and 
-0.37, p<0.05). 
Factor 2 items were all weakly negatively correlated to ELSI-sf scores (r=-0.28 and -0.38), 
and were weakly negatively correlated with butyrate-producing bacteria (r=-0.33 and -
0.39, p<0.05) and FODMAP consumption (r=-0.28 and -0.30, p<0.05). A single weak 
correlation was also found between HADS Depression scores and E. rectale (r=0.35, 
p<0.05).  
No significant correlations were found between Factor 3 items and demographics, 
butyrate concentration, nor fibre or FODMAP consumption. However, PROMIS Disrupted 
Swallowing was weakly to moderately positively correlated with an increased abundance 
of butyrate-producing bacteria (r=0.33 and 0.51, p<0.05). 
Finally, correlations between Factor 4 items (SAGIS and PROMIS Constipation), 
demographic, and components of the luminal microenvironment are reported in Table 
8.7. No consistent groups of correlations were found in either demographics or individual 





Table 8.35 Spearman’s rank correlations between gastrointestinal and non-gastrointestinal questionnaire items, grouped based on Factor analysis results, and components of 
the colonic luminal microenvironment in diarrhoea-predominant participants. Significant positive correlations are highlighted in red, and significant negative correlations are 





Table 8.36 Spearman’s rank correlations between gastrointestinal and non-gastrointestinal questionnaire items, grouped based on Factor analysis 
results, and components of the colonic luminal microenvironment in constipation-predominant participants. Significant positive correlations are 




However, a single, weakly negative correlation was found between Factor 4 items and 
butyrate-producing bacteria, similar to that observed in diarrhoea-predominant 
participants (Table 8.6). 
8.4 Discussion 
8.4.1 Differences in Butyrate Concentration between Constipation- and 
Diarrhoea-Predominant Participants 
Participants diagnosed with constipation-predominant disorders (IBS-C and FC) in the 
COMFORT study had lower butyrate concentration (dry weight) in their stool samples 
compared to diarrhoea-predominant (IBS-D and FD) participants. Butyrate was reported 
in the above analyses as µmol/g (dry weight) to normalise samples for stool form. This 
result is consistent with other studies that report lower and higher faecal butyrate 
concentration in IBS-C and IBS-D patients, respectively.(141, 290, 597) However, the 
concentration of faecal butyrate in IBS has been found to be higher in some IBS study 
populations.(479, 598) There are several possible explanations for this inter-study 
variation that may include methodological differences and/or differences in the study 
populations.(588) Additionally, differences in the GI microbiota composition could affect 
butyrate production.(591) Interestingly, the CCA results reported in Figure 4.3 show that 
PROMIS and SAGIS Constipation items were negatively correlated with Lachnospiraceae 
and Eubacteriaceae and positively correlated with Oscillospiraceae. Given that these three 
families house all of the major butyrate-producing bacteria of the GI tract included in the 
above analyses,(298) this finding raises the possibility that constipation symptoms may 
be exerting selection pressure on different bacterial families in these participants. 
Only an estimated 5-10% of SCFA are excreted in faeces due to the efficient uptake of 
SCFA by the colonic epithelium. In humans butyrate concentration is usually between 5-
20µmol/g (wet weight).(599, 600) The average concentration of butyrate in COMFORT 
study participants is 33.9µmol/g for constipation predominant participants and 




artefact of normalising stool samples for the water content of the sample by using the dry 
weight of the sample. Moreover, colonic transit time was negatively correlated with faecal 
butyrate concentration.(596) A by-product of the production of SCFA in the colon is 
hydrogen gas,(295) which is a vital substrate utilised by methanogens to produce 
methane.(601) Furthermore, IBS patients are known to have altered fermentation 
profiles as measured by altered hydrogen gas production (602) and decreased colonic 
pH, considered indicative of increased bacterial fermentation and associated SCFA 
production.(596) As mentioned in Section 1.4, methane gas has been shown to be 
sufficient to increase colonic transit time and reduce colonic motility in humans.(603) 
Subsequently, a potential explanation of the increased colonic transit time associated 
with decreased faecal total SCFA and butyrate concentration (141) could be the increased 
abundance of methane-producing organisms utilising the increased production of 
hydrogen gas.  
As noted in Section 4.4, an increased relative abundance of methanogens was associated 
with PROMIS and SAGIS Constipation questionnaire items. This positive correlation 
between methane-producing bacteria and questionnaire items assessing constipation 
suggests of increased methane production, which could lead to increased colonic transit 
time and therefore be associated with decreased concentration of observable faecal 
butyrate. Hydrogen, methane production, and colonic transit time were not measured in 
the participants of the COMFORT study and would be important to consider in future 
studies.  
8.4.2 Butyrate Relationship with Fibre and FODMAP Consumption 
Data from the COMFORT study suggested that there were no differences in fibre 
consumption between IBS-D, FD, IBS-C, and FC subgroups (Section 5.3.2). Interestingly, 
another study has reported that decreased faecal butyrate concentration in IBS-C 
patients is independent of fibre intake.(290) No difference in FODMAP consumption was 




evidence of a significant correlation between dietary fibre or FODMAP intake on day 
three of the diet diary and faecal butyrate concentration.  
As mentioned in Section 2.2.2.1.6, the three-day diet diaries were non-consecutive; 
therefore, only day three of the diet diary provided the most biologically relevant data for 
these analyses.(390) Other studies have reported that increased dietary fibre 
consumption is associated with increased production of SCFA.(594, 604) Complicating 
these results, butyrate-producing bacteria can utilise the mucus layer of the colonic wall 
as a substrate for SCFA production in the absence of dietary fibre.(605) Therefore, the 
observed concentration of faecal butyrate may not correlate with dietary fibre 
consumption and potentially explains the inconsistent relationship between faecal 
butyrate concentration and dietary fibre among studies.  
 
8.4.3 Butyrate-Producing Bacteria Relationships to Fibre and FODMAP 
Consumption 
Analysis of the COMFORT study data shows several different positive correlations found 
between dietary fibre, FODMAP consumption, and butyrate-producing bacteria in both 
diarrhoea- and constipation-predominant participants. Changes in the relative 
abundance of the faecal microbiota have been demonstrated to be associated with 
increased fibre intake. In particular, positive correlations exist between dietary fibres and 
the microbes that can utilise fibre as a substrate for fermentation.(487, 594) Furthermore 
differences in dietary fibre consumption have also been reported to alter the metabolic 
activity of butyrate-producing bacteria, as shown by alterations in SCFA production in 
populations that habitually consume different amounts of dietary fibre.(594, 606) 
The human GI microbiota is an incredibly complex, metabolically active ecosystem that 
is shaped by several different factors in humans; diet is prominent among these 
factors.(390, 607) One of the vital functions of the GI microbiota is the breakdown of food 




bacteria to utilise the indigestible components of the diet likely provides these species 
with a competitive advantage in the GI tract.(608) Dietary fibre comes in many forms that 
are broadly grouped as soluble and insoluble fibre.(609) Foods often contain a mixture 
of both.(610) Insoluble fibres are generally hydrolysed into smaller soluble fragments by 
a few specialised bacteria and are then fermented into SCFA by secondary degraders, 
while soluble fibres are easily fermentable.(589, 611) As previously mentioned, the 
distinction between soluble and insoluble dietary fibre was unable to be assessed in these 
analyses (Section 5.4.1).  
FODMAP are a mixed group of completely or partially unabsorbable carbohydrates 
available for fermentation by SCFA-producing bacteria.(480, 589, 612) Both fructans and 
GOS are both well studied and are increasingly added to foods as a ‘prebiotic’.(613-615) 
Fructans are short or long-chained polymers of fructose. Similarly, GOS are either short 
or long chains of galactose.(614) Humans do not express hydrolases capable of breaking 
down these polymers. Consequently, all dietary fructans and GOS are available to be 
scavenged by the colonic microbiota for fermentation, promoting the proliferation of 
bacteria capable of fermenting these compounds, including bifidobacteria and 
lactobacilli, both considered ‘good’ (health-promoting) bacteria.(615-618) Interestingly, 
different fructans appear to be fermented preferentially by different bacterial 
species,(173) and this may contribute to the different SCFA profiles reported in different 
studies.(141, 290, 479, 597, 598) For example, fermentation of some fructans resulted in 
mainly butyrate production,(173) whereas other fructans are metabolised to acetate and 
lactate, which are then cross-fed to butyrate-producing species.(619, 620) 
The ability to produce butyrate is not restricted to any one bacterial family or phylum. 
The most common butyrate-producers are members of the Lachnospriaceae, 
Eubacteriaceae and Oscillospiraceae families.(298) Interestingly, Figure 4.2 shows that 
while Lachnospiraceae were negatively correlated and Oscillospiraceae positively 
correlated with PROMIS and SAGIS Constipation items, the opposite correlations were 
found for PROMIS Diarrhoea and SAGIS IBS-D items. This finding suggests that rather 




GI environment in constipation-predominant participants supports the growth of 
Oscillospriaceae and inhibits the growth of Lachnospiraceae. Likewise, the opposite may 
be true in the diarrhoea-predominant participants.  
Almost all of the butyrate-producing members of the Lachnospiraceae family shown in 
Table 8.1 utilise acetate to produce butyrate.(298) This could potentially indicate a 
disruption in acetate metabolism in constipation-predominant participants in the 
COMFORT study, leading to decreased abundance of bacteria who rely on acetate cross-
feeding. Additionally, as mentioned earlier, a positive correlation also existed between 
methane-producing organisms and constipation symptoms. This finding suggests that 
methane production is associated with constipation and slower transit time in these 
participants, which are known to alter the GI microbiome.(145, 297) Oscillospiraceae may 
be better able to grow in a methane-rich environment(621), resulting in an increased 
relative abundance of this family over Lachnospiraceae in constipation-predominant IBS 
participants. Interestingly, the altered relative abundance of Lachnospiraceae has been 
shown previously in other IBS cohorts (290, 622) and animal models of IBS.(623) 
However, the faecal microbiome composition of IBS participants has been reported to 
differ among study populations,(486, 598, 622, 624-627) making it difficult to draw any 
significant conclusions. 
8.4.4 Gene Expression Relationship to Components of the Luminal 
Microenvironment 
CLDN-1 and ZO-1 gene expression correlated positively with butyrate-producing bacteria, 
while NGF gene expression negatively correlated with mannitol consumption. 
Additionally, ZO-1 and OCLN were strongly positively correlated with each other, while 
OCLN was negatively correlated with NGF. Studies investigating the relationship between 
butyrate production (or supplementation), altered TJ protein expression and/or 
microbiota are almost exclusively conducted in animal or in vitro models. These models 




may prevent inflammation, visceral hypersensitivity and/or the expression/distribution 
of OCLN.(623, 628, 629)  
Animal and cell culture studies have demonstrated that butyrate supplementation alters 
the expression and distribution of TJ proteins in colonic epithelia, particularly ZO-1, 
OCLN, and CLDN-1.(303, 305, 593) There are several possible mechanisms by which 
butyrate upregulates these proteins. Butyrate is the primary energy source of 
colonocytes, therefore increased butyrate or increased abundance of butyrate producers 
may allow the maintenance of energy-expensive components such as TJ.(303, 304, 630)  
Butyrate also acts as a histone deacetylase inhibitor, and therefore is able to upregulate 
gene expression. Wang et al. demonstrated that butyrate supplementation induced the 
upregulation of CLDN-1 by stabilising promoter/enhancer interactions.(593) A well-
known action of butyrate is as an anti-inflammatory agent. Supplementation of butyrate 
has been shown to inhibit inflammation (305) and down regulate Toll-like receptor 4 in 
cell culture (which induces inflammation reactions in the presence of bacteria).(301, 
631) Furthermore, butyrate has been shown to inhibit activation of NF-κB (a regulator of 
innate immunity) in rodent models.(309) Supplementation of butyrate in IBS, 
diverticulitis and IBD studies resulted in inconsistent outcomes. Some studies reported 
decreased visceral hypersensitivity (319, 632, 633) which is thought to be due to the 
desensitisation of TRPV-1, a nociceptor by butyrate.(322) Other studies of butyrate 
supplementation, however, have demonstrated no improvement to symptoms of 
diversion colitis (634) or left-sided colitis.(635) 
Interestingly, Long et al. found that butyrate enemas stimulated the expression of NGF 
protein in enteric glial cells, which were associated with visceral hypersensitivity.(636) 
Furthermore, butyrate supplementation was associated with an increased acid-sensing 
ion channel 1a, which is a known nociceptor in the GI tract and thought to be involved in 
the development of visceral hypersensitivity.(323) As discussed in Section 7.4, the 




(216, 637) and positively correlated with mast cell infiltration in children (363) and 
adults (216) with IBS.  
Interestingly, aberrant NGF signalling has been associated with altered GI barrier 
function in animal models of stress.(638) Additionally, corticotrophin-releasing hormone 
has been shown to stimulate the release of NGF from mast cells.(211) As discussed in 
Section 1.5, stress is a major trigger of symptoms in IBS patients who have been found to 
show exaggerated hypothalamic-pituitary-adrenal axis responses to stressors.(108, 189, 
191) Therefore, NGF may play a vital role in visceral sensitivity onset in patients with 
‘top-down’ FGID pathophysiologies.  
8.4.5 Relationship between GI and Non-GI symptoms and Components of 
the Luminal Microenvironment 
8.4.5.1 Factor 1 
PROMIS, SAGIS, and HADS questionnaire items were grouped according to the FA 
described and discussed in Section 4.3.2. Factor 1 items (SAGIS Epigastric, IBS-D and 
Nausea domains and PROMIS Belly Pain, Diarrhoea and Bloating items) from both the 
diarrhoea-predominant and constipation-predominant analyses showed negative 
correlations with age. As mentioned in Section 2.4, IBS incidence is known to be greatest 
in those aged less than 50 years.(411, 412) Additionally, abdominal pain has been 
reported to be milder in patients over 50 years of age.(419) The incidence of functional 
dyspepsia, which is characterised by upper GI symptoms, was negatively correlated with 
age.(639) Conversely, upper GI symptom severity associated with functional dyspepsia 
is positively correlated with age in both Asian and western populations.(640, 641) The 
prevalence of functional gastroduodenal disorders (to which functional dyspepsia 
belongs) was not assessed in COMFORT study participants. As mentioned in Section 4.4, 
these disorders often overlap, and the creation of Factor 1 in the FA supports that there 
may be some overlap of functional bowel disorders and functional gastroduodenal 
disorders in the COMFORT study.(642) Interestingly, Choi et al. reported that functional 




However, in an Australian population, there was a greater proportion overlap of 
functional dyspepsia with IBS-D and IBS-M patients.(644) 
In the COMFORT study, negative correlations of Factor 1 items were observed with fibre 
and FODMAP consumption. These results indicate that decreased fibre and FODMAP 
consumption are associated with Factor 1 including both lower and upper GI symptoms. 
Additionally, increases in these symptoms were associated with decreased relative 
abundances of butyrate-producing bacteria. A potential explanation for these results 
could be the decreased consumption of fibre and FODMAP, associated with increased 
Factor 1 symptoms could lead to the decreased relative abundance of butyrate-producers 
and therefore decreased faecal butyrate concentration,(589) resulting in increased upper 
and lower GI symptoms.(596) Butyrate concentration, however, was not associated with 
the observed decreased relative abundance of butyrate-producing bacteria in this study. 
Butyrate is produced by a functional group of bacteria. Other species may be functionally 
redundant in this situation and, therefore, a decrease in butyrate concentration was not 
found.(645) For example, C. catus, a member of the Lachnospiraceae family of Firmicutes, 
utilises acetate to produce butyrate.(646) In this study, a negative correlation with C. 
catus relative abundance and Factor 1 items was observed in both diarrhoea- and 
constipation-predominant participants, however faecal butyrate concentration is not. As 
previously mentioned, in the absence of dietary fibres, butyrate-producing bacteria can 
catabolise the mucus layer of the GI epithelium as a substrate for SCFA production.(310)  
Additionally, a thinner mucus layer, activation of the innate immune system and 
increased pathogen susceptibility are observed in fibre-deprived animal models (519) 
suggesting a fibre deprived environment leaves the GI epithelial barrier at higher risk of 
assault by luminal contents, with the likelihood of increased inflammation. Thus, while 
butyrate concentration may not be observably decreased, butyrate-producing bacteria 
and fibre consumption could lead to increased lower and upper GI symptoms due to 




correlated with colonic ZO-1 and OCLN gene expression in diarrhoea-predominant 
participants, which implies the GI epithelial barrier could be compromised.(647) 
8.4.5.2 Factor 2 
Factor 2 items (SAGIS and PROMIS Anxiety and Depression) negatively correlated with 
ESL scores in both diarrhoea and constipation-predominant participants. The association 
of ESL with anxiety and depression symptoms was demonstrated in Chapter 3, which 
showed that ESL was independently associated with increased symptom severity of 
HADS Anxiety and Depression in the COMFORT study participants.  
The relative abundance of E. ramulus was negatively correlated with Factor 2 items in 
both diarrhoea and constipation-predominant participants. Additionally, C. catus was 
associated with PROMIS Anxiety symptoms in constipation-predominant participants. 
Interestingly, HADS Depression symptoms have previously been associated with 
decreased relative abundances of Lachnospiraceae (485) to which C. catus belongs. E 
ramulus is a member of the Eubacteriaceae family within the Firmicutes phylum that, like 
C. catus, utilises acetate for butyrate production.(298) The consistent reduction of E. 
ramulus suggests that this species may be involved in the pathophysiology of anxiety and 
depression in IBS patients. It is also possible that the pathophysiology of Factor 2 items 
create an environment in which Eubacteriaceae growth is disadvantaged. There were 
also some positive correlations between butyrate-producing bacteria and Factor 2 items 
in both diarrhoea- and constipation-predominant participants. These results suggest that 
Factor 2 items are associated with alterations in the GI microbiota.(485, 648, 649) 
As with Factor 1 items, Factor 2 items were also negatively correlated with consumption 
of FODMAP. Diarrhoea-predominant participants also showed a negative correlation 
between faecal butyrate concentration and colonic ZO-1, OCLN and CLDN-1 gene 
expression and Factor 2 items. A potential explanation for these results could be 
decreased FODMAP consumption could be associated with decreased relative 




and the potential breakdown of the mucus layer. Subsequent inflammation and decrease 
of TJ gene expression could arise from this.(519, 589, 647)  
Interestingly, an increased relative abundance of C. catus has previously found to be 
associated with decreased depression symptoms.(650) One study found that IBS-D 
patients with increased GI permeability had higher HADS Depression and Anxiety 
scores.(574) This results was not, however, observed in another study,(365) likely 
reflecting that GI permeability could potentially be modulated by many different 
pathophysiologies. For instance, Vanuytsel et al. demonstrated that acute stress (a ‘top-
down’ pathophysiology), leading to the activation of mast cells through the hypothalamic-
pituitary-adrenal axis, increased GI permeability in vivo.(575) Additionally, GI infections 
by pathogens such as C. difficile have been shown to directly disrupt TJ by targeting the 
actin cytoskeleton (381) in an example of ‘bottom-up’ pathophysiology. 
8.4.5.3 Factor 3 
Factor 3 items (SAGIS Acid and PROMIS Disrupted Swallowing and Reflux) were found to 
positively correlate with the relative abundance of butyrate-producing bacteria in both 
constipation- and diarrhoea-predominant participants. This result could reflect that 
items in this factor are associated with a pathophysiology related to visceral 
hypersensitivity throughout the entire GI tract. Visceral hypersensitivity is a hallmark 
symptom of both FGID and functional gastroduodenal disorders.(651, 652)  
As mentioned in Section 4.4, overlaps between functional dyspepsia and IBS diagnosis 
have been observed in different studies.(643) Both Factors 1 and 3 contained items that 
assess upper GI symptoms. However, Factor 1 also contained IBS and lower GI symptoms. 
Factor 1, therefore, appears to group IBS participants who experience an overlapping set 
of FGID symptoms and upper GI symptoms. Factor 3 exclusively contains upper GI 
symptoms. Therefore, this factor may group IBS, FD, and FC participants who experience 
greater severity of upper GI symptoms. This finding may also reflect distinct 
pathophysiology within this group of participants. While faecal butyrate concentration 




producing bacteria suggests that these questionnaire items could be associated with 
increased SCFA production.(591, 592)  
Additionally, as previously mentioned, butyrate-induced visceral sensitivity, which has 
been demonstrated in animal models,(636) is believed to be related to the activation of 
TRPV-1 and subsequent signalling of nociception that is interpreted as visceral 
hypersensitivity.(322) A study of butyrate enemas in healthy volunteers, however, found 
decreased visceral pain scores upon distension by rectal barostat,(314) while an 
unrelated study found no correlation with symptom severity or quality of life in an IBS 
cohort.(141) The positive correlations found between butyrate-producing bacteria and 
Factor 3 items could reflect an increased abundance of the Firmicutes phylum in general, 
as an increase in Firmicutes : Bacteroidetes ratios appears to be one of the few consistent 
faecal microbiota alterations found in different IBS study populations.(140) 
8.4.5.4 Factor 4 
Factor 4 items (SAGIS and PROMIS Constipation) negatively correlated with colonic NGF 
expression and positively correlated with mannitol consumption in diarrhoea-
predominant participants. No consistent correlations between these items were found in 
the demographic, faecal butyrate-producing bacteria, faecal butyrate concentration, or 
fibre/FODMAP consumption categories in constipation-predominant participants. 
However, a negative correlation between Factor 4 items and Lachnospiraceae bacteria 
was found in both constipation- and diarrhoea-predominant participants.  
The negative correlation between colonic NGF expression and Factor 4 items is intriguing 
as animal models have shown that increased NGF protein signalling leads to increased 
differentiation of enterochromaffin cells and subsequently increased 5-HT release.(189, 
653) As mentioned in Section 1.3, 5-HT has many roles in the GI tract, including sensation 
perception and motility.(654, 655) Furthermore, NGF protein and 5-HT expression are 
reportedly positively correlated in rectal biopsies taken from children with IBS-D.(363) 
Colonic NGF mRNA was decreased in COMFORT study IBS-D participants and may 




discussed in Section 2.4, constipation symptoms were found to be significantly higher in 
IBS-D participants compared to controls, suggesting that constipation symptoms may be 
significant in IBS-D participants. The negative correlation seen here could represent a 
distinct pathophysiology in a subset of diarrhoea-predominant participants who report 
some constipation symptoms that, in turn, are mediated by decreased NGF expression 
and an associated decrease in 5-HT signalling.(656) In support of this hypothesis are 
studies that show butyrate and butyrate-producing bacteria affect both the secretion of 
5-HT in the GI tract (309, 322, 657) and the expression of NGF (636) in animal models.  
8.4.6 Limitations 
There are some limitations to the analyses performed in this chapter. Only faecal butyrate 
concentration has been examined in these analyses due to the in-vivo relationship 
between butyrate and tight junction gene and protein expression. Nor was faecal fibre 
measured, and so ongoing fermentation of fibre by faecal microbes is a possibility, 
particularly in participants who potentially have fast colonic transit. It is, however, 
notable that microbial fermentation of fibre was reduced when samples were kept at 4℃ 
for 24 hours.(490) The exploration of the other SCFA would provide more information 
about the dynamic environment of the GI tract in COMFORT participants. The Spearman’s 
rank correlations were used to correlate a large amount of data for these analyses, which 
can result in an increased risk of type 1 statistical error. However, these analyses were 
hypothesis-driven, and single correlations were not considered to reduce this risk of 
error. Additionally, as the COMFORT study is observational, and as correlations were 
performed in these analyses, causal relationships cannot be determined. As breath 
hydrogen and methane tests were not performed in COMFORT study participants, these 
analyses cannot determine if GI microbiota fermentation was altered in FGID cases 
compared to controls. Likewise, colonic intra-luminal concentrations of SCFA were also 





Biologically plausible correlations were found between contents of the luminal 
microenvironment (fibre/FODMAP consumption, butyrate-producing bacteria, faecal 
butyrate concentration and colonic TJ/NGF expression). Additionally, GI and non-GI 
items, grouped together by the factors determined in Chapter 4, were shown to associate 
with components of the luminal environment.  
Collectively these findings support the hypotheses outlined in Section 8.11. Items 
included in Factors 1 (IBS and upper GI) and 2 (anxiety and depression) were negatively 
correlated with contents of the luminal microenvironment, age, and ESL, respectively. 
Factor 3 items (upper GI) were positively correlated with butyrate-producing bacteria, 
and Factor 4 items (constipation) were negatively correlated with colonic NGF gene 
expression.  
These analyses utilised multiple datasets: dietary composition, faecal microbiome data, 
faecal butyrate concentration, colonic gene expression, and demographic data. By 
utilising data from these multiple biological systems, novel insights into potential 
pathophysiologies in FGID were found. These include the association of decreased colonic 
NGF expression and potentially decreased butyrate concentration with constipation 
symptoms in diarrhoea predominant participants, and the association of increased 















FGID have a complex and multifactorial pathophysiology, which has led to inconsistent 
and contradictory results in scientific literature. Furthermore, Rome IV, the current ‘gold 
standard’ diagnostic criteria for FGID, is a consensus criteria and does not take underlying 
pathophysiology into account. Rome IV is a useful tool in clinical practice; however, it may 
be insufficient to categorise patients, particularly for clinical trials or research.(461) 
Rome IV, released in 2016, made sweeping changes to the criteria, particularly in 
functional bowel disorders which encompasses IBS, FC, and FD. This major revision 
included considering that functional bowel disorders exist on a spectrum where the 
borders of diagnosis between these disorders are not always clear and can shift over 
time.(3) These updated criteria, however, meant that patients once diagnosable with an 
FGID under Rome III were know considered to have subclinical symptoms. Subsequently, 
patients diagnosable with FGID under Rome IV have more severe GI symptoms and more 
severe concomitant psychological distress.(71) This finding suggests that Rome IV 
criteria have potentially skewed the functional bowel disorder population to comprise 
significant patients with significant psychological comorbidities that modulate GI 
symptoms. 
This thesis aimed to compare the Rome IV diagnostic criteria to an unsupervised, agnostic 
analysis method (FA). Additionally, multiple biological systems were utilised to generate 
novel insights into FGID pathophysiology, the hypothesis generated, and whether they 
were supported are summarised in Table 9.1. This work subsequently describes the 
association of components of the luminal microenvironment with GI and non-GI 
symptoms using faecal microbiome composition, faecal butyrate concentration, colonic 
tissue gene (TJ and NGF) gene expression, and diet data. Additionally, these associations 
were carried out in the context of a novel FA and use a hypothesis driven approach to 





Table 37 A summary of the hypotheses generated by this thesis and whether these hypotheses were 




Chapter Hypothesis Outcome 
1. Introduction and Literature 
Review 
  
2. Recruitment and Cohort 
Description of COMFORT Study 
That differences in GI and non-GI 
symptoms will exist between 
FGID groups and controls 
Supported 
That IBS participants will 
experience increased GI and 
non-GI symptom severity 
compared to controls, FD, and FC 
participants 
Supported 
3. Risk Factors of Anxiety and 
Depression in FGID Participants 
That multivariate analysis will 
identify significant demographic 
or symptomatic risk factors for 
anxiety and depression in 
participants meeting the 
diagnostic criteria for IBS and 
FGID 
Supported 
4. Factor Analysis leading to 
Reclassification of Functional 
Bowel Disorders 
That a FA of the COMFORT study 
GI and non-GI symptom severity 
and symptom burden 
questionnaire data will cluster 
participants differently to Rome 
IV diagnostic groupings 
Supported 
That the results of a FA will 
reflect changes in the 
composition of the faecal 
microbiota better than Rome IV 
diagnostic groupings 
Supported 
5. Habitual Fibre Consumption in 
IBS Participants 
That FGID cases will experience 
more symptoms within three 
hours of meal consumption 
(acute symptoms) compared to 
controls 
Partially Supported 
That there will be decreased 
fibre consumption in FGID cases 
compared to controls 
Supported 
That increased fibre content in 
meals will be associated with 
acute symptom onset compared 
to meals with less fibre content 
Supported (in IBS participants) 
That increased fibre 
consumption will be associated 
with increased non-acute 
symptoms in FGID cases 
compared to controls 
Rejected 
6. Habitual FODMAP 
Consumption in IBS 
That increased FODMAP 
consumption will be associate 
with acute GI symptoms in IBS 
participants 
Supported 
That the relationship between 
FODMAP and acute GI symptoms 





7. Colonic Tight Junction and 
Nerve Growth Factor Gene 
Expression 
That TJ gene expression will be 
decreased in IBS-D patients 
compared to controls and FD 
participants 
Supported 
That NGF gene expression will be 
increased in IBS-D participants 
compared to control participants 
and FD participants 
Rejected 
That gene expression of the TJ 
components and NGF will 
respectively be negatively and 
positively associated with GI and 
non-GI symptoms 
Partially Supported 
8. Associations between 
Symptoms and Biological Data 
That a positive association 
exsists between dietary 
fibre/FODMAP consumption, the 
relative abundance of butyrate-
producing bacteria, faecal 
butyrate concentration and 
TJ/NGF gene expression in 
diarrhoea predominant FGID 
participants (IBS-D and FD) 
Supported 
That GI symptoms will be 
negatively correlated with 
TJ/NGF gene expression 
 
Supported 




9.2 How Do Functional Gastrointestinal Disorder Patients 
Cluster? 
Section One presented a series of analyses describing and exploring the structure of the 
COMFORT cohort. IBS, FC, and FD participants demonstrated higher GI and non-GI 
symptom scores compared to controls. The cohort was broadly comparable to the general 
New Zealand population and showed similar results to international FGID cohorts. 
Subsequently, risk factors of concomitant anxiety and depression were evaluated, 
demonstrating that ESL was independently associated with symptomatic anxiety and 
depression in this FGID cohort. However, when adjusted for ESL, participants who 
experienced diarrhoea-predominant symptoms (IBS-D, IBS-M, and FD) demonstrated a 




Subsequent grouping of FGID participants into factors revealed that diarrhoea-
predominant participants (IBS-D, IBS-M, and FD) grouped into an anxiety and depression 
cluster, suggesting that these participants have a distinct pathophysiology. Additionally, 
a cluster of IBS participants indicated an overlap of lower and upper GI symptoms. This 
observation is made in many studies using FA and suggests that potential overlap of 
functional bowel disorders and gastroduodenal disorders represent a distinct 
pathophysiology. Other clusters of constipation-predominant participants (IBS-C, IBS-M, 
and FC) and upper GI symptoms (IBS-M) reveal potentially distinct pathophysiologies for 
these clusters. These clusters also reveal the heterogeneity within Rome IV diagnostic 
groups, particularly IBS-M, as different members of this diagnostic group clustered into 
all four factors suggesting a diverse array of potential pathophysiologies. The application 
of these clusters to the GI microbiota supports a distinct anxiety and depression cluster 
and a distinct constipation cluster.  
Future work will focus on expanding upon the results of the FA by separating cohort 
participants into distinct groups and applying these criteria to other FGID cohorts. 
Additionally, the exploration of these groups in the context of their biological samples 
and diet could potentially provide a better understanding of the underlying 
pathophysiological mechanism(s) and therefore, potential biological targets. 
9.3 How Does Diet Affect IBS Symptoms? 
In Section Two, FGID participants were found to consume less carbohydrates and fibre 
compared to controls. Additionally, IBS patients were shown to experience more acute GI 
symptoms associated with meal consumption than FD, FC or controls. Analyses of meals 
associated with GI symptoms revealed higher dietary fibre and FODMAP compared to 
meals not associated with acute GI symptoms in IBS patients.  
Literature on fibre supplementation in IBS patients is inconsistent, although there 
appears to be a health benefit in fibre supplementation for IBS-C patients. However, 




limiting FODMAP intake.(658) Results in this thesis support the association of dietary 
fibre and FODMAP with acute GI symptoms. However there appears to be a long-term 
benefit, particularly in increased fibre consumption, in participants with acute GI and 
non-GI symptoms.  
Future work should include identifying dietary triggers of acute GI symptoms in IBS and 
evaluating the benefits of fibre/FODMAP consumption on a long-term basis. While 
mechanisms of GI symptom onset have been well studied for FODMAP, taking a multi-
omics approach to this could provide novel insights into the identification of FGID 
patients who do and do not respond to dietary manipulation, particularly using a 
diagnostic frame-work other than Rome IV. 
9.4 How do the Gastrointestinal Mucosa and Luminal Contents 
Affect Symptoms? 
Section Three aimed to establish if colonic mucosal TJ or NGF gene expression were 
altered in FGID participants compared to controls. Literature supported the restriction of 
these analyses to diarrhoea-predominant participants in order to maximise the 
likelihood of finding differing expression profiles.(343) IBS-D participants expressed less 
OCLN, ZO-1, and NGF mRNA compared to controls, suggesting that IBS-D participants may 
have a distinct pathophysiology involving reduced expression of some TJ components 
and potential GI barrier dysfunction. Alternatively, altered TJ component expression in 
IBS-D participants may result from multiple pathophysiologies that result in similar 
biological alterations.  
Analyses combining components of the luminal microenvironment including diet, faecal 
butyrate-producing bacteria, faecal butyrate concentration, and TJ/NGF gene expression 
in the colonic mucosa revealed plausible relationships between these components. 
Utilising the groupings of GI and non-GI items revealed by the FA, the relationship 
between these components of the luminal microenvironment provided insights in 




promise of combining data from multiple-systems in producing novel insights into 
complex, multifactorial physiological problems, such as those that FGID pathophysiology 
poses. 
Future work will include quantifying TJ/NGF protein abundance and activity and 
determine location in colonic tissue. These data will provide additional information on 
whether tight junctions in the colonic mucosa of diarrhoea-predominant FGID 
participants are disordered and provide validation of the gene expression results. 
Additionally, mast cell infiltration and activation status should be determined in these 
participants to determine the relationship between inflammation, TJ protein expression, 
and butyrate production. Furthermore, quantification of mast cells and systemic 
inflammatory reactions (by measuring systemic pro-inflammatory cytokines) or the 
presence of systemic LPS would provide potential insight into the permeability of the GI 
epithelial barrier. 
In addition, the expression of TJ/NGF mRNA and TJ/NGF protein should be determined 
in constipation-predominant participants and IBS-M participants. NGF protein 
expression is of particular interest in constipation-predominant participants to 
determine if an association exists between decreased NGF and increased colonic transit 
time. To this end, additional testing for 5-HT mRNA and protein concentrations should be 
determined in COMFORT participants in order to determine if expression is associated 
with NGF protein expression or faecal butyrate concentration. Finally, integration of the 
plasma/faecal metabolome (both host and microbiome), faecal microbiome, genome, and 
transcriptome, diet, demographics, and GI and non-GI symptoms should be completed in 
order to identify novel potential pathophysiologies in FGID. 
9.5 Conclusions 
Although diagnostic criteria such as Rome IV are clinically intuitive, I have shown that 
there is little to support this approach for pathophysiological research into FGID. The 




analysed agnostically, the resulting factors better reflect underlying alterations in the 
relative abundance of the GI microbiota compared to strict adherence to Rome IV 
diagnostic groupings. This conclusion suggests that while Rome IV criteria may be useful 
in clinical practice, they may be insufficient in their current state to uncover relevant 
biological differences. Subsequently, strict adherence to Rome IV diagnostic groups may 
hinder the identification of novel pathophysiologies and the development of novel 
treatments. 
The utilisation of data from multiple biological systems in this thesis demonstrates that 
participants outside of the Rome IV framework share biological, demographic, and 
symptomatic similarities which provide novel insight into potential shared 
pathophysiologies. Additionally, relationships between the components of the luminal 
microenvironment explored in this thesis are biologically plausible. While these have 
been reported in the literature, this body of research is novel. The integration of the 
various data sets (biological data, demographics, and symptom scores) in a human cohort 
of FGID participants provide a unique perspective of FGID and a novel avenue of research 
by including the integration of the novel FAST diary data. The research outlined in this 
thesis is, in its current form, is not clinically useful. Integration of the datasets collected 
has the potential to identify novel biomarkers and/or novel groupings of participants 
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Health and Disability Ethics Committees  
 Ministry of Health  
Freyberg Building  
20 Aitken Street  
PO Box 5013  
   Wellington  
6011  
  
 0800 4 ETHICS   
hdecs@moh.govt.nz  
  
12 April 2016  
  
  
Prof. Richard Gearry   
Gastroenterology  
Christchurch Hospital  
Private Bag 4710  
Christchurch 8140  
  
  
Dear Professor Gearry   
  
  
Re:  Ethics ref:  16/NTA/50  
  Study title:  COMFORT Cohort Tissue Bank  
  
  
I am pleased to advise that this application has been approved by the Northern A Health 
and Disability Ethics Committee.  This decision was made through the HDEC-Full Review 
pathway.  
  
Conditions of HDEC approval  
  
HDEC approval for this study is subject to the following conditions being met prior to the 
commencement of the study in New Zealand.  It is your responsibility, and that of the 
study’s sponsor, to ensure that these conditions are met.  No further review by the 
Northern A Health and Disability Ethics Committee is required.  
  
Standard conditions:  
  
1. Before the study commences at any locality in New Zealand, all relevant 
regulatory approvals must be obtained.  
  
2. Before the study commences at any locality in New Zealand, it must be 




the Australia New Zealand Clinical Trials Registry, www.anzctr.org.au). However 
https://clinicaltrials.gov/ is acceptable provided registration occurs prior to the 
study commencing at any locality in New Zealand.    
  
3. Before the study commences at a given locality in New Zealand, it must 
be authorised by that locality in Online Forms.  Locality authorisation confirms that 
the locality is suitable for the safe and effective conduct of the study, and that 
local research governance issues have been addressed.  
    
  
After HDEC review   
  
Please refer to the Standard Operating Procedures for Health and Disability Ethics 
Committees (available on www.ethics.health.govt.nz) for HDEC requirements relating to 
amendments and other post-approval processes.    
  
Your next progress report is due by 11 April 2017.  
  
Participant access to ACC  
  
The Northern A Health and Disability Ethics Committee is satisfied that your study is not a 
clinical trial that is to be conducted principally for the benefit of the manufacturer or 
distributor of the medicine or item being trialled.  Participants injured as a result of 
treatment received as part of your study may therefore be eligible for publicly-funded 
compensation through the Accident Compensation Corporation (ACC).  
  
  
Please don’t hesitate to contact the HDEC secretariat for further information.  We wish you 
all the best for your study.  
  
Yours sincerely,  
  
Dr Brian Fergus  
Chairperson  
Northern A Health and Disability Ethics Committee  
  
  
Encl:  appendix A:  documents submitted appendix B: 
 statement of compliance and list of members  
 
Appendix A  
Documents submitted  
  
   
Document     Version     Date     




Application Form   1   25 February 2016   
PIS/CF: Tissue Bank Consent Form   1   25 February 2016   
TOR COMFORT Tissue Bank   1   25 February 2016   
Application          
PIS/CF: Tissue Bank Consent Form   2   28 March 2016   
Covering Letter: Response to questions from ethics committee   1   30 March 2016   
Response to Request for Further Information      30 March 2016   
  




Appendix B  
Statement of compliance and list of members  
  
Statement of compliance  
  
The Northern A Health and Disability Ethics Committee:   
  
 is constituted in accordance with its Terms of Reference  
 operates in accordance with the Standard Operating Procedures for Health and 
Disability Ethics Committees, and with the principles of international good 
clinical practice (GCP)  
 is approved by the Health Research Council of New Zealand’s Ethics Committee 
for the purposes of section 25(1)(c) of the Health Research Council Act 1990  
 is registered (number 00008714) with the US Department of Health and Human 
Services’ Office for Human Research Protection (OHRP).  
  
  
List of members  
  
Name    Category    Appointed    Term Expires    
Dr Brian Fergus   Lay (consumer/community 
perspectives)   
11/11/2015   11/11/2018   
Ms Rosemary Abbott   Lay (the law)   15/03/2016   15/03/2019   
Dr Karen Bartholomew   Non-lay (intervention studies)   01/07/2013   01/07/2016   
Dr Charis Brown   Non-lay (intervention studies)   11/11/2015   11/11/2018   
Ms Susan  Buckland   Lay (consumer/community 
perspectives)   
11/11/2015   11/11/2016   
Ms Shamim  Chagani   Non-lay (health/disability service 
provision)   
11/11/2015   11/11/2016   
Dr Christine Crooks   Non-lay (intervention studies)   11/11/2015   11/11/2018   
Dr Kate Parker   Lay (consumer/community 
perspectives)   
11/11/2015   11/11/2018   
   
  
Unless members resign, vacate or are removed from their office, every member of 
HDEC shall continue in office until their successor comes into office (HDEC Terms of  
Reference)  
  












Health and Disability Ethics Committees  
 Ministry of Health  
Freyberg Building  
20 Aitken Street  
PO Box 5013  
   Wellington  
6011  
  
 0800 4 ETHICS   
hdecs@moh.govt.nz  
  
11 April 2016  
  
  
Prof. Richard Gearry   
Gastroenterology  
Christchurch Hospital  
Private Bag 4710  
Christchurch 8140  
  
  
Dear Professor Gearry   
  
  
Re:  Ethics ref:  16/NTA/21  
  Study title:  The Christchurch IBS Cohort to investigate Mechanisms For gut 
Relief and improved Transit (COMFORT)  
  
  
I am pleased to advise that this application has been approved by the Northern A 
Health and Disability Ethics Committee.  This decision was made through the HDEC-
Full Review pathway.  
  
  
Conditions of HDEC approval  
  
HDEC approval for this study is subject to the following conditions being met prior to 
the commencement of the study in New Zealand.  It is your responsibility, and that of 
the study’s sponsor, to ensure that these conditions are met.  No further review by the 
Northern A Health and Disability Ethics Committee is required.  
  
The Committee wish to emphasise that approval is given on the basis that;  
1. Samples will NOT be part of a general tissue bank  
2. Most of the tests will be done in New Zealand  






Standard conditions:  
  
1. Before the study commences at any locality in New Zealand, all 
relevant regulatory approvals must be obtained.  
  
2. Before the study commences at a given locality in New Zealand, it 
must be authorised by that locality in Online Forms.  Locality authorisation 
confirms that the locality is suitable for the safe and effective conduct of the 




Non-standard conditions must be completed before commencing your study. 
Nonstandard conditions do not need to be submitted to or reviewed by HDEC before 
commencing your study.   
  
For information on non-standard conditions please see section 128 and 129 of the 
Standard Operating Procedures at http://ethics.health.govt.nz/home.  
  
After HDEC review   
  
Please refer to the Standard Operating Procedures for Health and Disability Ethics 
Committees (available on www.ethics.health.govt.nz) for HDEC requirements relating 
to amendments and other post-approval processes.    
  
Your next progress report is due by 10 April 2017.  
  
Participant access to ACC  
  
The Northern A Health and Disability Ethics Committee is satisfied that your study is 
not a clinical trial that is to be conducted principally for the benefit of the manufacturer 
or distributor of the medicine or item being trialled.  Participants injured as a result of 
treatment received as part of your study may therefore be eligible for publicly-funded 
compensation through the Accident Compensation Corporation (ACC).  
  
  
Please don’t hesitate to contact the HDEC secretariat for further information.  We 
wish you all the best for your study.  
  
Yours sincerely,  
  
Dr Brian Fergus  
Chairperson  






Encl:  appendix A:  documents submitted appendix B: 
 statement of compliance and list of members Appendix 
A  
Documents submitted  
  
   
Document     Version     Date     
PIS/CF   1   20 February 2016   
Survey/questionnaire   1   20 February 2016   
Evidence of scientific review   1   20 February 2016   
Protocol   1   20 February 2016   
CV for CI   N/A   08 January 2016   
Application          
(None)           
PIS/CF: Revised PIS CF   2   28 March 2016   
Response to provisional approval for both Comfort Cohort and 
future unspecified use   
1   28 March 2016   
Response to Request for Further Information          
  




Appendix B  
Statement of compliance and list of members  
  
Statement of compliance  
  
The Northern A Health and Disability Ethics Committee:   
  
 is constituted in accordance with its Terms of Reference  
 operates in accordance with the Standard Operating Procedures for Health and 
Disability Ethics Committees, and with the principles of international good 
clinical practice (GCP)  
 is approved by the Health Research Council of New Zealand’s Ethics Committee 
for the purposes of section 25(1)(c) of the Health Research Council Act 1990  
 is registered (number 00008714) with the US Department of Health and Human 
Services’ Office for Human Research Protection (OHRP).  
  
  
List of members  
  
Name    Category    Appointed    Term Expires    
Dr Brian Fergus   Lay (consumer/community 
perspectives)   
11/11/2015   11/11/2018   
Ms Rosemary Abbott   Lay (the law)   15/03/2016   15/03/2019   
Dr Karen Bartholomew   Non-lay (intervention studies)   01/07/2013   01/07/2016   
Dr Charis Brown   Non-lay (intervention studies)   11/11/2015   11/11/2018   
Ms Susan  Buckland   Lay (consumer/community 
perspectives)   
11/11/2015   11/11/2016   
Ms Shamim  Chagani   Non-lay (health/disability service 
provision)   
11/11/2015   11/11/2016   
Dr Christine Crooks   Non-lay (intervention studies)   11/11/2015   11/11/2018   
Dr Kate Parker   Lay (consumer/community 
perspectives)   
11/11/2015   11/11/2018   
   
  
Unless members resign, vacate or are removed from their office, every member of 
HDEC shall continue in office until their successor comes into office (HDEC Terms of  
Reference)  
  







Participant Information Sheet  
  
  
Study title:  Development of the COMFORT Cohort  
Locality:  Christchurch Hospital,   Ethics committee ref. 16/NTA/21  
Southern Endoscopy Centre,  
University of Otago, Christchurch  
  
Lead investigator: Professor Richard Gearry Contact phone number: 03 3641567 You are invited to take 
part in a study of gut function and symptoms.  Whether or not you take part is your choice.  If 
you don’t want to take part, you don’t have to give a reason, and it won’t affect the care you 
receive.  If you do want to take part now, but change your mind later, you can pull out of the 
study at any time.    
  
This Participant Information Sheet will help you decide if you’d like to take part.  It sets out 
why we are doing the study, what your participation would involve, what the benefits and risks 
to you might be, and what would happen after the study ends.  We will go through this 
information with you and answer any questions you may have.    You do not have to decide 
today whether or not you will participate in this study. Before you decide you may want to talk 
about the study with other people, such as family, whānau, friends, or healthcare providers.  
Feel free to do this.  
  
If you agree to take part in this study, you will be asked to sign the Consent Form on the last 
page of this document.  You will be given a copy of both the Participant Information Sheet and 
the Consent Form to keep.  
  
This document is 8 pages long, including the Consent Form.  Please make sure you have read 
and understood all the pages.  
  
WHAT IS THE PURPOSE OF THE STUDY?  
We are performing this study to understand more about a common medical condition called 
irritable bowel syndrome (IBS). This affects 1/6 women and 1/9 men. People with IBS have 
abdominal pain and a change in their bowel habits (eg diarrhea or constipation) that can vary 
from day to day. The causes of IBS are not well understood. Current theories suggest that 
diet, stress, the types of bacteria in the bowel may all play a role. People with IBS see their 
doctor more and have more time away from usual activities. We aim to find differences 
between IBS patients and those without IBS so that we can understand potential causes of 
IBS. This may allow us to develop better ways of diagnosing and treating IBS.  
  
This is an observational study. No drugs or treatments are included in the study. We would 




urine, gut biopsies and faeces. We will then analyse the samples and compare the results 
between participants with and without IBS.   
  
The study is being performed by researchers from the University of Otago. It is funded by 
the Ministry of Business Innovation and Enterprise. Laboratory studies will be performed 
by researchers at University of Otago, AgResearch, Plant & Food and the Malaghan 
Institute.   
  
The study protocol has been reviewed by the Northern A ethics committee who have 
granted approval (Ref 16/NTA/21)  
  
WHAT WILL MY PARTICIPATION IN THE STUDY INVOLVE?  
You have been approached to participate in the study because you are having a 
colonoscopy soon. You may either have been diagnosed with IBS or this may be what 
your gastroenterologist believes is the most likely diagnosis in which case you are eligible 
to be a case for the purposes of the study. Otherwise, you may be having a colonoscopy 
to check your bowel for other reasons in which case you are eligible to be a control for 
purposes of the study. A control allows the researchers to compare similarities and 
differences with people who have IBS.  
  
If you choose to take part in the study we will ask you to do the following:  
  
1. Meet once with the researchers to discuss the study and obtain written consent. At 
this meeting the study will be explained to you and you may bring a support person 
if you wish. If you decide to participate in the study, the researcher will ask you to 
sign the consent form found at the end of this document. Then they will provide 
you with a range of questionnaires to take away with you. The questionnaires will 
include questions about your personal health, gastroenterological symptoms, 
mood, quality of life etc) The researchers will also give you containers to collect 
urine and faeces samples and give you instructions on how to complete your diet 
diary. At home, the questionnaires will take no more than 30 minutes to complete. 
The diet diary should take no more than 10 minutes for each of the three days to 
complete,  
  
2. Meet a second time with the researcher to drop off the faeces and urine samples, 
diet diaries and questionnaires and to give a breath sample (by breathing into a 
bag) and a blood test where 80mL of blood will be collected.   
  
3. On the day of your colonoscopy, your gastroenterologist will take eight additional 
biopsies of the colon.  
  
The samples that we receive will be used for a range of experiments. At this stage we plan 
for all analyses to be performed in New Zealand. However, it is conceivable that some 
future laboratory investigations may need to be performed overseas. In this case, samples 
would be sent without identifying information and the samples would subsequently be 







The blood will be split into its different components and stored. Experiments will include 
measuring proteins involved in inflammation, hormones that change with gut function and 
metabolites of normal body processes. In addition, a small amount of DNA will be collected 
from the sample to look for genetic markers linked to gut disease that may run in families.   
  
Each person has a DNA make-up (their genes), which is different from that of everybody 
else - except in the case of identical twins.  This genetic make-up is a mixture of the genes 
of our mother and father.  The precise way they are mixed varies from child to child within 
the same family, so having the same parents does not mean that two children will have 
exactly the same genes.  We already know that some health conditions and disorders are 
definitely inherited through the genes (hereditary conditions), but we do not know how 
many conditions are explained by genetic inheritance.  Inherited genes may explain why 
some people are more resistant and some people are more prone to disorders, which 
have not yet been identified as hereditary.  The research that you are invited to participate 
in will investigate genetic make-up to look for any link.  
  
Because the research will investigate genetic make-up, this is a way of identifying any 
individual participant and any particular characteristics of them genetically.  This 
information will be confidential and will not be disclosed or used in any way without your 
consent. In particular, the researcher/sponsor of the research will not claim any right, 
ownership or property in your individual genetic information or that of your kinship group, 
hapu or iwi, without your having first sought and obtained informed consent to the transfer 
of any such right, ownership or property.  Your consenting to participate in DNA sampling 
for the proposed study will not be construed as creating any right or claim on the part of 
the researcher/sponsor to your genetic information.  
  
Breath  
We will measure trace elements of volatile gases in your breath that may reflect aspects 
of health or disease.  
  
Urine  
We will measure proteins and metabolites in your urine that may reflect aspects of health 
or disease.  
  
Faeces  
The faeces sample will be used for a number of samples. We will measure the 
concentration of proteins that reflect inflammation in your bowel. We will also measure 
the concentration of a range of bacteria and other microbes that live in the gut.   
  
Intestinal biopsies  
The intestinal biopsies will be processed in the usual way so that the types of cells can be 
examined and counted. Biopsies will also be stored in a special way to enable RNA to be 
used to examine protein production by cells.   
  
You may hold beliefs about a sacred and shared value of all or any tissue samples 
removed. The cultural issues associated with sending your samples overseas and/or 




are a range of views held by Māori around these issues; some iwi disagree with storage 
of samples citing whakapapa and advise their people to consult prior to participation in 
research where this occurs. However, it is acknowledged that individuals have the right to 
choose. If you chose to participate in the study we will inform your General Practitioner.  
 WHAT ARE THE POSSIBLE BENEFITS AND RISKS OF THIS STUDY?  
There are no direct benefits to you in taking part in the study. However, the diet information 
that is collected may be useful to you if you were to look at the relationship between certain 
foods and your symptoms. However, the aim of the study is to understand IBS better. If 
we are successful in this then we may develop improved ways of diagnosing and treating 
IBS in the future.  
  
Potential risks of the study include slight bruising or discomfort from the blood test. 
Otherwise the collection of breath, urine and faeces has no specific risks associated with 
it. Colonic biopsies performed at colonoscopy are routine and do not place patients at 
increased risks. The completion of questionnaires and the diet diary have no specific risks 
associated with them.  
  
You will continue to be looked after by your usual doctors throughout the study.  
  
WHO PAYS FOR THE STUDY?  
The study is funded by the Ministry of Business Innovation and Enterprise. In recognition 
of your participation, you will be provided with a $20 petrol voucher. If discoveries are 
made from the information and samples that leads to the creation of intellectual property 
(where the discovery may have commercial benefits), these will belong to the researchers 
and their associated institutions.  
  
WHAT IF SOMETHING GOES WRONG?  
If you were injured in this study, which is unlikely, you would be eligible for compensation 
from ACC just as you would be if you were injured in an accident at work or at home. You 
will have to lodge a claim with ACC, which may take some time to assess. If your claim is 
accepted, you will receive funding to assist in your recovery.   If you have private health 
or life insurance, you may wish to check with your insurer that taking part in this study 
won’t affect your cover.  
WHAT ARE MY RIGHTS?  
Your participation in this study is voluntary and you are free to decline participation or 
withdraw from the study at any time without compromising your medical care.   
  
You have the right to access information about yourself that is collected part of the study. 
If new information becomes available during the study that may have an impact on your 
health, you will be informed immediately.  
  
At all times your privacy will be maintained. You will be given a unique number that will be 
used to label all information and samples. Your name will be linked to that number on a 
database that is separate to the database being used to store your information. Both 
databases are securely housed in the University of Otago server and are password 
protected. This means that we can link any important results from the research to your 




WHAT HAPPENS AFTER THE STUDY OR IF I CHANGE MY MIND?  
This is an observational study. Once the information and samples are collected there are 
no further requirements with regard to participation in the study and your care will continue 
with your Gastroenterologist and General Practitioner. All information and biological 
samples will be stored in the University of Otago on password-protected servers and in 
research freezers that are locked. No identifying data is kept in the same place that could 
link results to you as an individual. Secure storage is the responsibility of the University of 
Otago and the other institutions where the research will be undertaken. The information 
and samples will be stored securely and be used for ongoing research into the diagnosis 
and treatment of IBS. The samples will be destroyed 25 years after the commencement 
of the study.   
 
If you withdraw from the study after the samples and data have been collected, we will 
remove any data relevant to you or the samples that you have given from the study 
database. However, if the samples have already been processed and the data has been 
used for research purposes then the data cannot be removed from scientific reports. If 
you were to die, your family will not be able to withdraw the data and samples from the 
study. Findings from the study will be communicated to participants who wish this by 
newsletter.   
  
WHO DO I CONTACT FOR MORE INFORMATION OR IF I HAVE CONCERNS?  
If you have questions, concerns or complaints about the study at any stage, please contact:   
  
  Professor Richard Gearry  
  Department of Medicine  
 University of Otago, Christchurch  Tel 03 
3640640  
  
If you want to talk to someone who isn’t involved with the study, you can contact an independent 
health and disability advocate on:  
  
 Phone:   0800 555 050  
 Fax:    0800 2 SUPPORT (0800 2787 7678)  
 Email:    advocacy@hdc.org.nz  
  
For Maori health support please contact :  
  
  Nga Ratonga Hauora  
  Christchurch Hospital   
  Tel 3640 640 (Ext 86160)  
  
You can also contact the health and disability ethics committee (HDEC) that approved this study on:  
  
  Phone:   0800 4 ETHICS  







Consent Form  
  
If you need an interpreter, please tell us  
  
 
I have read, or have had read to me in my first language, and I understand the 
Participant Information Sheet.    
 
I have been given sufficient time to consider whether or not to participate in this study.  
 
I have had the opportunity to use a legal representative, whanau/ family support or a 
friend to help me ask questions and understand the study.  
 
I am satisfied with the answers I have been given regarding the study and I have a copy 
of this consent form and information sheet.  
 
I understand that taking part in this study is voluntary (my choice) and that I may 
withdraw from the study at any time without this affecting my medical care.  
 
I consent to the research staff collecting and processing my information, including 
information about my health.  
 
If I decide to withdraw from the study, I agree that the information collected about me 
up to the point when I withdraw may continue to be processed.  
 
I consent to my GP or current provider being informed about my participation in the 
study and of any significant abnormal results obtained during the study.  
 
I agree to my (blood, urine, faeces, colonic biopsy) samples being sent overseas 
and I am aware that these samples will be disposed of using established guidelines 
for discarding biohazard waste.  
 
I understand that future research may include the analysis of genetic markers and DNA  
 
I agree to an approved auditor appointed by the New Zealand Health and Disability 
Ethic Committees, or any relevant regulatory authority or their approved 
representative reviewing my relevant medical records for the sole purpose of checking 





I understand that my participation in this study is confidential and that no material, which 
could identify me personally, will be used in any reports on this study.  
 
I understand the compensation provisions in case of injury during the study.  
 
I know who to contact if I have any questions about the study in general.  
 
I understand my responsibilities as a study participant.  
 
I wish to receive a summary of the results from the study.  
 
I consent to be contacted by the researchers if there are other studies that I may be 
eligible to participate in.  
  
  
Declaration by participant:  
I hereby consent to take part in this study.  
  





Declaration by member of research team:  
  
I have given a verbal explanation of the research project to the participant, and have 
answered the participant’s questions about it.    
  
I believe that the participant understands the study and has given informed consent to 
participate.  
  







Signature:  Date:  





Optional Participant Information Sheet for 
the Use of Tissue for Future Unspecified 
Research  
Study title:  Development of the COMFORT Cohort  
Locality:  Christchurch Hospital,   Ethics committee    
 Southern Endoscopy Centre,  ref.: 16/NTA/50  
University of Otago, Christchurch  
  
Lead  Professor Richard Gearry  Contact phone number:  
investigator:  03 3640604  
  
You have already agreed to take part in a research study on gut symptoms and function. 
This participant information sheet tells you about an optional sub study, which will be 
conducted in subjects already enrolled in the main study. No further data or samples will 
be collected if you agree to take part in this study. If you agree to take part in this study, 
we will continue to store your information and samples for research in the future. This 
information sheet and consent form is in addition to the main study consent form that you 
have already signed.  
  
Whether or not you take part in this optional sub study is your choice.  If you don’t want to 
take part, you don’t have to give a reason, and it won’t affect the care you receive or your 
participation in the main study.  If you do want to take part now, but change your mind 
later, you can pull out of the study at any time.    
  
This Participant Information Sheet will help you decide if you’d like to take part.  It sets out 
why we are doing the study, what your participation would involve, what the benefits and 
risks to you might be, and what would happen after the study ends.  We will go through 
this information with you and answer any questions you may have.    You do not have to 
decide today whether or not you will participate in this study. Before you decide you may 
want to talk about the study with other people, such as family, whānau, friends, or 
healthcare providers.  Feel free to do this.  
  
If you agree to take part in this study, you will be asked to sign the Consent Form on the 
last page of this document.  You will be given a copy of both the Participant Information 
Sheet and the Consent Form to keep.  
  
This document is 6 pages long, including the Consent Form.  Please make sure you have 
read and understood all the pages.  
  




Undertaking a large study to collect information and biological samples takes a significant 
amount of time and money. Participants also give their own time to help with such studies. 
The resulting data and samples are a very valuable resource for researchers. If these 
samples are safely stored, research can be performed in the future. We would like to store 
the samples for future research into the diagnosis and treatment of IBS. As science makes 
advances with new knowledge, it is likely that the stored samples could be used to test 
new ideas and make new discoveries. These may include measuring a newly identified 
molecule in one of the samples that may help in the diagnosis of IBS, or identify patients 
who may respond to a specific treatment. While some of the research ideas may come 
from scientists, it is possible that commercial entities such as food companies may wish 
to learn more about iBS to develop new foods or treatments. While future research would 
only be related to the diagnosis and treatment of IBS, we are unable to describe the way 
in which this research would be performed on the stored samples at this point in time.  
  
WHAT WILL MY PARTICIPATION IN THE STUDY INVOLVE?  
Participation in the study requires no further actions from you except giving written 
informed consent. The same samples that will be collected will also be stored for future 
research. This includes blood (serum, white cells, red cells), DNA (from white blood cells), 
urine (50mL), breath (one breath), faeces (1 sample) and colonic biopsies (8). Each 
participant will be given a unique identifying number that will be used to label the samples. 
However, if important health information becomes available from the future research, then 
the participant can be identified by the unique identifier and this information shared with 
them and their general practitioner.   
  
WHAT HAPPENS TO MY SAMPLES AFTER THEY HAVE BEEN COLLECTED?  
The samples that we receive will be used for a range of experiments. They will be stored 
in a locked -80 degree celsius freezer in the University of Otago, Christchurch. At this 
stage we plan for all analyses to be performed in New Zealand. However, it is conceivable 
that some future laboratory investigations may need to be performed overseas. In this 
case, samples would be sent without identifying information and the samples would 
subsequently be disposed of according to local approved guidelines.  
  
The samples will be stored indefinitely.   
  
A Governance Group including local scientists, clinicians and lay people will consider all 
future research and approve it subject to the terms of this information sheet and consent 
form before any future research can be undertaken.  
  
All future unspecified research undertaken in New Zealand will be subject to ethical 
review. Overseas research will also be considered by overseas ethics committees but 
without New Zealand representation.   
  
It is important that you understand that the donation of any tissue for further research may 
raise cultural issues for you to consider. You may hold beliefs about a sacred and shared 




your samples overseas and/or storing your tissue should be discussed with your 
family/whanau as appropriate. There are a range of views held by Māori around these 
issues; some iwi disagree with storage of samples citing whakapapa and advise their 
people to consult prior to participation in research where this occurs. However, it is 
acknowledged that individuals have the right to choose.”  
  
WHAT ARE MY RIGHTS?  
Your participation in this study is voluntary and you are free to decline participation or 
withdraw from the study at any time without compromising your medical care. If you wish 
to withdraw consent then you should contact the researchers (see contact details below) 
and your information and samples will be withdrawn from the study.  
  
You have the right to access information about yourself that is collected part of the study. 
If new information becomes available during the study that may have an impact on your 
health, you will be informed immediately.  
  
At all times your privacy will be maintained. You will be given a unique number that will be 
used to label all information and samples. Your name will be linked to that number on a 
database that is separate to the database being used to store your information. Both 
databases are securely housed in the University of Otago server and are password 
protected.  
  
If discoveries are made from the information and samples that leads to the creation of 
intellectual property (where the discovery may have commercial benefits), these will 
belong to the researchers and their associated institutions.  
  
If you were injured in this study, which is unlikely, you would be eligible for compensation 
from ACC just as you would be if you were injured in an accident at work or at home. You 
will have to lodge a claim with ACC, which may take some time to assess. If your claim is 
accepted, you will receive funding to assist in your recovery.    
  
If you have private health or life insurance, you may wish to check with your insurer that 
taking part in this study won’t affect your cover.  
  
WHO DO I CONTACT FOR MORE INFORMATION OR IF I HAVE CONCERNS?  
If you have any questions, concerns or complaints about the study at any stage, you can 
contact:   
  
  Professor Richard Gearry  
  Department of Medicine  
  University of Otago, Christchurch  





If you want to talk to someone who isn’t involved with the study, you can contact an 
independent health and disability advocate on:  
  
 Phone:   0800 555 050  
 Fax:    0800 2 SUPPORT (0800 2787 7678)  
 Email:    advocacy@hdc.org.nz  
  
For Maori health support please contact :  
  
  Nga Ratonga Hauora  
  Christchurch Hospital   
  Tel 3640 640 (Ext 86160)  
  
You can also contact the health and disability ethics committee (HDEC) that approved this 
study on:  
  
  Phone:   0800 4 ETHICS  




   
Optional Consent Form for the Use of  
Tissue for Future Unspecified Research  
  
  




I have read, or have had read to me in my first language, and I understand the 
Participant Information Sheet.    
 
I have been given sufficient time to consider whether or not to participate in this study.  
 
I have had the opportunity to use a legal representative, whanau/ family support or a 
friend to help me ask questions and understand the study.  
 
I am satisfied with the answers I have been given regarding the study and I have a 
copy of this consent form and information sheet.  
 
I understand that taking part in this study is voluntary (my choice)   
 
I consent to the research staff collecting and processing my information, including 
information about my health.  
 
I agree to my tissue samples being sent overseas   
 
I agree for my tissue samples to be stored and used in future research into the 
diagnosis and treatment of irritable bowel syndrome.  
 
I agree for my tissue samples to be stored and used in future research of any type 
which has been properly approved  
 
I agree for my tissue samples to be stored and used in future research except for 
research about irritable bowel syndrome  
 





I understand that future research may include the analysis of genetic markers and 
DNA  
 
I want my identity to be kept with my tissue sample  
 
I want my identity to be removed from my tissue samples and understand that in this 
case I will not be able to withdraw my consent in the future  
 
I understand that I may withdraw from the study at any time   
 
If I decide to withdraw from the study, I agree that the information collected about me 
up to the point when I withdraw may continue to be used.  
 




Declaration by participant:  
  
I hereby consent to take part in this study.  
  





Declaration by member of research team:  
  
I have given a verbal explanation of the research project to the participant, and have 
answered the participant’s questions about it.    
  
I believe that the participant understands the study and has given informed consent to 
participate.  
  
Researcher’s name:  
 
  
Signature:  Date:  











 Blood sample priorities. An orange ring or square surrounding the sample or aliquot indicates a sample/aliquot that was prioritized 




















(Modified Hunter New England Health Survey) 
 




• Please use a black/blue pen or pencil. 
• Please erase or correct mistakes. 
• To answer each question you just need to tick   the appropriate response 
box. 














If you have any questions or need help filling in this survey please call the Research Assistants on (03) 364-
1788 or email  
comfortcohort@gmail.com 
 







A1 In the last 3 months, how often did you have pain anywhere 
in your abdomen? Please do not count cramps or pain with 
menstrual periods and do not count pain in your chest.  
(Please tick one box only) 
Never 
 
Less than one day a month 
 
One day a month 
 
Two to three days a month 
 
One day a week 
 











 Never/ Rarely Sometimes Often Most of the 
time 
    Always 
a The pain was made better or stopped by having a 
bowel movement? 
     
b The pain was made worse by having a bowel 
movement? 
     
c You had more bowel motions (stools) than usual? 
     
d You had less bowel motions (stools) than usual? 
     
e You had looser bowel motions (stools) than usual? 
     
f You had harder bowel motions (stools) than usual? 
     
 
A3 When did this pain in your abdomen, stomach, or tummy 
first begin? 
(Please tick one box only) 
Not Applicable 
 
Within the last 3 months 
 
3 to 6 months ago 
 
More than 6 months ago but less than 1 year ago 
 
More than 1 year ago but less than 2 years ago 
 
More than 2 years but less than 5 years ago 
 
More than 5 years ago 
 
Section A. 
We would like to ask you some questions about any discomfort or pain in your abdomen, stomach 
or tummy or bowel problems that you may have had in the past. 
Please mark the appropriate response box with a tick (for example ). 
A2. At the time when you had ANY pain in your abdomen, 
stomach, or tummy, how often would you say that:  
Use the options below to help you answer the following questions. 
Never / Rarely Sometimes: (about 25% of the time) Often: (about 50% of the time) 




A4 Bowel movements of Type 1 or 2 and also of Type 6 or 7 in the picture below can be considered to be abnormal. Type 1 or 
2 means you are constipated, and Type 6 or 7 means you have diarrhea. 
 
a In the last 3 months, when you had 
abnormal stools, what were they 
usually like? 
(Please tick one box only) 
Usually constipation (like Type 1 or 2 in the picture) 
 
 
Usually diarrhea (like Type 6 or 7)  
 
 
Both diarrhea and constipation - that is, more than 1/4 of all the abnormal bowel 
movements were constipation and more than 1/4 were diarrhea 
 
 
Not applicable, because I never or rarely had abnormal bowel movements  
 
b Did you have hard or lumpy stools 
(like Type 1 or 2) when you were not 
taking drugs for diarrhea? 




c Did you have mushy and watery stools 
(like Type 6 or 7) when you were not 
using drugs or other treatment for 
constipation? 








In the last 3 months, how often have Never/ 
Rarely 
Sometimes Often Most of 
the time 
Always 
a You had hard or lumpy stools that looked like Type 1 or 2 
in the picture above? 
     
b You had mushy or watery stools that looked like Type 6 or 
7 in the picture above when you were not using drugs or 
other treatment for constipation? 




A6 In the last 3 months, how often did you feel uncomfortably 
full after a regular sized meal that it interfered with your 
usual activities? 
(Please tick one box only) 
Never 
 
Less than one day a month 
 
One day a month 
 
A5. In the last 3 months, how often did you have any of the following 
problems with your bowels? 
Use the options below to help you answer the following questions. 
Never / Rarely Sometimes: (about 25% of the time) Often: (about 50% of the time) 




Two to three days a month 
 
One day a week 
 






  Multiple times per day or all the time 
 
 
A7 When did you first start having these episodes of 
feeling uncomfortably full after a regular sized 
meal that was severe enough to interfere with your 
usual activities? (Please tick one box only) 
Within the last 3 months 
 
3 to 6 months ago 
 
More than 6 months ago but less than 1 year ago 
 
More than 1 year ago but less than 2 years ago 
 
More than 2 years but less than 5 years ago 
 
More than 5 years ago 
 
 
A8 In the last 3 months, how often were you unable to finish 
a regular sized meal? 
(Please tick one box only) 
Never 
 
Less than one day a month 
 
One day a month 
 
Two to three days a month 
 
One day a week 
 






  Multiple times per day or all the time 
 
 
A9 When did you first start having these episodes of 
being unable to finish a regular sized meal? 
(Please tick one box only) 
Within the last 3 months 
 
3 to 6 months ago 
 
More than 6 months ago but less than 1 year ago 
 
More than 1 year ago but less than 2 years ago 
 
More than 2 years but less than 5 years ago 
 





    
 
A10. In the last 3 months, how often did you have any of the following 
problems with your bowels: 
Use the options below to help you answer the following questions. 
Never / Rarely Sometimes: (about 25% of the time) Often: (about 50% of the time) 




 Never/ Rarely Sometimes Often Most of the 
time 
    Always 
a If you had less than three (0-2) bowel motions each 
week? 
     
b You had more than three bowel motions each day? 
     
c Your stools been lumpy or hard? 
     
d Your stools been loose or watery? 
     
e You needed to strain to have a bowel motion? 
     
f You had been troubled by an urgent need to have a 
bowel movement that made you wish you had a toilet? 
     
g After finishing a bowel movement you felt that there was 
still bowel motion (stools) that needed to be passed? 
     
h You had a sensation that the stool could not be passed 
(e.g. Blocked) when having a bowel motion? 
     
i You needed to press your finger in or around the anus 
(back passage) or vagina (front passage) to help the 
bowel motion to come out? 
     
 
A11 When did problems with your bowels first begin? 
(Please tick one box only) 
Not Applicable 
 
Within the last 3 months 
 
3 to 6 months ago 
 
More than 6 months ago but less than 1 year ago 
 
More than 1 year ago but less than 2 years ago 
 
More than 2 years but less than 5 years ago 
 
More than 5 years ago 
 
 
A12 In the last 3 months, how often have you had the feeling 
that your abdomen, stomach or tummy was bloated? Please 
do not count cramps or pain with menstrual periods and do not 
count pain in your chest.  
(Please tick one box only) 
Never 
 
Less than one day a month 
 
One day a month 
 
Two to three days a month 
 
One day a week 
 






  Multiple times per day or all the time 
 
 
A13 Did your tummy and/or bowel problems start with 3 









A14 Did your tummy/bowel problems start within 3 months of 



































B2 The following questions are about activities you might do during a 
typical day. Does your health now limit you in these activities? If so, 





























































Yes, limited a 
lot 





a Moderate activities such as moving a table, pushing a vacuum cleaner, 
bowling, or playing golf    
b Climbing several flights of stairs 
   
 
B3 In the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health? (Please tick one box) 
YES NO 
a Accomplished less than you would like 
  
b Were limited in the kind of work or other activities 
  
 
B4 During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)?  (Please tick one box) 
YES NO 
a Accomplished less than you would like 
  
b Didn’t do work or other activities as carefully as usual 
  
 
B5 During the past 4 weeks, how much did pain interfere with 
your normal work (including both work outside the home 
and housework)? 
(Please tick one box only) 
Not at all 
 









B6 These questions are about how you feel and how things have 
been with you during the past 4 weeks. For each question, 
please give the one answer that comes closest to the way you 
have been feeling.  





















a Have you felt calm and peaceful? 
      
b Did you have a lot of energy? 
      
c Have you felt downhearted and blue? 
      
 
B7 During the past 4 weeks, how much of the time has 
your physical health or emotional problems interfered 
with your social activities (like visiting friends, 
relatives, etc.)? 
(Please tick one box only)  
None of the time 
 
A little of the time 
 
Some of the time 
 
Most of the time 
 
All of the time 
 
Section B. 
These next questions ask you about your views about your health, how you feel and how well 
you are able to do your usual activities. 








C1 Have you ever been diagnosed with diabetes by a 
doctor?  
(Please tick one box only) 





C2 In addition to diet, what sort of treatment are you 
following for diabetes? 
(Please tick one box only) 
Insulin injections only 
 
Insulin injections and blood sugar lowering 
tablets 
 
Blood sugar lowering tablets only 
 





C4 How would you rate the control of your blood sugar levels 
in general?  












C5 In the last 2 WEEKS, have you walked for sport, 
recreation or fitness? 
(Please tick one box only) 









C8 In the last 2 WEEKS, did you do any exercise which 
caused a MODERATE increase in your heart rate or 
breathing, that is, MODERATE exercise? 
 









C11 In the last 2 WEEKS, did you do any OTHER exercise 
which caused a LARGE increase in your heart rate or 
breathing that is, VIGOROUS exercise? 
(Please tick one box only) 










Now we would like to ask you some specific questions about your health. 
Please mark the appropriate response box with a tick (for example ). 
 
 How long have you had diabetes?  months 
 How many times did you walk in the last 2 WEEKS?  times 
 What was the TOTAL AMOUNT of time you spent walking in the last 2 WEEKS? 
 hours    minutes 
 How many times did you do any MODERATE exercise in the last 2 WEEKS?  times 
 What was the TOTAL AMOUNT of time you spent doing MODERATE exercise in the last 2 WEEKS? 
 hours    minutes 
 How many times did you do any VIGOROUS exercise in the last 2 WEEKS?   times 
 What was the TOTAL AMOUNT of time you spent doing VIGOROUS exercise in the last 2 WEEKS? 





D1 Over your lifetime, would you have smoked at least 100 
cigarettes or a similar amount of tobacco? (Please tick 
one box only) 




/.D2 How often do you NOW smoke cigarettes, cigars, 
pipes or other tobacco products? 
(Please tick one box only) 
Not at all 
 
Less often than weekly 
 
At least weekly (not daily) 
Number per week     
 




D5 Which of the following best describes YOU? 
(Please tick one box only) 
I am a life-long NON-drinker 
(Please got to E1) 
 
I currently drink alcohol 
(Please go to D6) 
 
I used to drink alcohol 








Now we would like to ask about your lifestyle. 
These questions ask you about smoking and alcohol. 
Please mark the appropriate response box with a tick (for example ). 
 
 If you don’t currently smoke, when did you finally stop s m o k i n g ? 
 weeks ago    or  months ago    or  years ago 
 
At what age did you first start smoking?  years old 
The next Question refers to a standard drink: 
Beer 1 stubby or can (375ml or 12oz, or about 1 ½ “pots” or “middies”) 
Wine 1 medium glass (125ml or 4oz,) 
Port or sherry 1 small glass (60ml or 2oz.) 
Spirits/liqueur 1 nip (30 ml or 1 oz.) 
 On how many DAYS in a typical week do you drink ANY alcohol? (Please tick one box only) 
 
None 




Less than 1 day per week 





6 days  7 days  
 
How many alcoholic drinks do you usually have each week? (Please tick one box only) 
None  Less than 1  








I feel tense or ‘wound up’: 
(Please tick one box) 
Most of the time 
 
A lot of the time 
 
From time to time/occasionally 
 





I still enjoy the things I used to enjoy: 
(Please tick one box) 
Definitely as much 
 
Not quite as much 
 
Only a little 
 





I get sort of a frightened feeling as if something 
awful is about to happen: 
(Please tick one box) 
Very definitely and quite badly 
 
Yes but not too badly 
 
A little but it doesn’t worry me 
 





I can laugh and see the funny side of things: 
(Please tick one box) 
As much as I always could 
 
Not quite as much now 
 
Definitely not so much now 
 





I feel as if I am slowed down: 
(Please tick one box) 











I get a sort of frightened feeling like ‘butterflies’ in the 
stomach: 












I have lost interest in my appearance: 
(Please tick one box) 
Definitely 
 
I don’t take so much care as I should 
 
I may not take quite as much care 
 
I take just as much care as ever 
 
Section E. 
Now we would like to ask you questions about how you have been feeling in the past week. Please 
read each question and cross the box which comes closest to how you have felt. 







I feel restless as if I have to be on the move: 
(Please tick one box) 
Very much indeed 
 
Quite a lot 
 
Not very much 
 





Worrying thoughts go through my mind: 
(Please tick one box) 
A great deal of the time 
 
A lot of the time 
 







I feel cheerful: 
(Please tick one box) 











I can sit at ease and feel relaxed: 












I look forward with enjoyment to things: 
(Please tick one box) 
As much as I ever did 
 
Rather less than I used too 
 
Definitely less than I used too 
 





I get sudden feelings of panic: 
(Please tick one box) 




Not very often 
 





I can enjoy a good book or radio or TV  programme: 


















F2 What is your date of birth? (Please write down) 
 
  day    month     year 
 
F3 What is your Height (in cm) and Weight (in kg)? Height:                                                          
Weight: 
 
F4 What is your highest level of educational 
training, or equivalent? 
Postgraduate qualifications 
 
University graduate (3 years or more) 
 
Completed Polytechnic or equivalent 
certificate/associate diploma, trades 
apprenticeship, or 2 years at university 
 
NCEA Level 3 / University Bursary 
 
Completed Year 11 (Fifth Form/School 
Certificate/NCEA level 1) 
 
Some years at High School 
 
Primary School only 
 
 












F7 What is the date that you filled in this survey? (Please write down) 
 
  / Day  / month  / year 
 
Section F. 
Now we would like to finish off by asking you some general questions about yourself. 
 















Your support is greatly appreciated. 
Please bring your completed questionnaires with you when 

























The following survey will ask you questions about your gastrointestinal 
(GI) medical history.  
The survey should only take about 10 minutes to complete.  
Please tick one box only for each question  
 


















 In the past 7 
days… 
Never Rarely Sometimes Often  Always 
1 I felt fearful 
     
2 I felt anxious 
     
3 I felt worried 
     
4 I found it hard 




     
5 I felt nervous 
     
6 I felt uneasy 
     
     7 I felt tense 
     
Section A.  
Emotional Distress – Anxiety 
In this section please respond to each option by marking one box per row on how 















In the past 7 days… Never Rarely Sometimes Often  Always 
1 I felt worthless 
     
2 I felt that I had 
nothing to look 
forward to 
     
3 I felt helpless 
     
4 I felt sad  
     
5 I felt like a 
failure      
6 I felt depressed 
     
 7 I felt unhappy 
     
 8 I felt hopeless 
     
Section B.  
Emotional Distress – Depression 
In this section please respond to each option by marking one box per row on how 







C1 In the past 7 days, how often did you 
have belly pain? (Please tick one) 






Once a day 
 
More than once a day 
 
 
C2 In the past 7 days, how would you rate 
your belly pain? (Please tick one) 
Not bad at all 
 









C3 Below is a picture showing the front of the 
body. The belly is divided into 9 areas, 
numbered 1 to 9. Please select the numbers 
that correspond with the areas where you felt 
your belly pain over the 7 days. (Please 







Area 1  
Area 2  
Area 3  
Area 4  
Area 5  
Area 6  
Area 7  
Area 8  
Area 9  




C4 In the past 7 days, how much did belly 
pain interfere with your day-to-day 
activities? (Please tick one) 
Not at all 
 









C5 In the past 7 days, how much did belly 
pain bother you? (Please tick one) 
Not at all 
 









C6 In the past 7 days, how often did you 
have discomfort in your belly? (Please 
tick one) 
Not at all 
 














D1 In the past 7 days, how often did you 
pass very hard or lumpy stools? 
(Please tick one) 






Once a day 
 
More than once a day 
 
D2 In the past 7 days, how much did hard 
or lumpy stools bother you? (Please tick 
one) 
Not at all 
 








D3 In the past 7 days, how often did you 
strain while trying to have bowel 
movements? (Please tick one) 










D4 In the past 7 days, how much did you 
usually strain while trying to have a 
bowel movement? (Please tick one) 
Not at all 
 












D5 In the past 7 days, how much did 
straining during bowel movements 
bother you? (Please tick one) 
Not at all 
 








D6 In the past 7 days, how often did you 
feel pain in your rectum or anus while 
trying to have bowel movements? 
(Please tick one) 










D7 In the past 7 days, how would you rate 
the pain in your rectum or anus during 
bowel movements? (Please tick one) 
Not bad at all 
 








D8 In the past 7 days, how often after a 
bowel movement did you feel 
unfinished – that is you had not 
















D9 In the past 7 days, how often did you 
use your finger or toilet paper to get 































  E1 In the past 7 days, how many days did 
you have loose or watery stools? 
(Please tick one) 










E2 In the past 7 days, how much did 
having loose or watery stools interfere 
with your day to day activities? (Please 
tick one) 
Not at all 
 








E3 In the past 7 days, how much did 
having loose or watery stools bother 
you? (Please tick one) 
Not at all 
 








E4 In the past 7 days, how often did you 
feel like you needed to empty your 
bowels straight away or you would 
have an accident? (Please tick one) 
Never (You have finished this 
section)   
One time during the past 7 days 
 
2-6 times during the past 7 days 
 
Often once a day 
 
More than once a day 
 




E5 In the past 7 days, how much did 
feeling you need to empty your bowels 
right away interfere with your day-to-
day activities? (Please tick one) 
Not at all 
 









E6 In the past 7 days, how much did 
feeling you needed to empty your 
bowels right away bother you? (Please 
tick one) 
Not at all 
 

























F1 In the past 7 days, how often did food 
get stuck in your chest when you were 











2 In the past 7 days, how often did food 
get stuck in your throat when you were 











F3 In the past 7 days, how often you feel 
pain in your chest when swallowing 











F4 In the past 7 days, how often did you 
have difficulty swallowing solid foods 
like meat, chicken or raw vegetables, 

















F5 In the past 7 days, how often did you 
have difficulty swallowing foods like 
ice cream, apple sauce or mashed 












F6 In the past 7 days, how often did food 
you have difficulty swallowing liquids? 












F7 In the past 7 days, how often did you 




















  G1 In the past 7 days, how often did you bowel 
incontinence – that is, have an accident 
because you could not make it to the 












  G2 In the past 7 days, how often did you soil or 
dirty your underwear before getting to a 
bathroom? (Please tick one) 











  G3 In the past 7 days, how often did you leak 
stool or soil your underwear? (Please tick one) 











  G4 In the past 7 days, how often did you think 
you were going to pass gas, but stool or 















  H1 In the past 7 days, how much swelling 
did you have in your belly? 
None (Go to H5) 
 









H2 In the past 7 days, how bad did the 
swelling in your belly get? 
Not bad at all 
 
A little bad 
 







H3 In the past 7 days, how much did the 
swelling in your belly interfere with 
your day-to-day activities? 
Not at all 
 









H4 In the past 7 days, how much did the 
swelling in your belly bother you? 
Not at all 
 












H5 In the past 7 days, how often did you 
feel bloated? 










H6 In the past 7 days, in general, how 
severe was your bloating? 
Not at all severe 
 




Quite a lot severe 
 
Very much severe 
 
H7 In the past 7 days, at its worst, how 
severe was your bloating? 
Not at all severe 
 




Quite a lot severe 
 
Very much severe 
 
H8 In the past 7 days, in general, how 
severe did your bloating feel? 
Not at all severe 
 




Quite a lot severe 
 






H9 In the past 7 days, how often did you 
know that you would feel bloated 











H10 In the past 7 days, in general, how 
much did feeling bloated interfere with 
your day-to-day activities? 
Not at all  
 




Quite a bit 
 
Very much  
 
H11 In the past 7 days, in general, how 
much did feeling bloated bother you? 
Not at all  
 




Quite a bit 
 
Very much  
 




Only once or twice a day 
 
About every 3-4 hours 
 
About every 2 hours 
 







I1 In the past 7 days, how often did you 
have nausea – that is, a feeling like 












I2 In the past 7 days, how often did you 
know that you would have nausea 











I3 In the past 7 days, how often did you 











I4 In the past 7 days, how often did you 















J1 In the past 7 days, how often did you 
have regurgitation – that is food or 
liquid coming back up into your throat 







Once a day 
 
More than once a day 
 
J2 In the past 7 days, what was the most 
food or liquid you had come back up 
into your mouth at one time? 
None 
 
Enough to fill a little in my mouth 
 
Enough to fill some of my mouth 
 
Enough to fill most of my mouth 
 
So much that it filled my entire 
mouth  
J3 In the past 7 days, after eating a meal 
how often did food or liquid come back 
into your throat without vomiting? 










J4 In the past 7 days, how often did you 
















J5 In the past 7 days, how often did you 
feel like you were going to burp, but 







Once a day 
 
More than once a day 
 
J6 In the past 7 days, how often did you 












J7 Look at the picture below. In the past 
7 days, how often did you feel burning 
in the red area shown in the picture – 








Once a day 
 
More than once a day 
 
J8 In the past 7 days, how often did you 















J9 In the past 7 days, how often did you 
burp? 






Once a day 
 
More than once a day 
 
J10 In the past 7 days, how much did 
burping bother you? 
Not at all 
 




















J12 In the past 7 days, how often did you 
















J13 In the past 7 days, how much did 
having a lump in your throat bother 
you? 
Not at all 
 








































0 = No problem No problem 
1 = Mild problem Can be ignored when you do not think about it 
2 = Moderate problem Cannot be ignored, but does not influence daily activities 
3 = Severe problem Influencing your concentration on daily activities 
4 = Very severe problem Markedly influences your daily activities &/or requires rest 
DATE            /              / 
 
Thank you for completing the following questionnaire, which is designed to 
determine the presence and severity of a range of gastrointestinal symptoms.  
 
Please mark the appropriate response with a tick   
 







Mild Moderate Severe Very 
Severe 
1 Belching with acid taste / 
heartburn / burning 
sensation in the 
oesophagus (tube 
joining mouth and 
stomach) 
     
2 Dysphagia (difficulty 
swallowing)      
3 Fullness (feeling of 
congestion of food 
without relation to prior 
food intake)  
     
4 Early satiety (stomach 
is overfilled soon after 
starting to eat, 
disproportional to the 
quantity of food taken, 
so that food cannot be 
finished) 
     
5 Postprandial pain or 
discomfort (upper 
abdominal symptoms 
start or get worse after 
meals) 
     
6 Epigastric pain / upper 
abdominal pain (pain 
between the belly 
button and chest / pain 
noticeable in the upper 
abdomen) 






Mild Moderate Severe Very 
Severe 
7 Retrosternal discomfort 
(unpleasant feeling behind 
the middle of the chest, 
painful or drawing) 
     
8 Pain or discomfort prior to 
bowel movement 
     
9 Difficulty with emptying the 
bowel 
     
10 Constipation      
11 Loose stools      
12 Incontinence      
13 Urgency to empty the bowel      
14 Diarrhoea      
15 Loss of appetite (listless for 
food intake) 
     
16 Abdominal cramps 
(spasmodic or colic like 
stomach pain without 
specified localisation) 
     
17 Sickness (discomfort 
combined with the 
impression for the need to 
vomit) 
     
18 Nausea (urgent feeling of 
the need to vomit) 









Mild Moderate Severe Very 
Severe 
19 Vomiting (vomiting of 
mucus and gastric 
contents, or strong 
unproductive retching) 
     
20 Bloating (feeling of 
distension and excessive 
gas in the abdomen) 
 
     
21 Excessive gas and 
passing of wind      
22 Excessive belching 
     
23 In your own words, what is your most 
important health concern or problem? 
 
 
24 In your own words, what is your 









b Chronic Fatigue 
  




e Sleep Disturbances 
  















Thank you for completing the following questionnaire, which will ask you questions 
about your Economic Living Standards.  
 
Please complete the questionnaire in blue or black pen and mark the appropriate 































 Yes-have it No-because I 
don’t want it 
No-because 




    
2 Washing Machine 
    
3 Heating available in all main 
rooms     
4 A good pair of shoes 
    
5 A best outfit for special 
occasions     
6 Personal Computer 
    
7 Home contents insurance 
    
For the following items, please indicate whether you have (or have 
access to) the item or not by ticking one of the four options. Tick the first 
box if you have the item. Tick box 2 if you don’t have the item because 
you don’t want it. Tick box 3 if you don’t have the item because of its 
cost. Tick box 4 if you don’t have the item because of some reason other 

























 Yes-do it No-because I 
don’t want to  
No-because 
of the cost 
No-for some other 
reason 
8 Give presents to family or 
friends on birthdays, 
Christmas or other special 
occasions 
    
9 Visit the hairdresser once 
every three months 
 
    
10 Have holidays away from 
home every year     
11 Enough room for family to 
stay the night     
12 Have a holiday overseas at 
least every three years     
13 Have a night out at least 
every fortnight     
14 Have family or friends over 
for a meal at least once a 
month 
    
For the following activities, please indicate whether you do the activity or 
not by ticking one of the following options. Tick box 1 if you do the 
activity. Tick box 2 if you don’t do the activity because you don’t want to. 
Tick box 3 if you don’t do the activity because of the cost. Tick box 4 if 
you don’t do the activity because of some reason other than not wanting 
















 Not at all A little A lot 
15 Gone without fresh fruit and 
vegetables to help keep down costs    
16 Continued wearing clothing that was 
worn out because you can’t afford a 
replacement 
   
17 Put off by buying clothes for as long 
as possible to help keep down costs    
18 Stayed in bed longer to save on 
heating costs    
19 Postponed or put off visits to the 
doctor to help keep down costs    
20 NOT picked up prescription to help 
keep costs down    
21 Spent less time on hobbies than you 
would like to keep down costs    
22 Done without or cut down on trips to 
the shops or other local places to 
help keep down costs  
   
The following are a list of things some people do to help keep costs 
down. In the last 12 months, have you done any of these things not at 























23 Generally, how 
would you rate your 






















24 Generally, how 
satisfied are you with 
your current material 
































25 How well does you 
(and your partners 
combined) total 
income meet your 
everyday needs for 
such things as 
accommodation, food, 
clothing and other 
necessities? Would 



















Not enough  
 
The following questions are about your material standard of living – the 
things that money can buy. Your material standard of living does NOT 
























COMFORT Study  
Food Diary  
Different eating patterns have an effect on people’s health.  To help us 
understand these eating patterns we would like you to complete this 
estimated food diary.  You need record all food and drink that you 
consume on three consecutive days. 
 
If you have any questions regarding this questionnaire please contact 
the COMFORT Research Team at comfortcohort@gmail.com or (03) 
364-1788 
 



















How to describe your food and drink using household measures 
Below are some suggestions on how to describe certain food and drink items together with their household measures. 
Food Description of food or drink and brand 
Household 
measure 
Bacon Shoulder or streaky; fried or grilled rashers, smoked or unsmoked Number 
Bread Type of bread, eg. white, brown, wholemeal, granary, French stick, ciabatta, 
currant. 
Description of slice e.g. sandwich, toast 
Number of slices 
Canned drinks Type, brand name 
For example: 335ml can Diet Coca Cola 
Number or full or 
half can 
Crisps Type, brand name e.g. 30g Rashuns Packet weight 
Fruit Type and size of fruit e.g. large Granny Smith apple 
For tinned fruit; slices/ halves etc in juice or syrup 
Number of pieces 
or tablespoons 
Jams Type, brand name e.g. Pam’s strawberry jam Teaspoons, heaped 
or flat 
Milk Type; full cream, trim, semi-trim Pints, glasses or 
cups 
Oil Type eg canola oil, sunflower oil, corn oil, olive oil 
Brand name e.g. Pam’s olive oil 
Tablespoons 
Prepacked foods 
eg pies, biscuits, 
confectionery 
Full name of product including brand name. 
For example: Bird’s Eye fish fingers.  
Keep the package. 
Number 
Sandwiches Describe fully if homemade or if bought; 
Full name, place of purchase and price, describe bread as above and note loaf 
size. 
Number of slices of 
bread or number 
of rolls 
Spreads on bread 
or toast 
Type e.g. butter, low fat spread, rice bran oil spread, canola spread, reduced fat 
canola spread, Weightwatchers spread.  
Full description, and brand name  
Keep the package 
Number of 
teaspoons or thinly, 
average or thickly 
spread 
Sugar Type e.g. caster, rich brown, white Teaspoons, heaped 
or flat 
Sweets, chocolate 
and snack bars 
Name, size (weight) and price (if known) 
For example: king size Mars bar 99c 
Keep the wrapper 
Weight of bar or 
number of sweets 
Takeaways Describe in full, give name of restaurant  
For example:  One scoop chips, The High Street chip shop. Standard chicken 
chow mein, Kwang Chow 
Portion size and 
price 
Vegetables Type; fresh, frozen, tinned or dried 
Brand name 
Tablespoons, full or 
heaped  




Sample record sheet 
Please record all food and drink consumed during the whole day, including snacks and water. 
Remember to report any additions to each food and drink, such as milk, sugar, salt, sauce or spreads. 
Meal When 
 
Where Who with Food or Drink Brand and details Preparation/ 
Cooking 
Quantity 
A 8 am In bed alone Gourmet muffin New World – double chocolate  None 1 
    Coffee Nescafe instant  
Sugar 
Green top milk  
Hot water added 1 heaped teaspoon in a 
mug 
1 heaped teaspoon 
1/8th of a mug 
B 10 am  Kitchen Family Tea Twinings Peppermint Hot water added 1 mug, no milk or sugar 
    Biscuits Tim Tam Double Chocolate None 2 
C 12pm   Creamy tuna pasta Homemade recipe 1 Pasta boiled in 
water 
1/3 recipe 
    French bread stick Bought–New World  6cm long 
    Margarine Pams–Canola low salt  1 level tsp 
    Chicken breast Skin and bone removed Fried in olive oil 1 medium chicken breast 
    Olive oil Luppi fried ½ tbsp 
    Cherry tomatoes  raw 2  
    Orange juice McCoy, unsweetened  200ml 
        










E 6.30pm Home  Friends Beer Monteiths Radler  2 bottles 
    Toast Vogels Rice and Rye Toasted 2 slices 
    Margarine Pams–Canola low salt  1 level tsp 
Please record brand names e.g. McCoy  






Live Gastrointestinal Symptom score (LGS) 
 
 
Over the next three days when you are recording what you are eating in the diet diary, we would 
like to understand your gastrointestinal symptoms in detail. At the top of each page please mark 




We would like you to use this record to tell us whether you have specific symptoms and, if so, 
when you noticed them and how bad they were. There are five symptoms that we would like you 
to comment on: 
 
1. Abdominal pain 
 
2. Abdominal swelling/distension 
 
3. Abdominal fullness 
 
4. Abdominal bloating 
 
5. Bowel motion 
 
Each question includes a 24 hour time scale and a tick box ☐ to indicate if you have not 
experienced that particular symptom. 
 
For example: the first time scale is about abdominal pain. If you did suffer from pain, please 
mark the time that the pain started and stopped on the 24-hour time scale. Between these 
two marks, please write the number between 1 and 5 which best reflects the severity of the 
pain. 
 
1) Not bad at all    2) A little bad   3) Somewhat bad    4) Quite bad   5) Very bad 
 
 
If you had multiple episodes of abdominal pain over the 24-hour period, please mark each 
one on the 24 hour time scale, with the severity of pain between each mark. Please see the 









Diet Diary Day 1              Date_____________________ 
Meal 
 
When Where Who 
with 
Food or Drink Brand and details Preparation/ 
Cooking 
Quantity 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        





Diet Diary Day 1 continued            
Meal 
 
When Where Who 
with 
Food or Drink Brand and details Preparation/ 
Cooking 
Quantity 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        









Please mark on the scale if you had any of the symptoms over the last 24 hours, and write the severity 
of the symptoms using the following scale:  
1   Not bad at all  2   A little bad  3   Somewhat bad  4   Quite bad  5   Very bad 
 

















If you had a Bowel Motion in the last 24 hours please mark on the scale. If you didn’t please tick the 
box.   






How much did you strain to pass the bowel 
motion? 
1. Not at all 
2. Slightly strain 
3. Moderately strain 
4. Significantly strain 
5. Unable to empty bowel 
 
Did you have abdominal pain before your bowel 
motion? 
0. No abdominal pain 
1. Not bad at all 
2. A little bad 
3. Somewhat bad 
4. Quite bad 
5. Very bad 
 
How much urgency do you experience when you 
need to have a bowel motion? 
1. Not at all 
2. A little urgency 
3. I have to hurry 
4. I have to go immediately 
5. I am incontinent (unable to control the 
urge and had an accident) 
Bowel Motion Chart         DAY 1 
Please complete the following chart reporting symptoms with each bowel motion that you passed in the 



























 BM1 BM2 BM3 BM4 BM5 BM6 BM7 BM8 BM9 
Bristol stool type 
(please write the number) 
         
How much did you strain? 
(please write the number) 
         
Abdominal pain before BM? 
(please write th  number) 
         
Urgency? 
(please wri e the nu ber) 
         
Abdominal pain r lieved by 
BM? 
(Yes/No/Not Applicable) 
         
Abdominal pain worsened 
by BM? 
(Yes/No/Not Applicable) 





Diet Diary Day 2            Date_____________________ 
Meal 
 
When Where Who 
with 
Food or Drink Brand and details Preparation/ 
Cooking 
Quantity 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        





Diet Diary Day 2 continued           Date_____________________ 
Meal 
 
When Where Who 
with 
Food or Drink Brand and details Preparation/ 
Cooking 
Quantity 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        











Please mark on the scale if you had any of the symptoms over the last 24 hours, and write the severity 
of the symptoms using the following scale:  
1   Not bad at all  2   A little bad  3   Somewhat bad  4   Quite bad  5   Very bad 
 
















If you had a Bowel Motion in the last 24 hours please mark on the scale. If you didn’t please tick the 







How much did you strain to pass the bowel 
motion? 
1. Not at all 
2. Slightly strain 
3. Moderately strain 
4. Significantly strain 
5. Unable to empty bowel 
 
Did you have abdominal pain before your bowel 
motion? 
0. No abdominal pain 
1. Not bad at all 
2. A little bad 
3. Somewhat bad 
4. Quite bad 
5. Very bad 
 
How much urgency do you experience when you 
need to have a bowel motion? 
1. Not at all 
2.  A little urgency 
3. I have to hurry 
4. I have to go immediately 
5. I am incontinent (unable to control the 
urge and had an accident) 
 
Bowel Motion Chart         DAY 2 
Please complete the following chart reporting symptoms with each bowel motion that you passed in the 



























 BM1 BM2 BM3 BM4 BM5 BM6 BM7 BM8 BM9 
Bristol stool type 
(please write the number) 
         
How much did you strain? 
(please write the number) 
         
Abdominal pain before BM? 
(please write the number) 
         
Urgency? 
(please write the number) 
         
Abdominal pain relieved by 
BM? 
(Yes/No/Not Applicable) 
         
Abdominal pain worsened 
by BM? 
(Yes/No/Not Applicable) 









When Where Who 
with 
Food or Drink Brand and details Preparation/ 
Cooking 
Quantity 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        




Day 3 continued              
Meal 
 
When Where Who 
with 
Food or Drink Brand and details Preparation/ 
Cooking 
Quantity 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        










Please mark on the scale if you had any of the symptoms over the last 24 hours, and write the 
severity of the symptoms using the following scale:  
1   Not bad at all  2   A little bad  3   Somewhat bad  4   Quite bad  5   Very bad 
 
















If you had a Bowel Motion in the last 24 hours please mark on the scale. If you didn’t please tick 







How much did you strain to pass the bowel 
motion? 
1. Not at all 
2. Slightly strain 
3. Moderately strain 
4. Significantly strain 
5. Unable to empty bowel 
 
Did you have abdominal pain before your bowel 
motion? 
0. No abdominal pain 
1. Not bad at all 
2. A little bad 
3. Somewhat bad 
4. Quite bad 
5. Very bad 
 
How much urgency do you experience when 
you need to have a bowel motion? 
1. Not at all 
2. A little urgency 
3. I have to hurry 
4. I have to go immediately 
5. I am incontinent (unable to control the 
urge and had an accident) 
 
Bowel Motion Chart        DAY 3 
Please complete the following chart reporting symptoms with each bowel motion that you passed in 



























 BM1 BM2 BM3 BM4 BM5 BM6 BM7 BM8 BM9 
Bristol stool typ  
(please write the number) 
         
How much did you strain? 
(please write the number) 
         
Abdominal pain before BM? 
(please write the number) 
         
Urgency? 
(please write the number) 
         
Abdominal pain relieved by 
BM? 
(Yes/No/Not Applicable) 
         
Abdominal pain worsened 
by BM? 
(Yes/No/Not Applicable) 














    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    











    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    






Are there any special reasons why this week may differ from ‘normal’ in 
terms of household food (for example a child’s birthday party or other family 
celebration)?   
Please circle either Yes or No 
  
No 
Yes   (Please state reason) __________________________________________________ 
________________________________________________________________________________________ 
Please let us know how you take your coffee or tea: 
 
☐    I don’t drink tea or coffee 
☐ Brand/strength eg. Maccona, medium ________________________ 
☐ With milk Approx.  ____________________ tablespoons; Brand __________________ 
☐ Without milk 
☐ With Sugar _______________________ teaspoons 
☐ No sugar  
☐ Other; please describe ______________________________________________________ 
 
Please check that you have answered all the questions in part 1, 2 and 3 and 
please make sure that you have filled in your diary for all three days. 
 
Don’t forget to include any: 
 
•Drinks e.g. tea, coffee, wine, beer, orange juice, soft drinks, water 
•Snacks between meals e.g. biscuits, crisps, peanuts, slices, muffins 








A. Tests for normal distribution in Demographics, PROMIS, SAGIS, and HADS questionnaires 
CASE_CONTROL  Kolmogorov-Smirnov Shapiro-Wilk 
  Statistic df Sig. Statistic df Sig. 
age_categories 
CASE 0.226 112 0.000 0.823 112 0.000 
CONTROL 0.238 107 0.000 0.854 107 0.000 
MET 
CASE 0.235 112 0.000 0.692 112 0.000 
CONTROL 0.232 107 0.000 0.636 107 0.000 
Have_you_ever_smoked 
CASE 0.396 112 0.000 0.619 112 0.000 
CONTROL 0.448 107 0.000 0.569 107 0.000 
Do_you_Smoke_now 
CASE 0.335 112 0.000 0.582 112 0.000 
CONTROL 0.395 107 0.000 0.525 107 0.000 
SAGIS_epigastric 
CASE 0.163 112 0.000 0.913 112 0.000 
CONTROL 0.295 107 0.000 0.596 107 0.000 
SAGIS_IBSD 
CASE 0.111 112 0.002 0.950 112 0.000 
CONTROL 0.218 107 0.000 0.777 107 0.000 
SAGIS_Acid 
CASE 0.284 112 0.000 0.758 112 0.000 
CONTROL 0.365 107 0.000 0.567 107 0.000 
SAGIS_Nausea 
CASE 0.280 112 0.000 0.664 112 0.000 
CONTROL 0.455 107 0.000 0.327 107 0.000 




CASE_CONTROL  Kolmogorov-Smirnov Shapiro-Wilk 
  Statistic df Sig. Statistic df Sig. 
CONTROL 0.328 107 0.000 0.647 107 0.000 
PROMIS_Anxiety 
CASE 0.092 112 0.021 0.963 112 0.004 
CONTROL 0.120 107 0.001 0.933 107 0.000 
PROMIS_BellyPain 
CASE 0.115 112 0.001 0.947 112 0.000 
CONTROL 0.350 107 0.000 0.740 107 0.000 
PROMIS_Bloating 
CASE 0.098 112 0.010 0.967 112 0.008 
CONTROL 0.183 107 0.000 0.902 107 0.000 
PROMIS_Constipation 
CASE 0.087 112 0.035 0.960 112 0.002 
CONTROL 0.227 107 0.000 0.879 107 0.000 
PROMIS_Depression 
CASE 0.107 112 0.003 0.957 112 0.001 
CONTROL 0.201 107 0.000 0.874 107 0.000 
PROMIS_Diarrhoea 
CASE 0.182 112 0.000 0.910 112 0.000 
CONTROL 0.339 107 0.000 0.703 107 0.000 
PROMIS_Disrupted_ 
Swallowing 
CASE 0.362 112 0.000 0.721 112 0.000 
CONTROL 0.460 107 0.000 0.465 107 0.000 
PROMIS_Reflux 
CASE 0.167 112 0.000 0.904 112 0.000 
CONTROL 0.238 107 0.000 0.754 107 0.000 
HADS_ANXIETY 
CASE 0.109 112 0.002 0.949 112 0.000 
CONTROL 0.124 107 0.000 0.906 107 0.000 
HADS_DEPRESSION 
CASE 0.176 112 0.000 0.888 112 0.000 






Tests of Normality 
CASE_CONTROL 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
age_categories CASE 0.226 112 0.000 0.823 112 0.000 
CONTROL 0.238 107 0.000 0.854 107 0.000 
MET CASE 0.235 112 0.000 0.692 112 0.000 
CONTROL 0.232 107 0.000 0.636 107 0.000 
Have_you_ever_s
moked 
CASE 0.396 112 0.000 0.619 112 0.000 
CONTROL 0.448 107 0.000 0.569 107 0.000 
Do_you_Smoke_n
ow 
CASE 0.335 112 0.000 0.582 112 0.000 
CONTROL 0.395 107 0.000 0.525 107 0.000 
SAGIS_epigastric CASE 0.163 112 0.000 0.913 112 0.000 
CONTROL 0.295 107 0.000 0.596 107 0.000 
SAGIS_IBSD CASE 0.111 112 0.002 0.950 112 0.000 
CONTROL 0.218 107 0.000 0.777 107 0.000 
SAGIS_Acid CASE 0.284 112 0.000 0.758 112 0.000 
CONTROL 0.365 107 0.000 0.567 107 0.000 
SAGIS_Nausea CASE 0.280 112 0.000 0.664 112 0.000 
CONTROL 0.455 107 0.000 0.327 107 0.000 
SAGIS_Constipati
on 
CASE 0.127 112 0.000 0.932 112 0.000 
CONTROL 0.328 107 0.000 0.647 107 0.000 




CONTROL 0.120 107 0.001 0.933 107 0.000 
PROMIS_BellyPai
n 
CASE 0.115 112 0.001 0.947 112 0.000 
CONTROL 0.350 107 0.000 0.740 107 0.000 
PROMIS_Bloating CASE 0.098 112 0.010 0.967 112 0.008 
CONTROL 0.183 107 0.000 0.902 107 0.000 
PROMIS_Constipa
tion 
CASE 0.087 112 0.035 0.960 112 0.002 
CONTROL 0.227 107 0.000 0.879 107 0.000 
PROMIS_Depressi
on 
CASE 0.107 112 0.003 0.957 112 0.001 
CONTROL 0.201 107 0.000 0.874 107 0.000 
PROMIS_Diarrhoe
a 
CASE 0.182 112 0.000 0.910 112 0.000 
CONTROL 0.339 107 0.000 0.703 107 0.000 
PROMIS_Disrupte
d_Swallowing 
CASE 0.362 112 0.000 0.721 112 0.000 
CONTROL 0.460 107 0.000 0.465 107 0.000 
PROMIS_Reflux CASE 0.167 112 0.000 0.904 112 0.000 
CONTROL 0.238 107 0.000 0.754 107 0.000 
HADS_ANXIETY CASE 0.109 112 0.002 0.949 112 0.000 
CONTROL 0.124 107 0.000 0.906 107 0.000 
HADS_DEPRESSI
ON 
CASE 0.176 112 0.000 0.888 112 0.000 





















Figure of histograms showing the distribution of HADS anxiety and depression scores. A) Control participants 
showing anxiety scores, B) Control participants showing depression scores. C) Total IBS participants showing 
anxiety scores, D) Total IBS participants showing depression scores. E) IBS-D participants showing anxiety 
scores, F) IBS-D participants showing depression scores. G) IBS-M participants showing anxiety scores. H) IBS-
M participants showing depression scores. I) IBS-C participants showing anxiety scores. J) IBS-C participants 














Wilcoxon test results showing if a difference existed between Rome IV 



















































Item not Available Substituted item 
Cider (alcoholic)  1:1 apple juice/beer 
Mixed Alcoholic Beverages/Cocktails estimated proportions spirits/mixer  
Baked goods 
recipe  ingredients entered as raw 
ingredients into MONASH FODMAP 
CALCULATOR 
recipes from  Edmonds Cookery Book© 
Sauces/pickle/chutney 
recipe  ingredients entered as raw 
ingredients into MONASH FODMAP 
CALCULATOR 
recipes from  Edmonds Cookery Book© 
Salad 
recipe  ingredients entered as raw 
ingredients into MONASH FODMAP 
CALCULATOR 
recipes from  Edmonds Cookery Book© 
Soup 
recipe  ingredients entered as raw 
ingredients into MONASH FODMAP 
CALCULATOR 
recipes from  Edmonds Cookery Book© 
Non-meat ingredients in meat dishes 
(if not specified by participant) 
recipe  ingredients entered as raw 
ingredients into MONASH FODMAP 
CALCULATOR 
recipes from  Edmonds Cookery Book©, 
Flavored ice cream 
vanilla ice cream; proportions of fruit 
and other flavourings as per Pams brand 










Flavored yoghurt  
plain yoghurt; proportions of fruit and 
other flavourings as per Meadowfresh 
brand 





FODMAP categories (x axis) with a significant difference in the proportion of participants (y axis) experiencing a GI 



































Average FODMAP intake of meals associated with a bowel motion compared 























































Reaction Mixture for polymerase chain reaction 














































Spearman’s rank correlation scores between 
TJ/NGF relative gene expression and age 
Welch’s t-test comparing TJ/NGF relative gene 

















Exon 1 NGF sequence, forward primer used in Chapter 7 highlighted in yellow and 
























Protocol for the extraction and quantification of organic acids 
SCFA (linear and branched, 14 total) were measured using a modified (659) MS-probe and stable 
isotope liquid chromatography-mass spectrometry (LCMS) method (660). This modified method 
quantitatively converts SCFA into 3-nitrophenylhydrazones using 12C/13C6-3-nitrophenylhydrazine 
(3NPH), increasing their sensitivity for analysis. The use of the isotope 12C/13C6-3NPH also enables 
isotope label coding, creating an internal standard for each sample.  
250mg of each sample was dissolved in 1.5mL of a solution of formic acid:H2O (50:50 ratio); 10µL of 
the resulting solution was added to an individual well of a 2mL 96 well deepwell plate (Phenomenex, 
Torrance, CA, USA). A solution of 200mM of 12C/13C6-3NPH is made by adding a 75:25 ratio of methanol 
and water (v/v). 20µL of the 12C/13C6-3NPH solution was added to each sample. 20µL of 120mM EDC-
6% pyridine (diluted in methanol v/v) was additionally added to each sample.  
The standards used for these analyses, described in Parkar et al., 2020 (659) were treated similarly, 
however, without the addition of the 75:25 methanol: water (v/v). Standards that were at a higher 
concentration (2-40mM) were diluted further with derivatising solutions (40µL). The reactions on the 
plate were calibrated using matrix spikes which were prepared at physiologically relevant 
concentrations. The plate was sealed with a silicone mat (Phenomenex, Torrance, CA. USA) and 
agitated using a Thermomixer® C (Eppendorf, Hamburg, Germany) at room temperature at 1000 rpm 
for 45 minutes. The reaction was then quenched using 20µL quinic acid (200mM diluted in methanol 
and water, 75:25 ratio v/v). Samples, standards, and matrix spikes were diluted with 10% aqueous 
methanol giving a total volume of 1mL. 100µL of each sample, standard and matrix spike were added 
to 100µL of the internal standard mixture (659) in a new 96 well plate. An aliquot of 1µL was injected 




Appendix U  
Spearman’s rank correlation of GI and non-GI symptoms, demographics, butyrate-producing bacteria, TJ/NGF gene 
expression, faecal butyrate concentration and fibre/FODMAP consumption in diarrhoea-predominant participants (Table 
















Spearman’s rank correlation of GI and non-GI symptoms, demographics, butyrate-producing bacteria, TJ/NGF gene 
expression, faecal butyrate concentration and fibre/FODMAP consumption in diarrhoea-predominant participants (Table 
















Spearman’s rank correlation of GI and non-GI symptoms, demographics, butyrate-producing bacteria, TJ/NGF gene 
expression, faecal butyrate concentration and fibre/FODMAP consumption in constipation-predominant participants 
















Spearman’s rank correlation of GI and non-GI symptoms, demographics, butyrate-producing bacteria, TJ/NGF gene 
expression, faecal butyrate concentration and fibre/FODMAP consumption in constipation-predominant participants 































































































Participant ID number Average Read Depth 
90281 9877.785 
90286 10587.39 
90290 10594.66 
90291 11042.06 
90296 16912.07 
90297 17227.44 
90299 11542.89 
90302 8262.599 
90303 10460.25 
90306 10647.51 
90309 11297.83 
90311 9565.204 
90317 12903.23 
90320 8905.122 
90321 10865.84 
90326 12727.46 
90330 12568.45 
90333 12516.8 
90344 7924.146 
 
